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The contents of this thesis are divided into two parts. The first part covers both existing 
and novel neurovestibular laboratory tests, with an emphasis on technical and practical 
issues. The second part offers a detailed overview of a study concerning neurovestibular 
analysis in persons with either Parkinson’s disease or a form of atypical parkinsonism, 
performed both at baseline and after one-year prospective follow-up.
PART ONE
Neurovestibular laboratory testing - practical and technical issues
The first step in making management decisions in patients with complaints of vertigo 
and/or dizziness is to find the correct diagnosis. With a few exceptions, it is an illusion 
that neurovestibular laboratory tests will provide the physician with an aetiological 
explanation concerning the patient’s underlying medical problem. The basis of making 
the correct diagnosis in neurology in general – and perhaps even more so in patients 
with neurotological medical problems – is to perform a detailed medical history, and 
a careful bedside clinical neurological as well as a neurotological examination. These 
findings will help in creating a clinical context which will then lead to a preliminary 
diagnosis or a list of differential diagnoses. Subsequently, neurovestibular laboratory 
tests can be helpful to: a) localize the problem to the peripheral or central vestibular 
system, b) determine the extent of the lesion, c) assess the status of the compensation 
process, and d) determine the prognosis in combination with the clinical context1. It 
is often necessary to complement the neurovestibular laboratory tests with additional 
audiometric analysis, neuroimaging, and/or laboratory examinations in order to make 
a final diagnosis. In the first part of this thesis, I will discuss a few practical and 
technical issues of several neurovestibular laboratory examinations (i.e. vestibular 
evoked myogenic potentials, VEMP; and the subjective visual vertical, SVV), which 
have not yet been addressed in the literature. 
Nystagmography, caloric and rotatory chair stimulation
Nystagmography is a method for recording eye movements, nystagmus in particular. 
These recordings can be made in two different ways: a) by using eye goggles with an 
infrared recording system (i.e. videonystagmography, VNG), or b) by using surface 
electrodes along the horizontal and vertical axis of the eyes to indirectly determine 
the eye movements by measuring the changes in the vector of the corneal-retinal 
dipole (i.e. electronystagmography, ENG)1,2. Eye movement recordings are 
subsequently made: a) during gaze in the neutral midline position and during eccentric 
Chapter 1
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gaze in all directions, both with and without fixation, b) during saccades at different 
angles, c) during smooth pursuit with the targets moving at different speeds, d) during 
optokinetic stimulation with the stimulus moving at different speeds, e) during and/
or after rotatory chair stimulation, and f ) after bithermal caloric stimulation with 
warm and cold water (i.e. 44 and 30 degrees Celsius) or air. Tests a. through d. are 
used to study the central ocular motor pathways and tests e. and f. are used to 
dynamically examine the vestibulo-ocular reflex pathways. We refer to the excellent 
textbook of Baloh and Kerber for a more detailed description of the tests and their 
interpretation2.
Vestibular Evoked Myogenic Potentials (VEMP)
For the last few decades, VEMP testing has come into use as a test suitable for detailed 
neurophysiological assessment of both the peripheral and central vestibular system. 
VEMP testing can be divided into a cervical and ocular response. VEMP responses 
can be evoked by short intense air conducted sound stimulation, bone conducted 
vibration, forehead tap stimulation, and galvanic stimulation3–8. 
Cervical VEMP measurements determine the integrity of the vestibulo-collic reflex 
pathway starting at the sacculus otolith end-organ through the inferior vestibular 
nerve, subsequently travelling through the vestibular nuclei and the ipsilateral medial 
vestibulospinal tract to end in the ipsilateral sternocleidomastoid muscle evoking an 
inhibitory motor response3,5,6,8,9. These responses can be measured by placing an active 
surface electrode over the upper middle part of the ipsilateral sternocleidomastoid 
muscle belly and a reference electrode over the sternal manubrium. The 
sternocleidomastoid muscles, however, have to be tightened before cervical VEMP 
responses can be elicited by flexing the neck or rotating the head contralaterally to 
the stimulated ear.
Ocular VEMP measurements determine the integrity of the vestibulo-ocular reflex 
pathway most likely starting at the utriculus otolith end-organ through the superior 
vestibular nerve, subsequently travelling through the vestibular nuclei and the medial 
longitudinal fasciculus to ultimately evoke an excitatory ocular motor response in the 
contralateral inferior oblique external eye muscle. The utriculus is the most likely 
otolith end-organ from where the ocular VEMP response originates, yet, this origin 
is debated extensively in the literature (whether it is the utriculus solely or a 
combination of both the utriculus and sacculus). However, there is consensus that 
the relevant afferents travel through the superior vestibular nerve3,5,6,8,10–13. Ocular 
VEMP responses can be obtained by placing active surface electrodes over the middle 
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infra-orbital margin and the reference electrodes 1-2 centimetres below them. The 
eyes have to be deviated upward during stimulation before ocular VEMP responses 
can be recorded. 
Historically, the clinical neurophysiological VEMP studies focussed on the peripheral 
vestibular system. Chapter 2 critically reviews the latest VEMP literature concerning 
central neurological disorders and explains how careful evaluation of the VEMP 
abnormalities can aid in localizing neurovestibular disorders. I would also like to refer 
to figure 1, chapter 2, for a schematic representation of the ocular and cervical VEMP 
pathways. Figure 2, chapter 2, shows an example of the characteristic ocular and 
cervical VEMP responses in a healthy volunteer, elicited by forehead taps. Chapter 
3 offers the results of an intra-, interobserver and test re-test reliability study. Both 
the intra- and interobserver reliability concerning the assessment of cervical and ocular 
VEMP responses need to be good or excellent in order for VEMPs to be a reliable 
clinical diagnostic tool. However, these important technical aspects of clinical VEMP 
assessment have as yet not been studied before. Also, the test-retest reliability has thus 
far received rather limited attention in literature, especially concerning ocular VEMPs 
and forehead tap evoked VEMPs. I would therefore like to refer to the methodology 
sections of chapters 3 and 5 for a detailed overview concerning the performance of 
both cervical and ocular VEMP measurements. Fortunately, an international guideline 
concerning the performance of cervical VEMPs4 was published recently.
Subjective Visual Vertical (SVV)
The static SVV test measures the integrity of the graviceptive pathways. Graviception 
is the ability of a person to correctly estimate the absolute vertical, being the 
gravitational force of the earth. These graviceptive pathways integrate the visual, 
vestibular, and proprioceptive sensory inputs to subsequently estimate the position 
of the person’s body relative to the absolute vertical14–17. The SVV test is performed 
in a completely darkened environment and in an upright sitting position in order to 
exclude visual references and to minimize proprioceptive inputs. Therefore, the static 
SVV results are primarily determined by otolithic balance as these are the primary 
receptors in the body to detect gravitational forces (i.e. linear accelerations)17. During 
SVV testing in our laboratory, subjects are asked to adjust a tilted laser projected line 
to the absolute vertical by means of a remote controller in a completely darkened 
environment. Chapter 4 has three main technical aims: a) to construct a robust static 
SVV testing protocol incorporating both binocular and monocular measurements, 
as SVV testing in literature is severely hampered by the lack of a uniform protocol, 
making generalization of SVV findings from literature very difficult, b) to study the 
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effects of different preset angle deviations and sides, and c) to study the test re-test 
variability. As noted above the test re-test reliability is an important technical parameter 
in determining whether the SVV test is a reliable clinical diagnostic tool yet it has 
thus far received rather limited attention in literature. Also, the size of the preset angle 
and side of the tilted laser projected line are important technical considerations as 
these factors can possibly influence the outcome of the SVV test results and have thus 
far not been studied extensively in literature. However, these technical issues need to 
be clarified before a uniform static SVV testing protocol could be constructed, which 
is one of the primary aims of this study.
PART TWO
Neurovestibular analysis and falls in persons with Parkinson’s disease 
and atypical parkinsonism – a baseline case-control study and prospec-
tive follow-up study after one year
Fall incidents and postural instability are a major problem in persons with Parkinson’s 
disease (PD), and even more so in persons with a form of atypical parkinsonism (AP). 
Approximately 70% of PD patients fall once each year, and about 50% of them 
experience recurrent fall episodes yearly18–22. PD patients have a 2.2-fold increase in 
fractures overall and a 3 to 4-fold increase in hip fractures in comparison to an age-
matched healthy population. Moreover, PD patients with hip fractures have higher 
rates of surgical and medical post-operative complications (e.g. hospital acquired 
pneumonia, urinary tract infection, pressure sores), longer post-operative hospital 
duration, and higher mortality rates23. Also, fall incidents in PD patients result in a 
fear of renewed falls, secondarily leading to social isolation and a reduced quality of 
life following self-imposed restrictions of daily activities18,20. 
Recently, a practical consensus-based overview concerning the risk factors for falling 
in PD patients was published24. However, vestibular function abnormalities were not 
addressed as an individual risk factor, which is surprising since the vestibular system 
is one of the key systems in maintaining balance by integrating multimodal sensory 
information (i.e. vestibular, proprioceptive, and visual sensory input) and by 
secondarily adjusting the outgoing motor response by means of the vestibulospinal 
reflexes25.  Moreover, there is very little literature concerning the risk of falling in PD 
and AP patients in relation to vestibular system abnormalities. Recent work showed 
that complaints of dizziness are common in patients with PD, and this is related not 
only to orthostatic hypotension (which most clinicians assume to be the most likely 
explanation), but also to underlying – and commonly undetected! – benign paroxysmal 
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positional vertigo26,27. The literature concerning vestibular system abnormalities in 
PD and AP patients in general, too, is very limited and consists of small case-series 
and case-control studies28–32. Chapter 5 presents the results of a case-control study in 
which the vestibular system function in PD and AP patients was systematically 
investigated by means of a vestibular testing battery, and the results were compared 
to an age and gender-matched healthy control group. The results of the vestibular 
testing battery were subsequently compared to the clinical neurological and 
neurotological test results and a possible correlation with fall incidents was examined. 
Chapter 6 shows the prospective follow-up results one year after the baseline study 
as described in chapter five. All patients and healthy volunteers received a telephone 
interview concerning their falls in the prior year and their fear of falling. The follow-
up results were compared to the baseline results, particularly the results of the baseline 
vestibular testing battery. The sensitivity and positive predictive values of the individual 
vestibular function tests were calculated in relation to future fall incidents. 
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Abstract (review)
Several types of acoustic stimulation (i.e. tone bursts or clicks), bone-conducted 
vibration, forehead taps, and galvanic stimulation may give rise to myogenic 
potentials. These may be recorded in cervical and ocular muscles, the so called 
vestibular evoked myogenic potentials (VEMPs). The cervical VEMP (cVEMP) 
resembles the vestibulo-collic reflex and the responses may be recorded from the 
ipsilateral sternocleidomastoid muscle. The ocular VEMP (oVEMP) resembles 
the vestibulo-ocular reflex and may be recorded from extra-ocular muscles by a 
surface electrode beneath the contralateral infraorbital margin. Initially, the 
literature concerning VEMPs was limited to peripheral vestibular disorders, 
however, the field of VEMP testing is rapidly expanding with an increasing interest 
for central neurological disorders. The current literature concerning VEMP 
abnormalities in central neurological disorders is critically reviewed, especially 
regarding the methodological aspects in relation to quality as well as clinical 
interpretation of the VEMP results. Suggestions for further research are proposed 
as well as some clinical useful indications.
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Introduction
In the last two decades vestibular evoked myogenic potentials (VEMPs) emerged as a 
test suitable for detailed physiological assessment of the vestibular system. VEMPs can 
be evoked by short intense auditory stimuli (i.e. tone bursts or clicks), bone-conducted 
vibration, forehead taps, and galvanic stimulation1–5. In daily practice, air-conducted 
acoustic stimuli are used most often, followed by bone-conducted vibration and forehead 
taps. The responses can be divided into a cervical response and an ocular response. 
The cervical vestibular evoked myogenic potential (cVEMPs) can be recorded by 
placing an active surface electrode over the upper middle part of the sternocleidomastoid 
muscles with a reference electrode on the sternal manubrium. The sternocleidomastoid 
muscles, however, both have to be activated by flexing the neck, or have to be 
ipslaterally activated by rotating the head contralaterally away from the stimulated 
ear (i.e. when cVEMPs are acoustically elicited by air-conducted clicks or tone bursts, 
AC-cVEMPs). cVEMPs check the integrity of the vestibulo-collic reflex from the 
saccular afferents to the brainstem vestibular nuclei (through the inferior vestibular 
nerve), evoking an inhibitory motor response in the ipsilateral sternocleidomastoid 
muscle (through the medial vestibulospinal tract, upper cervical motor neurons and 
the accessory nerve)1,3,4,6 (figure 1). 
Figure 1.
Neurophysiological pathways concerning the ocular and cervical vestibular evoked myogenic potentials. 
We refer to the text for further explanation. CM: cervical motor neuron; FLM: medial longitudal 
fasciculus; IVN: inferior division of the vestibular nerve; MVST: medial vestibulospinal tract; N. 
III: oculomotor nucleus; n. XI: accessory nerve; SVN: superior division of the vestibular nerve; VN: 
vestibular nuclei.
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The ocular vestibular evoked myogenic potential (oVEMP) measures the function of 
the vestibulo-ocular reflex arc from the otolith end-organ(s) to the brainstem vestibular 
nuclei through the superior vestibular nerve and medial longitudal fasciculus, evoking 
an excitatory oculomotor response in the inferior oblique muscle mainly in the 
contralateral eye. The precise localisation of the end-organ involved in the origin of 
the oVEMP is controversial and extensively debated in the literature (i.e. whether the 
end-organ is predominantly the sacculus, the utriculus, or a combination of both), 
however there is consensus that the relevant afferents travel through the superior 
division of the vestibular nerve1,3,4,6–11 (figure 1). By maintaining an upward gaze 
during the stimulation oVEMPs can be recorded by an active electrode just below the 
middle of the infraorbital margin and the reference electrodes 1-2 centimetres below 
the active electrode1,12. 
The cVEMPs morphology can be divided into two parts. The early biphasic positive-
negative component (p13-n23) is presumed to be of mainly saccular origin. The 
second biphasic negative-positive complex (n34-p44) is thought to be auditory in 
acoustic stimulation and of an unknown origin in forehead tap evoked responses 
(possibly a stretch reflex) (figure 2). The oVEMPs morphology consists of a 
quadriphasic negative-positive deflection (n1-p1 and n2-p2 complex) (figure 2).
Figure 2.
A: Ocular vestibular evoked myogenic potentials in a healthy subject elicited by forehead taps with the 
typical quadriphasic negative-positive-negative-positive response (n1-p1-n2-p2) with normal latencies 
and amplitudes. B: Cervical vestibular evoked myogenic potentials in a healthy subject elicited by 
forehead taps with a typical biphasic p13-n23 response of vestibular origin followed by a biphasic 
n34-p44 biphasic response with normal latencies and amplitudes. (Both tap-evoked oVEMP and 
cVEMP responses were obtained in our own neurovestibular research laboratory) * The trigger delay, as 
used in forehead tap evoked ocular and cervical vestibular evoked myogenic potentials, apparently leads 
to the shortening of both oVEMP and cVEMP latencies (e.g. when compared to acoustically elicited 
oVEMP and cVEMP latencies). 
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Historically the clinical research concerning VEMPs has so far focused on peripheral 
neurovestibular disorders. However the field of VEMP testing is rapidly expanding 
with an increasing interest for central neurological disorders. For an overview on 
VEMP abnormalities in mainly peripheral vestibular disorders we refer to Brantberg 
(2009)13. Reviews concerning VEMP abnormalities in central neurologic conditions 
are scarce, despite the growing number of clinical studies. In this paper, we present 
an overview concerning VEMP abnormalities in central neurological disorders, the 
interpretation of these VEMP results, and clinical application. In addition we stress 
the importance of applying a correct methodological procedure in future clinical 
VEMP research and clinical VEMP testing in individual patients. Therefore we 
critically assessed the available literature concerning VEMP abnormalities in central 
neurological disorders to get an impression of the applied technical aspects as well as 
the methodology and the interpretation of the studies in order to estimate the level 
of diagnostic evidence.
 
Demyelinating Disease
Multiple sclerosis (MS) is a chronic, demyelinating disease of the central nervous 
system. MS is a leading cause of disability in young adults with a prevalence of 1 out 
of 1000 persons living in northern Europe14. 
The presence of AC-cVEMP abnormalities varies from 31 to 70 percent in the 
literature; delayed p13 often in combination with increased n23 latencies are the most 
common abnormalities, followed by absent responses. There was a significant 
correlation between abnormal AC-cVEMPs and vestibular symptoms, expanded 
disability status scale (EDSS) equal or greater than 5.5, EDSS brainstem functional 
system score equal or greater than 1, and a longer disease duration (i.e. disease duration 
more than 10 years)15–24.
Recently, studies of acoustic air-conducted ocular vestibular evoked myogenic 
potentials were reported (AC-oVEMPs). The presence of abnormal responses ranged 
from 37.5 to 69 percent19,21,25. Increased latency of the response was the most prevalent 
abnormality followed by absent AC-oVEMPs. Rosengren and Colebatch (2011)25 
studied AC-oVEMPs in thirteen patients (twelve of whom had MS and one had a 
presumed vascular aetiology) with internuclear ophthalmoplegia (INO). In the 
patients with a unilateral INO three out of five (60 percent) had abnormal AC-
oVEMPs. In one patient the side of the INO was in concordance with the absent 
AC-oVEMPs response and in the other two patients AC-oVEMPs were bilaterally 
absent or delayed. All of the eight tested patients with bilateral INO showed abnormal 
AC-oVEMPs (five patients showed bilaterally abnormal AC-oVEMPs responses and 
three patients showed unilaterally abnormal AC-oVEMPs responses). The patients 
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with a partial INO (slowing of ipsilesional ocular adduction rather than failure of 
adduction) had prolonged latencies of the AC-oVEMPs, and patients with a complete 
INO showed absent AC-oVEMPs25.
Most of these studies include a limited number of patients (i.e. mostly between the 
20 and 40 patients with a few exceptions). The variation in sensitivity between the 
studies could possibly be explained by a difference in patient’s disease characteristics 
(i.e. some studies contain substantially more multiple sclerosis patients with a longer 
disease duration, or have more patients with progressive forms of multiple sclerosis 
compared to other studies). Most studies15,16,18,20–23 also did not correct the cVEMP 
amplitudes (i.e. by using the rectified mean pre-stimulus EMG background signal 
at the desired level of sternocleidomastoid muscle contraction to correct the raw 
p13-n23 amplitude from the unrectified EMG signal), or by standardizing the level 
of sternocleidomastoid muscle contraction (e.g. for instance with a pressure gauge 
to assure that the same level of force is applied during muscle contraction at both 
sides and between measurements as described by Vanspauwen et al. 2006)26,27. The 
raw p13-n23 cVEMP amplitudes cannot be reliably compared between groups, sides 
within the same patient, or between measurements within the same patient at 
different moments if standardization and correcting methods, as described above, 
are not used (i.e. changes in the level of muscle contraction will influence the raw 
p13-n23 amplitude)3,28. Sartucci and Logi (2002)23 examined cVEMPs in fifteen MS 
patients; the control group consisted of fifteen volunteers in whom the mean age 
was considerably lower than the MS group (i.e. 44.5 ± 10.3 years in the MS group, 
and 26.7 ± 3.4 years in the control group). The difference in the raw p13n23 amplitudes 
between groups was significantly different (i.e. with lower amplitudes in the MS 
group).  However, the cVEMP amplitudes, especially when acoustically elicited, 
decrease with advancing age29,30, so differences in p13-n23 amplitudes should be 
interpreted with caution when the study group and control group are not age-
matched. 
 
The hypothesis is that relatively small demyelinating lesions in the brainstem can cause 
conduction slowing in the vestibulo-spinal and vestibulo-ocular pathways resulting 
in prolonged latencies with a more or less preserved configuration of the responses. 
When demyelination is more pronounced, a partial conduction block may occur 
(possibly in combination with axonal damage) and a lack of synchronisation will 
induce phase cancellation and a decrease in amplitude and prolongation of latencies 
of the vestibulo-ocular and vestibulo-spinal responses. More severe demyelination 
eventually accompanied by secondary axonal loss will eventually result in a total 
conduction block with absence of responses18,22,23,25.
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In our opinion cVEMP and oVEMP may be useful in the evaluation of brainstem 
involvement in MS patients with neurovestibular complaints without brainstem 
lesions on cerebral MRI. So in our clinic VEMPs are used in these patients as a 
complementary diagnostic tool when the cerebral MRI is not explanatory. At this 
moment there is no place for standard VEMP testing in all MS patients, or in the 
work-up of new suspected MS patients due to the lack of treatment consequences. 
VEMP research can be relevant in evaluating brainstem involvement in early MS and 
clinically isolated syndromes or during the course of the disease for further 
pathophysiological clarification and may play a part in selecting those patients with 
clinically isolated syndromes that would benefit from early immunomodulatory 
treatment.
Cerebrovascular Disease
Ischemic stroke occurring in the vascular territory of the vertebrobasilar arterial system 
accounts for approximately 20 percent of all ischemic strokes. The most common 
aetiologies are atherosclerotic large and/or small vessel disease. Vertebrobasilar stroke 
can present with a variety of symptoms such as vertigo, ataxia, dysphagia, hearing loss, 
diplopia, alterations of consciousness, and hemiparesis which may rapidly progress to 
quadriparesis or locked-in-syndrome31. Several small case series in the literature describe 
VEMP abnormalities in patients with recent vertebrobasilar artery strokes. 
Abnormalities of AC-cVEMPs in localized brainstem strokes range from 11 percent 
to 100 percent, however most reside between the 40 and 50 percent; for BCV-oVEMPs 
and AC-oVEMPs the range is from 50 to 80 percent. Most VEMP abnormalities 
consist of absent responses followed by a diminished amplitude, however, delayed 
latencies were described in a few patients32–40. Kim et al. (2014)35 described AC-oVEMP 
and AC-cVEMP studies in twelve patients with isolated internuclear ophthalmoplegias 
due to vascular origin. Eight of the twelve patients (67 percent) had abnormal AC-
oVEMPs and 25 percent had abnormal AC-cVEMPs. The abnormal AC-oVEMPs 
were on the lesion side in 86 percent of the patients (seven out of eight patients) in 
combination with a contraversive ocular tilt reaction (i.e. triad consisting of skew-
deviation, ocular torsion and head tilt)35. In another case series by Oh et al. (2013)36 
fifty-two patients with acute brainstem strokes were studied with AC-oVEMPs. Out 
of five patients with midbrain strokes, four had abnormal AC-oVEMPs, mostly in 
combination with a contraversive ocular tilt reaction and tilt in the subjective visual 
vertical. Out of twenty-eight patients with a pontine stroke, sixteen (57 percent) had 
abnormal AC-oVEMPs. Responses in medullary strokes were abnormal in 47 percent 
of the patients. The authors concluded that abnormal AC-oVEMPs are associated with 
lesions of the dorsomedial tegmentum from the upper medulla oblongata to the 
201804 proefschrift Jeroen Venhovens.indd   27 26-01-18   15:06
PART ONE  |  Chapter 2
28
midbrain, where the medial longitudinal fasciculus, the crossed ventral tegmental tract, 
oculomotor nuclei, and oculomotor neurons are located36. 
VEMP studies in cerebellar infarctions concern small case series and most patients 
also have concomitant brainstem involvement32,34,37,38,40. Weng and Young (2014)40 
studied AC-cVEMPs and BCV-oVEMPs in eighteen patients with anterior inferior 
cerebellar artery (AICA) strokes and posterior inferior cerebellar artery (PICA) strokes. 
AC-cVEMPs were abnormal in 50 percent in PICA stroke patients and 66 percent 
in AICA stroke patients; while BCV-oVEMPs were abnormal in 86 percent and 100 
percent,  respectively (i.e. only one AICA patient had BCV-oVEMPs testing which 
was abnormal). Abnormal caloric testing in combination with abnormal visual 
suppression tests were present in 93 percent of the patients. Electronystagmography 
also showed high rates of abnormal visual pursuit, saccade, and optokinetic nystagmus 
disturbances in both stroke groups varying from 67 to 100 percent. There was, 
however, a significant difference between the two groups concerning hearing loss 
complaints and documented mean hearing levels greater than 25 decibels (i.e. 100 
percent of the AICA stroke patients and 9 percent of the PICA stroke patients, 
respectively)40. From this it can be concluded that the higher AC-cVEMPs and BCV-
oVEMPs abnormality rate in AICA stroke patients may partially be explained by 
labyrinthine ischemia (because the proximal branches of the AICA supply the 
labyrinthine artery). This conclusion is supported by the result of Ahn et al. (2011)32 
who studied AC-cVEMPs in sixteen AICA stroke patients. Eight out of sixteen 
patients (50 percent) had abnormal AC-cVEMPs (i.e. absent responses or a decrease 
in amplitude). In the AICA stroke group with abnormal AC-cVEMPs 75 percent had 
sensorineural hearing loss and a canal paresis on caloric testing versus none of the 
patients with normal AC-oVEMPs (however, 25 percent of the latter group had an 
isolated sensorineural hearing loss and 13 percent had an isolated canal paresis)32. 
Choi et al. (2014)34 studied AC-cVEMPs and BCV-oVEMPs in patients with acute 
unilateral cerebellar infarction (i.e. PICA strokes in 63 percent, combined PICA and 
superior cerebellar artery strokes in 26 percent, superior cerebellar artery strokes in 7 
percent, and AICA strokes in 4 percent). The patients with an ocular tilt reaction had 
significantly more AC-cVEMP and BCV-oVEMP abnormalities versus patients 
without an ocular tilt reaction (eleven out of fifteen patients versus three out of twelve 
patients, respectively)34. The authors concluded that the cerebellum has lateralized 
effects on the otolithic modulation as shown by the asymmetric VEMP responses in 
unilateral cerebellar lesions. However, the absence of correlation between the 
directionality in the ocular tilt reaction and the VEMP abnormalities concerning the 
lesion side suggests deactivation or disinhibition of the cerebellar structures involved 
in otolithic modulation34. However in a small case series by Su and Young (2011)38 
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oVEMPs and cVEMPs in all patients with localized cerebellar lesions (i.e. three 
patients with a localized cerebellar meningioma, and one patient with a metastatic 
adenocarcinoma, all without brainstem involvement on MRI) were normal. This in 
contrast to the other eight patients with cerebellar lesions and adjacent brainstem 
involvement, whom showed a high degree of VEMP abnormalities (i.e. 88 percent 
of the oVEMPs where abnormal, and 75 percent of the cVEMPs were abnormal). 
Also Pollak et al. (2006)37 could not demonstrate significant cVEMP differences in 
patients with a cerebellar stroke. The topic whether localized cerebellar lesions without 
adjacent brainstem involvement cause VEMP abnormalities has therefore yet to be 
clarified, with additional research needed.
Miwa et al. (2013)41 described five patients with superficial siderosis of the central 
nervous system (SSCNS). This disorder is the result of iron deposition from 
hemosiderin onto the surface of the brain and around some of the cranial nerves (i.e. 
the nerves and brain tissue areas rich in microglia as they synthesize ferritin) due to 
continued bleeding into the subarachnoid space. SSCNS is clinically characterized 
by sensorineural hearing loss, ataxia, dizziness, pyramidal signs and dementia. AC-
cVEMPs were abnormal in three out of five patients and calorics were abnormal in 
all patients. There was a correlation between the results of AC-cVEMP measurements 
and the caloric testing; when AC-cVEMPs were absent, the caloric testing showed 
areflexia. When the AC-cVEMPs were normal, caloric testing showed hyporeflexia. 
There also was a correlation between the duration of the disease and vestibular function 
testing. Disease duration ranging from weeks to months showed normal AC-cVEMPs 
and a duration longer than several years showed absent AC-cVEMPs. This could be 
the result of secondary fibre tract degeneration. Brain MRI, however, showed 
hemosiderin depositions around the vestibulocochlear nerve in just one patient, so 
the authors concluded that the symptoms and vestibular dysfunction in SSCNS are 
probably the result of a peripheral labyrinthine problem due to secondary decreased 
blood flow41. Ushio et al. (2006)42 described a patient with SSCNS for a period of 21 
years who also had absent AC-cVEMPs. 
Most studies however share the same methodological problems as described earlier in 
the chapter on demyelinating disorders, namely that a) cVEMP raw p13-n23 
amplitudes were neither corrected nor was the level of muscle contraction 
standardized32,34,37–41,43, and b) most small case series do not have a control group, 
whereby the laboratory’s own normative data were used as a reference36,39–41,43, from 
which the group characteristics (e.g. (mean) age) were unknown. Therefore amplitude 
differences between the groups or inter-aural differences should be interpreted with 
caution. Also Choi et al. (2014)34 described remarkable cVEMP and oVEMP 
amplitude differences (i.e. oVEMP amplitudes were about five times higher than the 
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cVEMP amplitudes in both the control group and the patient group), whereas mostly 
the cVEMP amplitudes in the literature and in our laboratory are much higher than 
the oVEMP amplitudes.
In our opinion VEMP testing should not be performed in the standard work-up of 
all stroke patients. However when confronted with a patient with acute vertigo, it can 
be difficult sometimes to differentiate between a peripheral or central neurovestibular 
disorder. Kattah et al. (2009)44 described the HINTS examination (i.e. normal head-
impulse test, direction-changing nystagmus, and/or skew deviation) which, as stated 
by the authors, has a high sensitivity of 100 percent and high specificity of 96 percent 
for the clinical detection of a vestibular disorder of central neurological origin in 
patients with a moderate to high risk acute vestibular syndrome (AVS). However, the 
study has some methodological issues whereby some patients with an AVS could 
possibly have been falsely classified as having a peripheral vestibular disorder instead 
of a central one. The peripheral AVS group in the study was defined as, a) the absence 
of acute stroke in the brainstem or cerebellum by MRI with diffusion-weighted 
imaging (DWI), b) lack of clinical signs on serial examination, and c) characteristic 
clinical course. However, this study and other studies44–46 have concluded that cerebral 
MRI with DWI has a limited sensitivity of about 90 percent for the detection of 
brainstem infarctions. Also, a) patients in the peripheral AVS group were not followed 
with serial MRI scans in contrast to some patients of the central AVS group, and b) 
the authors stated that the diagnosis of the peripheral AVS group was confirmed by 
caloric testing. However, caloric testing showed vestibular paresis in nineteen of the 
twenty-five patients (i.e. which is highly suggestive of a peripheral vestibular disorder), 
but showed a directional preponderance in three patients (i.e. which gives no 
information to the localisation of the problem concerning a possible peripheral or 
central origin), and could not be performed in another three patients. Therefore the 
diagnosis of a peripheral origin AVS could not be confirmed in six of the twenty-five 
patients (i.e. 24 percent), which could, in combination with the lack of serial MRI 
follow-up, have potentially lead to the misclassification of AVS patients (i.e. to the 
peripheral AVS group instead of the central origin group) and a falsely high sensitivity 
of the HINTS examination. Also, the HINTS examination was performed by an 
experienced neuro-ophthalmological subspecialist, and only moderate to high risk 
AVS patients were included in the study. Therefore the findings of this study cannot 
be easily generalized to the everyday practice of patients with acute vertigo visiting 
the emergency department. Additional VEMP testing possibly in combination with 
videonystagmography testing and calorics can be helpful in localizing the lesion in 
individual patients (with normal cerebral MRI with DWI results). VEMPs also are 
important for research. The issue of VEMP abnormalities in localized cerebellar lesions 
still has to be clarified as the literature on this topic has shown conflicting results. 
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VEMPs might also be applied to assess the risk of falling in the individual patient. 
However the additional prognostic value of VEMP testing to assess the risk of falling 
has to be studied prospectively in a large cohort.
Neurodegenerative Disease
The literature concerning VEMPs in neurodegenerative disorders is very scarce. 
Takegoshi and Murofushi (2000)47 studied collic VEMPs in spinocerebellar 
degeneration. Ten patients with olivo-ponto-cerebellar atrophy (OPCA), three patients 
with cortical cerebellar atrophy (CCA), and three patients with Machado-Joseph 
disease (MJD) were studied with AC-cVEMPs and caloric testing. Machado-Joseph 
disease is also known as spinocerebellar ataxia type 3. MJD is an autosomal dominantly 
inherited disease (i.e. expansion of abnormal CAG trinucleotide repeats in the 
Ataxin-3 gene) which is characterized by cerebellar ataxia, pyramidal signs and 
progressive external ophthalmoplegia with square wave jerks. The disease is, to varying 
degrees, also associated with symptoms of polyneuropathy (sensory more than motor), 
bulging eyes, dystonia, and diplopia. OPCA is characterized by progressive cerebellar 
ataxia in combination with pyramidal and extrapyramidal signs whereas CCA only 
has signs of a pure progressive cerebellar ataxia without any additional symptoms. 
Patients with OPCA and CCA had reasonably well preserved AC-cVEMPs but in 
MJD VEMPs were abnormal in two out of three patients; in one patient AC-cVEMPs 
were bilaterally absent, in another AC-cVEMPs were absent on one side and 
significantly prolonged on the other side. The AC-VEMPs correlated with the caloric 
responses in these patients; when the AC-cVEMPs were absent, the caloric responses 
were absent too, and the caloric response in the patient with delayed AC-cVEMPs 
was decreased)47. 
The study performed by Takegoshi and Murofushi (2000)47 has three methodological 
shortcomings which are, a) the study population is very small, however it should be 
noted that the studied spinocerebellar disorders are rare therefore making it difficult 
to obtain larger groups, b) the subjects in the patient group were not matched for age 
with the control group, and c) the level of muscle contraction of the sternocleidomastoid 
muscles was neither standardized nor was the raw p13-n23 amplitude corrected, as 
discussed above. 
Pollak et al. (2009)48 described AC-cVEMP studies in fifty-four Parkinson’s disease 
patients. In this group twenty patients had unilaterally absent responses (37 percent) 
and four had bilaterally absent responses (7.4 percent). However, mean peak latencies 
did not significantly differ between the groups with preserved AC-cVEMPs. There 
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was no significant correlation between AC-cVEMPs and demographic features, disease 
characteristics and treatment modalities. Patients on anti-depressive agents, however, 
had a higher chance of having abnormal AC-cVEMPs; fifteen of the twenty-four 
patients with depression and anti-depressive medication had abnormal AC-cVEMPs, 
which was significant. 
Progressive supranuclear palsy (PSP) is a parkinsonian disorder which distinguishes 
itself from Parkinson’s disease by frequent falls, vertical gaze paresis or delayed vertical 
saccades, and dysphagia. Liao et al. (2008)49 found normal AC-cVEMP latencies in 
nine out of ten PSP patients. However, the amplitude of the p13-n23 complex was 
significantly lower in the PSP group compared to the control group. The authors 
concluded that the diminished vestibulo-collic reflex in the PSP group could 
contribute to the higher fall-rate in PSP patients. 
The study performed by Pollak et al. (2009)48 has two main shortcomings 
methodologically which are, a) the age difference between the control group and the 
Parkinson’s disease group is significantly lower in favour of the control group (i.e. in 
the control group 46 ± 15 years, and in the Parkinson’s disease group 66 ± 10 years; 
p <0.001), and b) the level of muscle contraction of the sternocleidomastoid muscles 
was neither standardized nor was the raw p13-n23 amplitude corrected. The authors 
mentioned the first shortcoming in their discussion, but not the second. Therefore 
the amplitude difference between the groups is not reliable. It should be stated that 
the authors only concluded that the cVEMPs were abnormal if the latency was 
significantly prolonged or if the response was absent (i.e. amplitude differences were 
not an argument). Thereby amplitude differences between the groups, possibly with 
lower amplitudes in Parkinson’s disease patients as a hallmark of a reduced vestibulo-
collic reflex, could be missed. The study performed by Liao et al. (2008)49 matched 
the PSP patients and the correct control group concerning age, but also in this study 
the raw cVEMP amplitudes were neither corrected nor standardized. The authors 
concluded that the mean p13-n23 amplitude differed significantly between the PSP 
and control group; however without correct standardization or correction of the raw 
amplitude this difference is far less reliable than stated by the authors and could 
possibly be influenced by technical issues and/or patient non-compliance.
Birdane et al. (2012)50 studied AC-cVEMPs in ten patients with mild cognitive 
impairment, ten with mild to moderate Alzheimer’s disease, and ten with moderate 
to severe Alzheimer’s disease. Neurofibrillary tangles and amyloid plaques in the 
neocortex are believed to be pathognomic for Alzheimer’s disease. AC-cVEMPs could 
be obtained bilaterally in eighteen of the thirty patients, however the amplitudes were 
decreased when compared to the control group and the latencies were prolonged in 
all of them. In eight patients (26.6 percent) only unilateral responses could be obtained 
and in four patients AC-cVEMPs were bilaterally absent. The p13 latency was 
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significantly prolonged and the p13-n23 amplitude was significantly lower in the 
patient group compared to the control subjects. The level of muscle contraction of 
the sternocleidomastoid muscle was not standardized nor was the raw p13-n23 
amplitude corrected. Therefore amplitude differences should be interpreted with 
caution and are less reliable than stated by the authors, possibly because cognitive 
problems in patients with neurodegenerative disorders can easily result in non-
compliance, secondarily resulting in decreased amplitudes or absent responses. The 
authors concluded that the brainstem too, was affected early in the course of 
Alzheimer’s disease and that AC-cVEMPs could be a sensitive method and helpful in 
the early diagnosis of Alzheimer’s disease50.
In our opinion at this moment there is no place for standard VEMP testing in patients 
with neurodegenerative disorders. However when confronted with a patient who has 
a neurodegenerative disorder with complaints of dizziness, which cannot be accurately 
localized to either the peripheral or central neurovestibular system, VEMPs can have 
additional localizing value in combination with video-, or electronystagmography. 
VEMP testing in patients with neurodegenerative disorders, however, is important 
for research, because the extent of brainstem involvement can be examined during 
the evolution of the disease possibly giving insights into the pathophysiological 
evolution of the disorder.
Space occupying lesions in the posterior fossa
Vestibular schwannomas are benign tumors arising from the vestibulocochlear nerve 
(VIIIth cranial nerve). These tumors most often arise from the superior or inferior 
vestibular nerve, although they sometimes arise from the cochlear nerve. The sensitivity 
of abnormal ipsilesional AC-cVEMPs in vestibular schwannomas is 64 to 80 percent 
according to the literature51–61. The most common finding is an ipsilaterally absent 
AC-cVEMP which is five times more common than decreased AC-cVEMPs 
amplitudes13. Most studies51–54,57,59–61 have the same methodological shortcoming that 
raw p13-n23 cVEMP amplitudes are not corrected (i.e. by dividing them through 
the rectified pre-stimulus EMG signal) or standardized, as discussed earlier. Therefore 
amplitude differences between groups or between sides within the same patient 
(i.e. when cVEMPs are measured ipsilaterally during monaural acoustic stimulation) 
should be cautiously interpreted. 
Ocular vestibular evoked myogenic potentials elicited by bone-conducted vibration 
(BCV-oVEMPs) were studied recently by Iwasaki et al. (2010)53 and Kinoshita et al. 
201804 proefschrift Jeroen Venhovens.indd   33 26-01-18   15:06
PART ONE  |  Chapter 2
34
(2013)54. The authors concluded that the sensitivity of BCV-oVEMPs for contralateral 
abnormal results was 63 percent and 86 percent, respectively53,54. Chiarovano et al. 
(2014)51 also studied cVEMPs and oVEMPs elicited by both bone-, and air-conducted 
stimuli in patients with vestibular schwannomas. The overall sensitivity of combined 
BCV- and AC-oVEMPs in their study was 62 percent (i.e. thirty-nine of the sixty-
three patients) for the detection of superior vestibular nerve dysfunction in patients 
with vestibular schwannomas. Some studies did not find a positive correlation between 
vestibular schwannoma tumor size and AC-cVEMPs13,55,60,61. However, patients with 
larger extracanicular vestibular schwannomas tended to have a higher chance of having 
abnormal AC-cVEMPs in comparison with patients with a smaller tumor size (when 
intracanalicular vestibular schwannomas were excluded)60,61. Patients with smaller 
vestibular schwannomas with a mean tumor size between 10 and 19 millimetres 
without evident brainstem compression could have p13 latency prolongation in AC-
cVEMPs, possibly due to underlying demyelination of the inferior vestibular nerve. 
Patients with larger extracanicular vestibular schwannomas with brainstem 
compression also had p13 latency prolongation in AC-cVEMPs, perhaps due to 
additional demyelinating lesions in the central vestibulospinal tract. So, increased 
latency of the AC-cVEMPs could be explained by demyelination of the peripheral 
and or central neurovestibular pathways13,60,61. Hu et al. (2009)33 showed that the 
chance of finding vestibular schwannomas with a tumor size of more than 2.5 
centimetres increased when both AC-cVEMPs and calorics were absent. Brantberg 
(2009)13 concluded that vestibular evoked myogenic potentials are at present not a 
useful screening test for vestibular schwannomas because of their limited sensitivity, 
but they can be used for pre-operative vestibular function assessment or for additional 
follow-up and monitoring in a ‘watchful waiting’ policy13. 
After vestibular schwannomas, meningiomas are the second most common tumors 
in the cerebellopontine angle. Hu et al. (2009)33 described five patients with large 
cerebellopontine angle meningiomas (i.e. mean tumor size more than 2.5 centimetres), 
however cVEMPs were only measured in four patients, three with abnormal AC-
cVEMPs and one patient with bilaterally absent AC-cVEMPs who also had bilateral 
absent calorics. This is in contrast to the abnormal AC-cVEMPs and calorics in all 
five patients with large vestibular schwannomas. Su and Young (2011)38 studied three 
patients with posterior fossa meningiomas with localized cerebellar involvement 
without brainstem or vestibular nerve compression. All had normal BCV-oVEMPs 
and AC-cVEMPs38. From these studies one could conclude that VEMPs are more 
sensitive than calorics in detecting vestibulocochlear nerve involvement due to external 
compression (as is the case in large cerebellopontine angle meningioma) and that 
VEMPs and caloric testing are equally reliable in detecting parenchymal 
vestibulocochlear nerve involvement in vestibular schwannomas. These results should 
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be cautiously interpreted as, a) the case series only contain a very small number of 
patients33,38, b) there was no age-matched control group in the study by Hu et al. 
(2009)33, c) the control group in the study by Su and Young (2011)38 was not matched 
for age (i.e. the mean age of the control group was significantly lower), and d) 
abnormal VEMPs were defined as absent or delayed responses, so amplitude differences 
between the groups, possibly as a hallmark of vestibular nerve dysfunction, could 
possibly be missed. 
Chu et al. (2006)62 described cVEMPs in three patients with epidermoid cysts in the 
posterior fossa. Epidermoid cysts are slowly progressive congenital tumors derived 
from ectopic epithelial cells during neural tube closure and are most often located in 
the cerebellopontine angle. One patient had cVEMPs testing prior to and after surgery. 
Pre-operative cVEMPs testing showed absent ipsilateral responses which normalized 
after surgery in concordance with the caloric testing (ipsilesional pre-operative canal 
paresis which was post-operatively restored to normal). The other two patients only 
had post-operative cVEMP testing which showed normal responses in one patient 
and bilaterally delayed responses in the other patient (possibly due to brainstem 
demyelination secondary to compression)62. 
In three out of four patients with cerebellar tumors (i.e. two patients had metastatic 
adenocarcinomas, one patient had a metastatic neuroblastoma, and one patient had 
a primary lymphoma) Su and Young (2011)38 found abnormal BCV-oVEMPs and 
AC-cVEMPs (i.e. two patients had bilaterally absent BCV-oVEMPs and AC-cVEMPs, 
one patient had ipsilesional delayed BCV-oVEMPs and AC-cVEMPs, and one patient 
had bilateral normal responses). However in this study the patients with abnormal 
VEMPs had extended cerebellar lesions with brainstem compression and the patient 
with normal VEMPs had a localized cerebellar lesion without brainstem involvement38. 
The authors concluded that abnormal oVEMPs could differentiate between isolated 
cerebellar involvement (i.e. normal oVEMPs) and cerebellar lesions with adjacent 
brainstem involvement (i.e. abnormal oVEMPs), but these conclusions should be 
interpreted with caution, because of the very limited number of patients included in 
this series, and the lack of an age-matched control group as discussed earlier.
In our opinion VEMPs should not be used as a screenings test or in the standard work-
up of patients with vestibular schwannomas or other posterior fossa tumours because 
of their limited sensitivity. MRI with gadolinium contrast is the investigation of first 
choice. However when patients have contra-indications for MRI (e.g. extreme 
claustrophobia, and some types of pacemakers or metal cardiac valve prostheses) 
screening by means of VEMP testing in combination with cerebral computed 
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tomography (CT) could be considered as an alternative. We agree with Brantberg 
(2009)13 that VEMPs could be useful in monitoring patients with vestibular 
schwannomas in whom a ‘watchful-waiting’ policy is applied without additional 
therapy (e.g. no radiation or surgical therapy). Chiarovano et al. (2014)51 also concluded 
that the role of VEMPs in vestibular schwannomas was not primarily relevant for the 
diagnosis (e.g. however, some of their patients were discovered through VEMP testing), 
but mainly in the function testing of the vestibular nerve prior to treatment. Pre-
operative VEMP testing measures the residual superior and inferior vestibular nerve 
function, and thus can give insight into the necessity for post-treatment vestibular 
rehabilitation. Also, baseline VEMP measurements in radiosurgically treated vestibular 
schwannoma patients can be helpful in the detection of further vestibular nerve 
compromise when confronted with progressive decline of balance51. However more 
long-term prospective follow-up research is needed in large groups to ascertain the 
additional prognostic or follow-up value of VEMP testing after a therapeutic 
intervention (i.e. radiation therapy or surgery) or rehabilitation therapy.
Migraine
Liao and Young (2004)63 described AC-cVEMPs, electronystagmography and calorics 
in twenty patients with migraine with brainstem aura (formerly known as basilar-type 
migraine) during the headache attack. The control group in this study was not clearly 
defined (e.g. the mean age is not known) and the laboratory’s own upper limit cVEMP 
values for the latencies and amplitudes were used. Therefore the comparison of the 
results of migraine with brainstem aura patients with the control group should be 
interpreted with caution. Migraine with brainstem aura is a rare form of migraine 
with aura symptoms and signs which seem to originate from the brainstem. During 
the migraine attack 30 percent of the eye-tracking tests, 45 percent of the optokinetic 
response tests, 55 percent of the caloric tests (five out of twenty patients had a 
unilateral canal paresis, four out of twenty patients had a directional preponderance, 
and two patients had a combination of both), and 50 percent of the AC-cVEMPs 
were abnormal. Most prominent were absent responses in the AC-cVEMPs; eight out 
of twenty patients had absent unilateral or bilateral responses followed by delayed 
responses (two out of twenty patients had bilaterally delayed response and one patient 
had a unilaterally delayed response in combination with a unilaterally absent response). 
When AC-cVEMPs and caloric testing results were combined 75 percent of the 
patients had abnormal results (four patients had abnormal AC-cVEMPS only, five 
patients had abnormal calorics only, and six patients had abnormal calorics and AC-
cVEMPs). The authors concluded that these findings were due to ischemia, attributed 
to hypoperfusion in the territory of the basilar artery63. However, most experts 
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nowadays believe that an aura also in migraine with brainstem aura is due to cortical 
spreading depression in which vascular constriction is a secondary phenomenon 
resulting from the neuronal depression due to neurometabolic coupling, instead of 
the previous explanation64,65.
Vestibular migraine (VM) is an uncommon subtype of migraine with paroxysmal 
vertigo as the main symptom. Recently, this disorder was included in the third edition 
of the International Classification of Headaches Disorders (ICHD-III). The estimated 
prevalence of VM is 9 percent of all the migraine patients66,67. Although the 
pathophysiology of VM is unknown, some experts believe that this disorder shares a 
pathophysiological mechanism with Menière’s disease (i.e. endolymphatic hydrops). 
Murofushi et al. (2009)68 studied eleven patients with migraine associated vertigo, 
eleven patients with Menière’s disease, and eight control subjects. Healthy control 
subjects had an average negative slope concerning the p13-n23 amplitudes when 
acoustic tone-burst stimulation at 500 Hertz was compared with 1000 Hertz 
stimulation (i.e. higher amplitudes at 500 Hertz). However, patients with Menière’s 
disease had an average positive slope when the affected ear was tested with an 
amplitude shift towards the 1000 Hertz. The results of the unaffected ear were similar 
to those of the healthy subjects. On average, the VM patients showed a very mild 
negative slope, however, 27 percent of the VM patients showed a positive slope with 
an amplitude shift towards the 1000 Hertz, comparable with the Menière’s disease 
patients. The authors concluded that the underlying pathophysiology concerning VM 
is probably heterogeneous, but might share a link with Menière’s disease68. The authors 
also concluded that the mean corrected p13-n23 amplitude of the affected side of the 
Menière’s disease patients was significantly lower than the VM and control group at 
500 Hz and 1000 Hz auditive tone-burst stimulation. However the mean age differed 
between groups (i.e. Menière’s disease group 58.2 years, VM 41.3 years, and control 
group 37.3 years). Therefore, the amplitudes of the Menière’s disease group cannot 
be reliably compared to the other groups, even though cVEMP amplitudes were 
corrected for contraction force. This conclusion was also drawn by Baier and Dieterich 
(2009)69 from a study in sixty-three patients with VM and sixteen patients with 
Menière’s disease. In this study 52 percent of the VM patients and 25 percent of the 
Menière’s disease patients had abnormal AC-cVEMPs (i.e. bilaterally reduced 
amplitudes) which could also suggest a possible underlying pathophysiological link 
between these diseases69. Abnormal responses in AC-cVEMPs testing in VM patients 
in literature ranged from 23 to 68 percent. The most common abnormality was a 
reduction in amplitude with mainly preserved latencies, followed by absent 
responses69–72. 
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Most of the studies described above share the same methodological shortcoming, i.e. 
that studied groups were relatively small, and that the raw unrectified cVEMP p13-n23 
amplitude was neither standardized nor corrected63,70–72, as described earlier, with the 
exception of the studies performed by Baier and Dieterich (2009)69, and Murofushi 
et al. (2009)68. Therefore amplitude differences between the groups should be 
interpreted with caution. The study performed by Zuniga et al. (2012)72 tested vertical 
saccades in both eyes prior to oVEMP testing. The electrodes beneath the eyes were 
replaced if the unrectified EMG signal amplitude during vertical saccades differed by 
more than 25 percent. This seams an interesting method for further oVEMP 
standardization, but further studies on this topic have to be performed in larger groups 
to confirm this finding.
In our opinion nowadays standard VEMP testing in headache patients has no 
additional value in the individual patient, because diagnostic or therapeutic 
consequences are lacking. VEMP testing in different headache disorders can be 
important for research, e.g. further elucidating the underlying pathophysiology, as 
shown in Menière’s disease and vestibular migraine. 
In summary
VEMP abnormalities in central neurological disorders may be seen rather often, but 
are not disease specific and usually do not give any information about the underlying 
aetiology. In contrast, VEMPs may give important localising information (table 1). 
In peripheral labyrinthine disorders like Menière’s disease or labyrinthine infarction 
one may expect a reduction in amplitude or even disappearance of the ipsilateral 
cVEMP response and/or contralateral oVEMP response. In contrast to this, increased 
amplitudes and lower thresholds of the contralateral oVEMP and of the ipsilateral 
cVEMP may be found in the superior semicircular canal dehiscence syndrome, 
however, amplitude differences in oVEMPs are more pronounced. The cause of this 
phenomenon is supposed to be due to an increased sound and pressure sensitivity of 
the ipsilateral labyrinth in comparison to the contralateral side73,74. Delayed latencies 
are in general considered to be of retro-labyrinthine origin. As discussed elsewhere in 
this paper, VEMP changes are obviously not only affected by peripheral labyrinthine 
end-organ damage or vestibular nerve pathology, but also central neurological disorders 
can affect both cVEMP and oVEMP results. So VEMP testing done for suspected 
peripheral vestibular disorders should therefore be interpreted with great care when 
central neurological disorders, that could also possibly affect the VEMP results, are 
present and vice versa.
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Tabel 1. Expected VEMP abnormalities at different anatomical localizations.
Anatomical 
localization 
Expected abnormalities
oVEMP cVEMP
Peripheral labyrinth Contralesionally absent responses 
or low amplitudes.
Ipsilesionally absent responses or 
low amplitudes.
Vestibular nerve Contralesionally absent responses 
or low amplitudes >> latency 
prolongation (due to external 
vestibular nerve compression).
Ipsilesionally absent responses or 
low amplitudes >> latency 
prolongation (due to external 
vestibular nerve compression).
Brainstem Pontine Contralesionally or bilaterally 
absent responses, low amplitudes, 
or latency prolongation are all 
possible.
Bilaterally normal responses are 
expected. However, with more 
caudal disease progression absent 
responses, low amplitudes, or 
latency prolongation, mostly 
ipsilesional or bilateral, are all 
possible.
Medulla Bilaterally normal responses are 
expected. However, with more 
rostral disease progression absent 
responses, low amplitudes, or 
latency prolongation mostly 
contralesional or bilateral are all 
possible.
Ipsilesionally or bilaterally absent 
responses, low amplitudes, or 
latency prolongation are all 
possible.
Cerebellar Normal responses or possibly 
contralesionally absent responses 
or amplitude differences (both 
decrease and increase are possible).
Normal responses or possibly 
ipsilesionally absent responses or 
amplitude differences (both 
decrease and increase are possible).
Due to the physiology as described elsewhere in this paper, abnormalities limited to 
the inferior or superior vestibular nerve will result in either ipsilateral cVEMP or 
contralateral oVEMP abnormalities, respectively. This may be of help in differentiating 
these type of lesions. Most commonly decreased or abolished responses are found, as 
for example in vestibular schwannomas or vestibular neuritis3. Less commonly, 
prolongation of latencies can also occur, due to focal demyelination, as for example 
can be seen in external vestibular nerve compression due to a cerebellopontine angle 
meningioma38.
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In brainstem and cerebellar disorders, abnormal VEMPs may be found due to 
demyelination or axonal degeneration. Obviously, significant prolongation of 
response latencies is associated most commonly with demyelination and decreased 
response amplitudes with conduction block or axonal damage. As can be concluded 
from figure 1 for instance, brainstem lesions rostral to the decussation of the 
ascending medial longitudinal fasciculus (MLF) will most likely result in ipsilesionally 
absent oVEMPs, when concerning a unilateral lesion with normal cVEMPs (e.g. in 
case of internuclear ophthalmoplegia)25,35. However, lesions caudal to the decussation 
of the ascending MLF and rostral to the vestibular nuclei will result in absent 
oVEMPs contralateral to the lesions, however, with bilaterally preserved and normal 
cVEMPs. In a similar way careful interpretation of VEMP abnormalities would be 
expected to lead to localization. The literature concerning VEMP abnormalities in 
localized cerebellar lesions is conflicting, because some studies could not show 
significant VEMP changes in localized cerebellar disorders without adjacent brainstem 
involvement, as discussed earlier37,38.
VEMPs may be easily performed by well-trained neurophysiological technicians, are 
well tolerated by patients, and therefore readily applicable in the outpatient clinic. 
Methodology and a correct control group are very important as stated before. 
Recently international guidelines were published concerning the clinical application 
as well as standardization of cVEMPs2 in research as well as the clinical testing. In 
addition, we would like to advice the acquisition of data from a healthy age-matched 
control group, particularly as amplitudes in acoustically elicited VEMPs decrease at 
advanced ages2,29,30.
Most studies, as discussed in the previous sections, share the same methodological 
and technical concerns which are, a) that the control group sometimes is not correctly 
matched for age to the patient group, b) that most case-series do not have a control 
group at all whereby laboratory’s own reference values were used, c) that the VEMP 
amplitudes mostly are not standardized for force of contraction, nor corrected by 
the raw mean pre-stimulus EMG background signal, and d) that most studies 
consisted of small sized case-series or case-control studies with a few exceptions 
(mostly concerning diagnostic studies in Multiple Sclerosis, vestibular schwannomas, 
and vertebrobasilar stroke). Therefore the diagnostic level of evidence for all studies 
according to the Oxford Centre of Evidence-Based Medicine mainly consists of level 
4 evidence with a few exceptions, reaching a maximum level of 2b evidence, whereby 
the total diagnostic evidence is very limited concerning VEMPs in central neurological 
disorders.
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In our opinion the primary indication for VEMP testing should be in patients in 
whom the neurovestibular complaints cannot reliably be localized to the central or 
peripheral neurovestibular system clinically nor with (video)nystagmography or brain 
MRI. Also VEMP testing can help in confirming central nervous system involvement 
in patients with vestibular complaints with normal brain MRI. At the moment 
VEMPs are more important in research than in clinical practice in most patients with 
central nervous system disorders. However, VEMPs can have additional diagnostic 
value in a selected group of patients, as discussed earlier. Suggestions for future research 
have been made in the previous sections.
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Abstract
Objective
The aims of the study are to determine the intra-, interobserver, and the test re-
test reliability of the cervical and ocular vestibular evoked myogenic potentials 
(VEMPs). 
Methods
Twenty healthy subjects underwent acoustically and forehead tap elicited cervical 
and ocular VEMPs. The measurements were repeated one week later. 
Results
The intra- and interobserver reliability of both ocular and cervical VEMPs is 
excellent. The test re-test reliability of the raw p13n23 peak-to-peak amplitudes 
of the cervical VEMPs is excellent (ICC: 0.76, 0.87) and the p13 latencies show 
a good reliability (ICC: 0.56, 0.73). The raw n1p1 peak-to-peak amplitudes of 
the ocular VEMPs show a fair-to-good test re-test reliability (ICC: 0.51, 0.64) 
and the n1 and p1 latencies show a poor reliability (ICC: -0.17 ≤ x ≤ 0.44). 
Conclusions
The intra- and interobserver reliability of the cervical and ocular VEMPs is 
excellent. The raw ocular and cervical VEMP peak-to-peak amplitudes are the 
most reliable parameters, followed by the cervical VEMP latencies. The ocular 
VEMP latencies shows a poor test re-test reliability. The individual VEMP results, 
however, remained within normal limits despite the test re-test variability.
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Introduction
The classical detailed neurophysiological examination of the vestibular system can be 
time consuming, uncomfortable for the patient, and is in most laboratories limited 
to the examination of the horizontal semicircular canal and the superior vestibular 
nerve by means of calorics and rotary chair testing in combination with electro- or 
videonystagmography. Vestibular evoked myogenic potentials (VEMPs), however, 
emerged as a test suitable for detailed neurophysiological examination of both the 
peripheral and the central vestibular system in the last two decades, and can be easily 
performed by well-trained technicians. VEMP responses can be divided into a cervical 
and an ocular response; which can be elicited by short intense auditory stimuli (i.e. 
tone bursts or clicks), bone-conducted vibration, forehead taps, and galvanic 
stimulation1–6. We refer to the review by Brantberg (2009)7 for a detailed overview 
concerning VEMP abnormalities in peripheral vestibular disorders, and to the recent 
review article by Venhovens et al. (2016)5 for an overview concerning VEMP 
abnormalities resulting from central nervous system disorders. 
The cervical VEMPs can be recorded by placing active surface electrodes over the 
middle upper part of both sternocleidomastoid (SCM) muscle bellies with a reference 
electrode on the sternal manubrium. The SCM muscles, however, first have to be 
tightened before cervical VEMPs can be obtained. This can be done by rotating the 
head to the contralateral side in monaural stimulation (in auditory stimuli such as 
short tone bursts or clicks) or by flexing the neck (which can be used in all the types 
of stimuli and especially when bilateral responses need to be obtained simultaneously, 
for instance when tap stimulation is applied at Fz). The primary end-organ responsible 
for generating cervical VEMPs is the sacculus. The signal is thereafter transmitted to 
the vestibular nuclei through the inferior vestibular nerve, and subsequently to the 
ipsilateral sternocleidomastoid muscle through the medial vestibulospinal tract, the 
cervical motor neurons, and the accessory nerve. The cervical VEMPs represent an 
inhibitory motor response in the ipsilateral sternocleidomastoid muscle, and measure 
the integrity of the vestibulo-collic reflex2–5,8,9.   
The ocular VEMPs can be recorded by placing active surface electrodes beneath the 
infraorbital margin and reference electrodes 1 to 2 centimetres below them. The ocular 
VEMPs measure the integrity of the vestibulo-ocular reflex and represent an excitatory 
motor response of the inferior oblique muscles, mainly in the contralateral side in 
reference to the stimulated ear. The best method of measuring these ocular VEMP 
responses is to have the subject maintain an upward gaze during the stimulation. The 
exact otolith end-organ for generating the ocular VEMPs is uncertain (i.e. if it is the 
sacculus, the utriculus, or a combination of the both) and this matter is extensively 
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debated in the literature. However, there is consensus that the responsible afferents 
travel through the superior division of the vestibular nerve to the vestibular nuclei, 
and subsequently to the contralateral oculomotor nerve through the medial 
longitudinal fasciculus and the oculomotor nucleus before reaching the contralateral 
inferior oblique muscle2–6,8–14.
The primary aim of our study is to determine the intra- and interobserver reliability 
concerning the assessments of individual ocular and cervical VEMP recordings by 
three different experienced clinical neurophysiologists. We hypothesize that the 
reliability within and between observers needs to be good to excellent in order for the 
VEMPs to be a reliable clinical tool; to our knowledge this is the first study on this 
important aspect of clinical VEMP judgement. The secondary aim of our study is to 
assess the test re-test reliability for ocular and cervical VEMPs by both acoustic and 
bone conducted stimuli; to our knowledge, only one prior study has been published 
concerning this reliability in ocular VEMPs15 and a few studies concerning the cervical 
VEMPs15–22, some of which show conflicting results as will be discussed later on. We 
calculated the reliability between the two consecutive tests, which were separated by 
one week, and compared the outcomes with the existing literature.
Methodology
Study Participants
Twenty volunteers, none of whom had a relevant medical history (they did not have 
neurological, otological, and/or ophthalmological diseases or complaints), were 
included. The study was approved by the local medical ethical committee and all 
volunteers signed an informed consent. Twenty participants (mean age 24, range 21-
29 years old, 8 men) were included in the study.
Tests and procedure
The VEMPs were recorded using Ag/AgCl surface electrodes; abrasive gel was applied 
on the recording sites before the surface electrodes were placed to assure that the 
impedance levels were well below the maximum of 2kΩ. The difference between the 
side-to-side impedance levels had to be less than 1kΩ to assure that the possible 
amplitude differences between both sides could not be attributed to differences in the 
background noise. The active electrodes for the cervical VEMP were applied on 
symmetrical sites over the upper middle part of the muscle belly of the 
sternocleidomastoid muscles and the reference electrode was placed on the sternal 
manubrium. The active electrodes for the ocular VEMP were symmetrically placed 
over the middle part of the lower eyelids, on top of the inferior orbital edges, and the 
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reference electrodes were placed 2 centimeters below them. The ground electrode was 
placed at Cz. All subjects had a subjective hearing threshold of less than 20 dB for 
acoustic 500Hz tone bursts.
The cervical and ocular VEMPs were measured separately and were recorded with a 
Medelec Synergy T-EP5 EMG/EP machine (Oxford Medical Instruments, Surrey, 
England). All evoked responses were amplified, band-pass filtered (10-1000Hz), 
notch-filtered (50Hz), and averaged. We did not apply artifact rejection during the 
recording and did not perform electromyographic analysis on the pre-stimulus signal. 
The cervical and ocular VEMPs were elicited by: a) forehead taps at Fz with a triggered 
reflex hammer (Aesculap, type AC012C, Oxford Medical Instruments, England), and 
subsequently b) acoustically by means of short tone bursts with an acoustically shielded 
headphone (TDH49P acoustically shielded headphone, Oxford Medical Instruments, 
England, rise/fall time: 1ms, plateau time 2ms, repetition rate 5Hz, frequency 500Hz, 
100dB NHL). For each trial, twenty forehead taps at Fz with a tap frequency of 1Hz 
(in tap evoked VEMPs) or two hundred acoustic stimuli were averaged. We checked 
three trials for reproducibility. 
During the cervical VEMP measurements, subjects were asked to sit upright and push 
their chins downward against an inflated blood pressure cuff (inflated to 60 mmHg) 
as proposed by Vanspauwen et al. (2006)20,21. A target pressure of 80 mm Hg was 
chosen with a maximal variance of 2 mmHg above or below this target pressure, as 
was visually monitored by both the examiner and the subject using the manometer. 
We interrupted the VEMP measurements every 30 seconds of contraction, with a 
pause of 30 seconds, to minimize the effects of muscle strain23. The peak latencies (in 
milliseconds, ms) of the p13 and n23 were measured, as well as the p13-n23 peak-
to-peak amplitude (in microvolts, mcV).
During the ocular VEMP measurements, subjects were asked to sit upright and to 
look upwards at a fixed target (upward eye deviation of about 30 degrees). The peak 
latencies (in milliseconds, ms) of the n1, p1, n2, and p2 were measured, as were the 
n1-p1 and n2-p2 peak-to-peak amplitudes (in microvolts, mcV).
The four VEMP tests (forehead tap and acoustically evoked cervical and ocular 
VEMPs) were performed at baseline in the subjects and all measurements were 
repeated one week later. 
Statistical analysis
The three experienced clinical neurophysiologists (JV, WV, and JM) had a consensus 
meeting prior to the start of the study, where the local guidelines concerning the ocular 
and cervical VEMP assessment were run through. The three clinical neurophysiologists 
received the individual unmarked VEMP traces of all the subjects in print and in 
duplicate (both the test and re-test traces), and they were asked to assess al traces for 
reproducibility and to place the markers on the prints. Afterwards, the corresponding 
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latencies and amplitudes of all the traces were calculated by the clinical 
neurophysiological research assistant and were entered into the SPSS 21.0 statistical 
database (by Mrs. P. Kap, SPSS software version 21.0, SPSS inc., USA). A significance 
level of 5 percent was adopted for each analysis.
The intra- and interobserver reliability was assessed by the intraclass correlation 
coefficient (ICC); a two way random effect model with absolute agreement and 
average measures was used for analysis. The same ICC ranking as in the other recent 
literature15,16,18,21,22 was adopted: ICC values above 0.75 represent excellent reliability, 
values between 0.4 and 0.75 represent fair-to-good reliability, and values below 0.4 
represent poor reliability. The intraclass correlation coefficient is considered to be the 
key statistical indicator of relative reliability21. 
The mean latencies (p13, n23, n1, p1, n2, and p2) and mean amplitudes (p13-n23, 
n1-p1, and n2-p2) for both the test and re-test were calculated by averaging the results 
of all three clinical neurophysiologists. The ICC two way random effect model with 
absolute agreement and average measures was also used for the test re-test reliability 
analysis, and the ICC ranking that was described above was adopted. 
Results
We refer to table 1 and 2 for the intra- and interobserver ICC values, for all three 
clinical neurophysiologists (WV, JV, and JM), for both the acoustically and forehead 
tap evoked cervical and ocular VEMPs. The overall reliability between the observers 
(interobserver reliability) is excellent for almost all ocular and cervical VEMP 
parameters with exception of the p2 latency reliability in the forehead tap evoked 
ocular VEMPs, which fluctuates between good and excellent. The overall intraobserver 
reliability too is excellent for most parameters, however particularly the n2 and p2 
forehead tap evoked ocular VEMP latencies fluctuate between poor, fair-to-good, and 
excellent reliability between the different clinical neurophysiologists.
We refer to table 3 for the test re-test results concerning the acoustically and forehead 
tap evoked cervical and ocular VEMPs. The ICC was calculated to evaluate the test 
re-test reliability of different VEMP parameters. The test re-test reliability of the p13 
latency in both acoustically and forehead tap evoked cervical VEMPs is overall good, 
with the p13n23 peak-to-peak amplitude having an excellent reliability in both. The 
overall test re-test reliability for both the acoustically and forehead tap evoked ocular 
VEMPs was poor concerning the latencies, fair-to-good for the acoustically elicited 
amplitudes, and good for forehead tap elicited amplitudes.
201804 proefschrift Jeroen Venhovens.indd   52 26-01-18   15:06
VEMPs: the intra-, interobserver and test re-test reliability
C
ha
pt
er
 3
53
Table 1. 
Intra- and interobserver reliability concerning the acoustically evoked VEMP test and re-test assessments 
done by three different experienced clinical neurophysiologists (WV, JV, and JM) and analysed by the 
intraclass correlation coefficient (ICC, two way random effect model, average measures, and absolute 
agreement). We refer to the text for further explanation. 
Acoustically evoked VEMPs (test) Acoustically evoked VEMPs
 (re-test)
WV* JV* JM* INTER** WV* JV* JM* INTER**
Cervical VEMPs:
p13 latency
n23 latency
p13-n23 amplitude
0.99
0.98
0.98
0.97
0.98
0.98
0.99
0.93
0.98
0.99
0.96
0.99
0.90
0.90
0.96
0.91
0.91
0.96
0.85
0.80
0.99
0.99
0.95
0.99
Ocular VEMPs:
n1 latency
p1 latency
n2 latency
p2 latency
n1-p1 amplitude
n2-p2 amplitude
0.85
0.97
0.95
0.95
0.99
0.99
0.98
0.99
0.98
0.97
0.99
0.97
0.95
0.98
0.95
0.95
0.99
0.98
0.96
0.99
0.97
0.97
0.99
0.99
0.87
0.72
0.70
0.92
0.96
0.99
0.98
0.99
0.99
0.94
0.97
0.99
0.98
0.98
0.88
0.91
0.99
0.99
0.90
0.87
0.82
0.90
0.99
0.99
* Intraobserver reliability ICC values. ** Interobserver reliability ICC values between the three different 
clinical neurophysiologists.
Table 2.
Intra- and interobserver reliability concerning the forehead tap evoked VEMP test and re-test assessments 
done by three different experienced clinical neurophysiologists (WV, JV, and JM) and analysed by the 
intraclass correlation coefficient (ICC, two way random effect model, average measures, and absolute 
agreement). We refer to the text for further explanation.
Forehead tap evoked VEMPs (test) Acoustically evoked VEMPs 
(re-test)
WV* JV* JM* INTER** WV* JV* JM* INTER**
Cervical VEMPs:
p13 latency
n23 latency
p13-n23 amplitude
0.90
0.98
0.99
0.81
0.98
0.98
0.87
0.80
0.99
0.95
0.98
0.99
0.92
0.99
0.99
0.99
0.99
0.98
0.99
0.96
0.98
0.99
0.94
0.98
Ocular VEMPs:
n1 latency
p1 latency
n2 latency
p2 latency
n1-p1 amplitude
n2-p2 amplitude
0.99
0.99
0.99
0.96
0.78
0.99
0.83
0.97
0.99
0.99
0.99
0.99
0.73
0.98
0.98
0.76
0.99
0.99
0.80
0.80
0.80
0.76
0.89
0.99
0.86
0.82
0.33
0.47
0.99
0.99
0.77
0.86
0.73
0.89
0.99
0.99
0.75
0.64
0.47
0.49
0.99
0.99
0.90
0.88
0.83
0.70
0.99
0.99
* Intraobserver reliability ICC values. ** Interobserver reliability ICC values between the three different 
clinical neurophysiologists. 
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Table 3.
Test re-test reliability concerning the acoustically and forehead tap evoked VEMP assessments done by 
three different experienced clinical neurophysiologists (WV, JV, and JM) and analysed by the intraclass 
correlation coefficient (ICC, two way random effect model, average measures, and absolute agreement). 
We refer to the text for further explanation.
First test Re-test ICC***
Mean (SD)* Range** Mean (SD)* Range**
cVEMP (acoustic)
p13 latency (ms)
n23 latency (ms)
p13n23 amplitude (mcV)
15.7 (2.2)
25.1 (2.8)
55.5 (58.2)
11.3-20.1
19.5-30.7
< 171.9
15.9 (2.2)
24.9 (2.6)
61.4 (78.9)
11.5-20.3
19.7-30.1
< 219.2
0.56
0.23
0.87
cVEMP (forehead tap)
p13 latency (ms)
n23 latency (ms)
p13n23 amplitude (mcV)
15.0 (3.0)
25.2 (2.7)
180.0 (131.8)
9.0-21.0
19.8-30.6
< 443.6
16.5 (3.3)
25.0 (3.0)
161.4 (75.4)
9.9-23.1
19.0-21.0
< 312.2
0.73
0.74
0.76
oVEMP (acoustic)
n1 latency (ms)
p1 latency (ms)
n2 latency (ms)
p2 latency (ms)
n1p1 amplitude (mcV)
n2p2 amplitude (mcV)
12.1 (2.2)
17.8 (2.3)
24.5 (3.2)
31.1 (4.6)
4.9 (6.1)
4.9 (4.0)
7.7-16.5
13.2-22.4
18.1-30.9
21.9-40.3
< 17.1
< 12.9
11.9 (2.0)
17.2 (2.3)
22.6 (2.8)
28.2 (4.1)
3.6 (3.9)
3.5 (2.9)
7.9-15.9
12.6-21.8
17.0-28.2
20.0-36.4
< 11.4
< 12.8
0.41
0.053
-0.44
-0.45
0.51
0.50
oVEMP (forehead tap)
n1 latency (ms)
p1 latency (ms)
n2 latency (ms)
p2 latency (ms)
n1p1 amplitude (mcV)
n2p2 amplitude (mcV)
7.4 (1.5)
12.0 (1.8)
17.4 (2.4)
22.9 (2.9)
16.4 (14.7)
27.3 (24.5)
4.4-10.4
8.4-15.6
12.6-22.2
17.1-28.7
< 45.8
< 76.3
7.9 (1.9)
12.0 (1.6)
17.1 (1.5)
22.4 (2.1)
18.1 (21.3)
44.0 (49.7)
4.1-11.7
8.8-15.2
14.1-20.1
18.2-26.6
< 60.7
< 143.4
-0.17
0.24
0.37
0.60
0.64
0.59
* Mean (standard deviation). ** Range is defined as the mean ± 2x standard deviations. *** Test re-test 
reliability ICC
Discussion
The primary aim of our study was to determine the intra- and interobserver reliability 
in and between three experienced clinical neurophysiologists (WV, JV, and JM). 
However, JV was the only clinical neurophysiologist with extensive experience in 
performing and assessing VEMPs, and the other two experienced clinical 
neurophysiologists (WV and JM) did not have any clinical experience in relation to 
the assessment of VEMPs. Therefore, a consensus meeting was planned at the 
beginning of our study, at which the local guidelines concerning ocular and cervical 
VEMP assessments were run through, in combination with a general instruction 
during a period of about forty-five minutes. Our results show that the intra- and 
interobserver reliability is excellent overall and especially for the most important 
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Table 4.
Comparison of the test re-test intraclass correlation coefficient (ICC) concerning the cervical and ocular 
VEMP parameters (i.e. p13, n23, n1, and p1 latencies; p13n23 and n1p1 peak-to-peak amplitudes) of 
the present study with the existing literature. We refer to the text for further explanation.
Cervical VEMP Ocular VEMP
p13* n23* p13n23** n1* p1* n1p1**
Forehead tap evoked
Present study
Nguyen et al. (2010) [8]
0.73
0.57
0.74
0.63
0.76
0.54
-0.17
-0.033
0.24
0.44
0.51
0.82
Acoustically evoked
Present study
Eleftheriadou et al. (2009) [5]
Isaradisaikul et al. (2008) [6]
Maes et al. (2009) [7]
Nguyen et al. (2010) [8]
Qian et al. (2012) [12]
Vanspauwen et al. (2009) [17]
Versino et al. (2001) [19]
0.56
0.61 / 0.78
0.37 / 0.64
0.78
0.33
0.80
0.63
0.69 / 0.74
0.23
0.83 / 0.76
0.65 / 0.70
0.82
0.71
0.93
0.81
0.89 / 0.86
0.87
0.92 / 0.89
0.86 / 0.81
0.90
0.68
0.97
0.77
0.83 / 0.76
-0.17
-
-
-
0.17
-
-
-
0.24
-
-
-
0.055
-
-
-
0.64
-
-
-
0.79
-
-
-
* cervical and ocular VEMP latencies. ** cervical and ocular VEMP peak-to-peak amplitudes. VEMP 
parameters with ICC values corresponding with an excellent reliability are printed in bold.
VEMP parameters (i.e. ocular VEMPs: n1, p1 latencies, and n1-p1 peak-to-peak 
amplitude; cervical VEMPs: p13, n23 latencies, and p13-n23 peak-to-peak amplitude). 
Therefore, we demonstrated that experienced clinical neurophysiologists without 
clinical experience in relation to VEMP assessment can be trained in a very short time 
period, and that these assessments show an excellent reliability both between and 
within the assessors. To our knowledge, we are the first to study this important aspect 
of clinical VEMP assessment.
The second aim was to study the test re-test reliability for both forehead tap and 
acoustically elicited cervical and ocular VEMPs. We refer to table 4 for the comparison 
of our cervical VEMP test re-test reliability results with the existing literature. The 
raw peak-to-peak p13n23 amplitude seems to be the most reliable cervical VEMP 
parameter with an excellent test re-test reliability in both forehead tap and acoustically 
elicited cervical VEMPs, followed by the forehead tap evoked cervical VEMP latencies 
which consistently show a good reliability. The test re-test reliability of the acoustically 
evoked cervical VEMP latencies show results that fluctuate between poor and excellent, 
which are inconsistent and therefore less reliable. The studies have a few methodological 
differences, which may possibly explain these different results: (a) that in our and in 
some other studies18,19,21,22 patients were tested sitting in an upright position while in 
other studies15,17 patients were tested in a recumbent position, (b) that some studies 
used unilateral sternocleidomastoid muscle (SCM) activation9,17,18,21 (i.e. by rotating 
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the head to the contralateral shoulder) while our and other studies15,19,22 used bilateral 
SCM activation (i.e. by flexing the neck), (c) that our and most other studies18,19,21,22 
used pressure gauges to maintain a chosen target pressure during the VEMP 
measurements while others15,17 did not (however, Nguyen et al. (2010)15 corrected 
the raw peak-to-peak p13n23 amplitude after the measurements by dividing the 
amplitude by the rectified pre-stimulus EMG activity), and (d) that most studies15,17,18,21 
used disposable surface electrodes without applying abrasive gel before attachment, 
possibly resulting in higher impedance levels which may have affected the measured 
VEMP parameters (and especially the amplitudes due to a higher level of background 
noise). However, it should be noted that all the acoustically and forehead tap evoked 
cervical VEMP parameters remained within normal limits despite the individual test 
re-test variability.
There was only one prior study which measured the test re-test variability in ocular 
VEMPs, which was performed by Nguyen et al. (2010)15. We refer to table 4 for the 
comparison of our ocular VEMP test re-test reliability results with the existing literature. 
Nguyen et al. (2010)15 concluded that the ocular VEMP test re-test reliability was 
excellent for n1p1 peak-to-peak amplitudes and poor for the n1 and p1 latencies. We 
agree that the reliability concerning acoustically and forehead tap elicited ocular VEMP 
latencies is poor, however we found a fair-to-good reliability concerning the n1p1 
amplitudes. There also were a few differences between the studies: (a) Nguyen et al. 
(2010)15 used disposable surface electrodes, as was discussed earlier, (b) electrode 
placement in the study by Nguyen et al. (2010)15 was checked by performing vertical 
saccades before ocular VEMP testing was performed, and the electrode placement was 
adjusted if there was an amplitude asymmetry of more than 25 percent resulting in an 
optimal electrode positioning, and (c) the patients in the study by Nguyen et al. 
(2010)15 were tested in a recumbent position while patients in our study were tested 
while sitting upright. These differences can possibly explain the differences in the test 
re-test reliability between our studies. Correction of the ocular VEMP electrode 
placement, if the vertical saccade amplitude asymmetry is greater than 25 percent in 
particular, as was done by Nguyen et al. (2010)15, could possibly significantly enhance 
the ocular VEMP n1p1 amplitude test re-test reliability. However, it should again be 
noted that, in spite of the test re-test variability, all the acoustically and forehead tap 
evoked ocular VEMP parameters remained within normal limits.
To conclude, the assessment of both cervical and ocular VEMPs shows an excellent 
intra- and interobserver reliability. The raw p13n23 peak-to-peak amplitude in cervical 
VEMPs seems to be the most stable and reliable parameter with an excellent test re-
test reliability, in which the p13 and n23 latencies show an overall good reliability. 
The raw n1p1 peak-to-peak amplitude in ocular VEMPs shows a good-to-excellent 
test re-test reliability, but the n1 and p1 latencies show an overall poor reliability. 
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It should, however, be noted that the results of all subjects of both the test and the 
re-test remained within normal limits notwithstanding their individual variability. 
Correction of the ocular VEMP electrode position, when vertical saccade amplitudes 
show a greater asymmetry than 25 percent, seems to be a particular interesting method 
for further ocular VEMP standardization. This correction is very likely to enhance 
the n1p1 ocular VEMP raw peak-to-peak amplitude test re-test reliability and we 
advise further research concerning this method for standardization.
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Abstract
Objective
The effects of different preset angle deviations on the static subjective visual 
vertical (SVV) were assessed in healthy volunteers as the primary aim. The 
secondary aim was to assess the test re-test variability of the static SVV in healthy 
volunteers. 
Methods
We recruited twenty-four healthy volunteers for the assessment of the static SVV 
under different preset angle deviations (i.e. 10, 20, and 30 degrees). In twenty 
other healthy volunteers the static SVV was tested and re-tested one week later.
Results
The static SVV did not differ significantly between the different preset angle 
deviations and between the test re-test measurements, at a group level. However, 
the combined clockwise deviations and counter-clockwise deviations differed 
significantly (Wilcoxon test, P≤0.001). Also, the individual absolute test re-test 
SVV differences showed clinically relevant variations.
Conclusions
The static SVV results are influenced by the side of the preset angle, however not 
by the preset angle deviation (i.e. deviations greater than 10 degrees). The test 
re-test static SVV outcomes are stable at a group level, however, show clinically 
relevant differences at the individual level. A robust static SVV protocol was 
described in this paper.
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Introduction
Graviception is the perception of a person’s orientation relative to the gravitational 
force, which can be measured by means of the subjective verticals. These subjective 
verticals can be divided into three tests, which are: a) the subjective visual vertical 
(SVV), b) the subjective postural vertical (SPV), and c) the subjective haptic vertical 
(SHV)1. These graviceptive pathways integrate the vestibular, the visual, and the 
proprioceptive inputs, and subsequently estimate the relative position of one’s body 
with respect to the absolute vertical, being the gravitational field of the earth2,7,9. The 
static SVV is an easily applicable test, which aims to detect otolithic imbalance and 
is a sensitive sign of brainstem dysfunction2. The static SVV is tested in complete 
darkness, in order for visual references to be excluded, and in an upright sitting 
position, so proprioceptive inputs contribute only minimally. Therefore, the static 
SVV is almost exclusively determined by the otolithic function and balance, as these 
are the main receptors in the peripheral vestibular system sensitive to gravitational 
forces (i.e. linear accelerations), with the semicircular canals being predominantly 
sensitive to angular accelerations7. 
Clinical static SVV testing is severely hampered by the lack of a uniform static SVV 
testing protocol, subsequently resulting in a marked heterogeneity concerning the 
SVV methodology in the literature. This makes generalization of the SVV findings 
in the literature very difficult. The main goal of this study is to further explore and 
propose a robust static SVV protocol, as was already studied in previous reports by 
Crevits et al. (2007, 2012)3,4. We defined three aims concerning the SVV methodology 
and reliability to study in more detail. 
The first aim of the present study was to measure the effects of different preset angle 
deviations on the final static SVV results in healthy volunteers. The second aim was 
to investigate the test re-test variability in a group of healthy volunteers, as this to our 
knowledge is unknown in the literature at this moment. We expected that the static 
SVV findings would not differ significantly at a group level, however, that small 
variations would very likely exist at an individual level. Therefore, we estimated the 
size of these variations and the possible clinical relevance. The third aim was to further 
explore and propose a robust study protocol combining monocular and binocular 
static SVV measurements by using the method of adjustment.
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Methods
Study Participants
From the neurological and clinical neurophysiological hospital staff forty-four healthy 
volunteers were recruited, none of whom had a relevant medical history (they did not 
have neurological, otological, and/or ophthalmological diseases or complaints). All 
had a normal vision or their vision had been corrected to normal with contact lenses 
or glasses. Clinical neurological and neurotological examinations (i.e. clinical 
oculomotor examination, testing for a skew-deviation with the alternate cover test, 
head-impulse test, Dix-Hallpike and supine roll tests) were normal in all healthy 
volunteers. The study was approved by the regional and local medical ethical 
committee (CMO Arnhem-Nijmegen, the Netherlands, number 2012/393) and all 
participants signed an informed consent. 
Twenty-four participants (mean age 27 years, range 22-34 years old, 9 men) were 
included in the study concerning different preset angle deviations and twenty other 
participants (mean age 24 years, range 21-32 years old, 8 men) were included in the 
test re-test study. 
Tests and procedure
Before measuring, the system was checked and if necessary adjusted to the absolute 
vertical with the aid of a plumb line. The subjects were sitting upright and 2 metres 
away from a viewing screen and we assured that both the (corrected) vision and the 
visual field of the subjects were sufficient to perform the test. The tests were performed 
in a totally darkened room to prevent visible landmarks from being seen, and the 
investigator operated the equipment in an adjacent room. Communication was 
possible by means of an intercom system. A laser projected straight red line (1.6 metres 
long and 5 millimetres wide) could be tilted and shown or taken away from a distance 
by the investigator (VERTITEST-II, Difra Instrumentation, Belgium). The subject 
was instructed to adjust the laser projected line to the gravitational vertical with a 
hand-held infrared remote controlled potentiometer (steps of 0.1˚/click and with an 
angle speed of 3.85˚/second when the button was pressed continuously) and to wait 
for 5 seconds at the chosen end position to reconsider and thereafter to vocally confirm 
this definitive position. After this definitive confirmation the line was taken away by 
the investigator and tilted to the new starting position before it was projected again 
to prevent the subject from being influenced. As a convention, deviations counter-
clockwise from the absolute vertical were indicated by negative values and deviations 
clockwise from the absolute vertical were indicated by positive values. The deviations 
were measured with a precision of 0.1˚.
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For the first study aim, the static SVV was tested with different preset angle starting 
deviations. The investigator tilted the laser projected red line at random to a preset 
angle that was either clockwise or counter-clockwise with a random starting deviation 
of 10, 20, or 30 degrees. Every starting deviation was tested four times so that a total 
of twelve measurements were obtained for every testing condition. The measurements 
were obtained under three different testing conditions in a random order: (i) both 
eyes viewing, (ii) right eye viewing, and (iii) left eye viewing. When all measurements 
in all the testing conditions were combined, a total of thirty-six static SVV results 
were obtained per subject. The lights were turned on for a few minutes after each 
viewing condition to check the head position and to prevent the SVV drift, resulting 
from being in the darkness for prolonged periods of time8.
For the second study aim, the static SVV was tested at baseline and one week later in 
the same subject to assess the test re-test variability. The investigator tilted the laser 
projected red line at random to a preset angle that was either clockwise or counter-
clockwise with an absolute starting deviation of 20 degrees. The measurements were 
taken twice so that four measurements were obtained for every testing condition, and 
measurements were also made for all the three testing conditions, as described above. 
Thus, a total of twelve static SVV results were obtained per assessment and the test 
was repeated one week later. Also in this study, the lights were turned on for a few 
minutes after each viewing condition to check the head position and to prevent the 
SVV drift, resulting from being in the darkness for prolonged periods of time8.
For the third study aim, based on our findings of the observed variance between the 
methodologies of prior studies, we explored and constructed a robust SVV study 
protocol, mainly to improve observer variation and to make the test results suitable 
for comparison among different laboratories.
Statistical analysis
Because of the non-parametrical distribution of the three dependent groups concerning 
the different angle preset deviations study (i.e. 10, 20, and 30 degrees), the Friedman 
test for repeated measures analysis of variance by ranks was applied for comparison. 
Concerning the two non-parametrically distributed and dependent groups in the test 
re-test study, the Wilcoxon test was applied for comparison.
Additionally, the test re-test reliability was assessed by the intraclass correlation 
coefficient (ICC); a two way random effect model with absolute agreement and 
average measures was used for analysis. The following ICC ranking was adopted: ICC 
values above 0.75 represent excellent reliability, values between 0.4 and 0.75 represent 
fair-to-good reliability, and values below 0.4 represent poor reliability. The intraclass 
correlation coefficient is considered to be the key statistical indicator of relative 
reliability. The statistical database software SPSS version 23.0 (SPSS inc., USA) was 
used for statistical analyses.
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Results
We refer to table 1 for the results concerning the different preset angle deviations 
study. The Friedman test for repeated measures analysis of variance by ranks showed 
a P-value < 0.001 for all binocular and monocular measurements in all different 
deviations (i.e. 10, 20, and 30 degrees) combined, meaning that some groups differed 
significantly. We subsequently ran a series of bivariate comparisons (Friedman test) 
for further analysis between the three groups themselves in different deviations (i.e. 
10, 20, and 30 degrees). The binocular and monocular measurements between the 
different deviations did not differ significantly according to the Friedman test. 
The combined clockwise preset angle measurements, which were taken from the three 
conditions (i.e. binocular and monocular viewing conditions), did not differ 
significantly either between the different deviations, according to the Friedman test. 
The same was true for the combined counter-clockwise preset angle measurements. 
There was, however, a statistically significant difference between the static SVV results 
of the combined clockwise preset angle measurements in comparison to the combined 
counter-clockwise measurements at all deviations separately and combined according 
to the Wilcoxon test, see table 2. The same was true for the test re-test measurements 
in the second part of the study (P = 0.005 for the first measurements, and P = 0.002 
for the re-test measurements, according to the Wilcoxon test).
We refer to table 3 for test re-test study results. At a group level there was no statistically 
significant difference between the test and re-test measurements, according to the 
Wilcoxon test. 
Table 1.
Effects of the different preset angle deviations study. The mean deviation for every condition was given 
in degrees (with the standard deviation). Abbreviations: CW, clockwise starting deviations; CCW, 
counter-clockwise starting deviations; OS, oculus sinister; OD, oculus dexter; SD, standard deviation. 
10 degrees
Mean (SD) [range]
20 degrees
Mean (SD) [range]
30 degrees
Mean (SD) [range]
P-Value
(Friedman 
test)
Binocular (CW+CCW)
OS (CW+CCW)
OD (CW+CCW)
CW (all conditions)
CCW (all conditions)
-0.4 (1.2) [-2.5-2.2]
-0.2 (1.4) [-3.4-3.1]
-0.2 (1.4) [-3.1-3.0]
0.1 (1.3) [-2.1-3.0]
-0.6 (1.2) [-2.4-2.3]
-0.2 (1.3) [-2.3-3.4]
-0.2 (1.7) [-3.0-4.0]
-0.3 (1.5) [-2.9-2.6]
0.2 (1.4) [-2.1-4.3]
-0.6 (1.3) [-2.9-2.6]
-0.2 (1.1) [-3.0-1.4]
-0.4 (1.6) [-3.1-3.4]
-0.2 (1.5) [-3.0-2.5]
0.1 (1.5) [-2.7-4.0]
-0.6 (1.0) [-3.0-2.5]
0.236
0.243
0.989
0.409
0.620
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Also the individual absolute mean differences and standard deviations were calculated 
for all volunteers, which were defined as: ABSOLUTE Δ = ABSOLUTE (SVVfirst test 
– SVVre-test). However, at the individual level the test re-test reliability according to 
the intraclass correlation coefficient was poor overall. 
Table 2.
Data concerning the clockwise starting deviations of all conditions in comparison with the counter-
clockwise starting deviations of all conditions. 
10 degrees
Mean (SD)
20 degrees
Mean (SD)
30 degrees
Mean (SD)
All deviations 
combined
CW (all conditions) 0.1 (1.3) 0.2 (1.4) 0.1 (1.5) 0.1 (1.4)
CCW (all conditions) -0.6 (1.2) -0.6 (1.3) -0.6 (1.0) -0.6 (1.2)
P-Value (Wilcoxon test) <0.001* <0.001* 0.001* <0.001*
* statistically significant differences with a P-value < 0.05. Abbreviations: CW, clockwise starting 
deviations; CCW, counter-clockwise starting deviations; SD, standard deviation. 
Table 3.
Test re-test study. The mean deviation for test was given in degrees (with standard deviation). Also the 
absolute individual differences between the test and the re-test were given (with the standard deviation) 
[and range, mean +/- 2x standard deviations]. Abbreviations: CW, clockwise starting deviations; CCW, 
counter-clockwise starting deviations; OS, oculus sinister; OD, oculus dexter; SD, standard deviation.
First Test
Mean (SD) [range]
Re-Test
Mean (SD) [range]
 Absolute 
Individual 
difference between 
tests Mean (SD) 
[range]
P-Value
Wilcoxon 
test
Intraclass 
Correlation 
Coefficient
Binocular (CW+CCW) -0.6 (1.1) [-2.7-1.5] -0.5 (1.1) [-2.3-1.6] 1.2 (1.0) [0-3.2] 0.705 -0.095
OS (CW+CCW) -0.1 (1.2) [-1.9-2.0] -0.3 (1.8) [-3.0-2.2] 1.4 (1.1) [0-3.6] 0.395 0.508
OD (CW+CCW) -0.4 (1.9) [-3.1-3.0] -0.5 (1.7) [-2.9-2.4] 2.0 (1.6) [0-5.2] 0.896 -0.240
CW (all conditions) -0.8 (1.3) [-2.4-2.6] -0.9 (1.2) [-2.7-2.5] 1.2 (1.1) [0-3.4] 0.601 0.234
CCW (all conditions) 0 (1.4) [-3.5-1.1] -0.1 (1.6) [-2.7-1.5] 1.5 (1.2) [0-3.9] 0.507 0.251
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Discussion
The first aim of our study was to assess the influence of different preset angle starting 
deviations (i.e. 10, 20 and 30 degrees) on the final static SVV outcomes. We found 
a statistically significant difference concerning the side of the preset angle (clockwise 
or counter-clockwise) in relation to the static SVV outcomes, with the static SVV 
measurements shifting towards the side of the preset angle. However, this SVV shift 
did not increase with increasing preset angle deviations, since the influence of the 10 
degrees preset angle starting deviation was the same as in the 20 and 30 degrees 
deviations. This is in concordance with the previously published papers by Pagarkar 
et al. (2008)6 and Baccini et al. (2014)1; both noted that the static SVV results were 
biased in the direction of the preset angle. Baccini et al. (2014)1 also tested the static 
SVV at different preset angle deviations (i.e. 1, 2, 4, 8, and 12 degrees according to 
the ADJ method) and concluded that the bias was more pronounced at higher 
deviations, without significant differences between 8 and 12 degrees of deviation. The 
authors speculated that deviations greater than 8 to 12 degrees do not result in a more 
pronounced bias of the final static SVV result. However, the methodology of their 
study in comparison to ours is markedly different, as we tested preset angle deviations 
with greater deviations and we also included monocular measurements besides the 
binocular measurements. We confirm the hypothesis of Baccini et al. (2014)1 that 
preset angle starting deviations greater than 12 degrees do not have an additional 
effect on the static SVV shift.
A few explanations for the shift of the static SVV towards the side of the preset angle 
have been proposed so far. The first explanation is the entrainment effect proposed 
and studied by Mezey et al. (2004)5. The entrainment effect states that a rotating 
environment in the roll plane, but also a rotating line, causes a torsional movement 
of the eyes in the same direction as the rotation itself. They concluded that this is a 
kind of optokinesis, which, however, could not be classified as an optokinetic 
nystagmus since the mean decay time of this effect is about 1 second after cessation 
of the stimulus and is therefore too slow. This effect is predominantly active in the 
last 10 degrees of the rotating stimulus in reference to the absolute vertical. Surprisingly, 
it is not significantly influenced by the presence of a visible non-rotating background. 
The entrainment effect is present when the laser projected line is both actively or 
passively rotated. Mezey et al (2004)5 stated that the otoliths have a dampening 
influence on this entrainment effect; therefore, patients with a disturbed vestibular 
function have an increased visual reliance and this in combination with the lowered 
dampening effect results in an increased entrainment effect, secondarily possibly 
resulting in greater static SVV deviations. This could be the reason why preset angle 
deviations greater than 8 to 12 degrees do not result in a greater deviation of the static 
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SVV towards the preset angle. In our opinion, however, there is one major problem 
with this explanation; the subjects in our study were instructed to reconsider their 
final line adjustments for 5 seconds after rotating before approving. In this period the 
line stood still and was not rotated. The entrainment effect could not play a significant 
part during this period of reconsideration, since the decay time of this effect is only 
1 second. Therefore, the ocular torsion had normalized during the time of 
reconsideration and the volunteers were, at that moment, still able to change the 
rotation of the line.
The second explanation is the uncertainty theory1, which states that volunteers rotate 
the line towards the point at which they are uncertain whether the perceived line is 
already vertical. This uncertainty range is variable between healthy persons and extends 
from clockwise to counter-clockwise and also encloses the absolute vertical. Most 
people stop rotating the line when they just entered this uncertainty range and mostly 
without further rotation, until the moment that they perceive the line as directing 
towards the opposite side, before re-adjusting the line to their subjective vertical. We 
support Baccini et al. (2014)1, that the uncertainty theory in combination with the 
entrainment effect is the most likely explanation for the static SVV bias towards the 
preset angle. We hypothesize that the subject is at first biased by the entrainment 
effect, which could possibly increase the subject’s uncertainty range during rotation, 
and is then possibly hesitant to second guess his or her first choice when the 
entrainment effect subsides. However, we have to state that the hypothesis above is 
purely speculative and we do not have definitive proof for confirmation. 
A tilt in the static SVV could also be induced by tilting the head and/or the body. 
The E-effect was first described by Muller in 1916; a moderate lateral tilt of the head 
resulted in a tilt of the static SVV to the contralateral side. A more outspoken lateral 
tilt of the head and/or the body resulted in a static SVV tilt to the ipsilateral side. This 
effect is called the A-effect and was first described by Aubert in 1861.9 Both effects 
are thought to be somatosensory in origin. In our study the subjects sat upright in a 
vertical position in front of the viewing screen and the position was regularly checked 
during and between the measurements, so we do not believe that either the E-effect 
or the A-effect can explain our findings. 
The second aim of our study was to assess the test re-test variability of the static SVV 
results. Our study could not demonstrate a significant difference of the static SVV 
results at a group level between the measurements. However, when the individual 
absolute differences were calculated, a variation could be seen. For instance, the 
absolute variation could be up to 3.2˚ for binocular viewing, up to 5.2˚ for monocular 
viewing, and up to 3.9˚ for all conditions starting with the counter-clockwise preset 
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angle. This was supported by the overall poor test re-test intraclass correlation 
coefficient results (ICC). To our knowledge, we are the first to note this individual 
static SVV test re-test variation. Tesio et al. (2011)10 also calculated the static SVV 
test re-test reliability showing excellent reliability in young healthy volunteers and fair 
to good reliability in older volunteers (ICC values were respectively 0.84 and 0.48). 
However, the study of Tesio et al.10 has some important differences in comparison to 
our study, being: a) our study was performed in a totally darkened room to prevent 
visual references from biasing the static SVV results while Tesio et al. performed their 
study in a dim-light surrounding, b) the preset angle deviation in our study was greater 
in comparison with the study of Tesio et al. (respectively 20 and 2.8 degrees) and from 
the results of Baccini et al.1 one can conclude that greater preset angle deviations will 
result in greater static SVV deviations (with a maximum of 8 degrees), and c) the 
volunteers in our study used a remote control to manually rotate the laser line, whereas 
the volunteers in the study by Tesio et al. only had vocal control over the line rotations 
(rotations were performed manually by a technician) possibly influencing the amount 
of ocular torsion.
A limitation of our study is that we only studied the test re-test variability in a group 
of a relatively young age, and not in other groups, especially of a more advanced age. 
Baccini et al. (2014)1 demonstrated that the static SVV measurements were age 
dependent, and that older persons had more difficulty in judging the absolute vertical, 
resulting in higher deviations away from the true vertical at higher preset angle 
deviations (i.e. 8 and 12 degrees). We started our study before the publication of 
Baccini et al. (2014)1, therefore we were not able to look for the older age group. The 
second limitation is the rather small size of the group of healthy volunteers. 
The third and last aim of our study was to explore and propose a robust static SVV 
study protocol, we refer to the methods section and table 4 for details. The static SVV 
is a psychophysical test, which can be measured by two methods. The most commonly 
used method is the adjustment method (ADJ), also known as the method of average 
error1. However, recently Baccini et al. (2014)1 extensively tested the static SVV by 
means of the two-alternative forced choice method (2AFC) in comparison to the 
ADJ. They concluded that the two testing methods were equally reliable, however, 
that the 2AFC method was, in their opinion, easier to perform and therefore more 
practical to use. The main problem concerning static SVV testing, at this moment, 
is the lack of a uniform testing protocol resulting in a marked heterogeneity in the 
testing procedures across the different studies. Therefore, the different study results 
cannot be easily generalized to the everyday clinical practice and furthermore a few 
methodological issues still need to be addressed. The present study was started before 
the publication of the article by Baccini et al. (2014)1; however, we feel that our study 
201804 proefschrift Jeroen Venhovens.indd   70 26-01-18   15:06
SVV: different preset angle deviations and test re-test reliability
C
ha
pt
er
 4
71
both supports and complements their findings, as was described earlier. We would 
like to refer to the methodology section and to prior papers by Crevits et al. (2007 
and 2012)3,4 for a detailed overview concerning our proposed SVV protocol. The 
main advantage of this approach is that both binocular and monocular assessments 
are systematically made, which may give insight into the nature of the static SVV 
deviations. For instance, patients with an ocular tilt reaction secondarily resulting 
from a brainstem infarction are very likely to show an SVV tilt in at least two static 
SVV conditions, including the binocular viewing condition2. Patients with a 
monocular torsion secondarily resulting from an isolated oblique or vertical ocular 
motor palsy are very likely to show an abnormal static SVV under ipsilateral monocular 
viewing conditions, but the other monocular and binocular viewing conditions are 
Table 4.
Static subjective visual vertical testing protocol.
Static Subjective Visual Vertical (SVV) testing protocol
Preset angle of 20 degrees (clockwise and counterclockwise) 
Binocular measurements
First measurement Second measurement
Clockwise preset angle B1 B2
Counter clockwise preset angle B3 B4
Monocular measurements (Oculus Sinister viewing)
First measurement Second measurement
Clockwise preset angle L1 L2
Counter clockwise preset angle L3 L4
Monocular measurements (Oculus Dexter viewing)
First measurement Second measurement
Clockwise preset angle R1 R2
Counter clockwise preset angle R3 R4
Results
Mean binocular deviation Mean (B1, B2, B3, B4)
Mean monocular oculus 
(sinister viewing deviation)
Mean (L1, L2, L3, L4)
Mean monocular oculus 
(dexter viewing deviation)
Mean (R1,R2, R3, R4)
Mean clockwise deviation Mean (B1, B2, L1, L2, R1, R2)
Mean counter-clockwise deviation Mean (B3, B4, L3, L4, R3, R4)
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expected to be normal3,4. The proposed study protocol is robust and incorporates 12 
static SVV measurements per subject, which can be easily performed clinically in 15 
to 20 minutes and which requires only minimal instrumentation. 
The reference values for the static SVV testing according to our own normative data 
by using the protocol discussed above are: a) for binocular measurements -3.0 ≤ x 
≤ +3.0 degrees; b) for monocular measurements -3.5 ≤ x ≤ +3.5 degrees; c) for counter-
clockwise measurements combined -5.0 ≤ x ≤ +2.0 degrees; and d) for clockwise 
measurements combined -2.0 ≤ x ≤ +5.0 degrees. However, we advise all laboratories 
to obtain their own reference values in different age groups, as the results of the static 
SVV are age dependent1. 
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Abstract
Objectives
Our primary aim was to determine the extent of vestibular dysfunction in patients 
with Parkinson’s disease (PD). Our secondary aim was to determine if vestibular 
dysfunction in PD is a risk factor for falling. The tertiary aim was to determine 
both the extent of vestibular dysfunction and if this dysfunction is a risk factor 
for falling in patients with atypical parkinsonism (AP). 
Methods
25 healthy subjects, 30 PD patients, and 14 AP patients were matched for age 
and gender in a case-control study design. All subjects underwent clinical 
neurological and neurotological assessments, cervical and ocular vestibular evoked 
myogenic potentials (VEMPs), brainstem auditory evoked potentials (BAEPs), 
subjective visual vertical measurements, and videonystagmography with caloric 
and rotatory chair stimulation.
Results
90% of PD patients (27 of 30) and all 14 AP patients had signs of vestibular 
dysfunction on laboratory examinations. The evoked potential (VEMPs and 
BAEPs) test results of PD patients showed significant prolongation of the p13, 
n1, interpeak III-V latencies on the symptomatic brainstem side (0.003 ≤ P ≤ 
0.019) compared to healthy subjects. Also, vestibular testing abnormalities were 
correlated with an increased risk for falling when fallers among PD and AP 
patients were compared to the non-fallers (P ≤ 0.001).
Conclusions
Vestibular dysfunction on vestibular laboratory testing is highly prevalent in both 
PD and AP patients compared to healthy subjects, and is associated with an 
increased risk for falling.
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Introduction
Postural instability and recurrent falls are a major problem in patients with Parkinson’s 
disease (PD), and even more so for patients presenting with a form of atypical 
parkinsonism (AP). Approximately 70% of patients with PD fall each year1 and about 
50% have at least two fall incidents annually2–4, some of which result in referrals to 
hospital for treatment of injuries5. Falls can induce a fear for renewed falls, resulting 
in a reduced quality of life because a self-imposed restriction of daily activities can 
lead to social isolation3,4.
A practical consensus-based overview concerning the risk factors and management of 
falls in PD emphasized the importance of a multifaceted and personalized approach6. 
One of the many contributing factors relates to vestibular dysfunction, but this aspect 
has thus far received rather limited attention in the literature. Indeed, among the few 
published studies on this subject, most only contained small case series or case-control 
studies7–11. The vestibular system and especially the vestibular nuclei in the brainstem 
play a crucial role in integrating multiple sensory information (i.e. visual, 
proprioceptive, and vestibular sensory input) and to subsequently adjust the outgoing 
motor response to maintain balance.
The primary aim of this study is to determine the extent of vestibular dysfunction in 
a group of patients with PD. Four different tests may be useful for this purpose, being: 
a) the subjective visual vertical (SVV), b) ocular and cervical vestibular evoked 
myogenic potentials (VEMP), c) the brainstem auditory evoked potentials (BAEP), 
and d) videonystagmography, rotatory chair tests, and caloric stimulation. The SVV 
test focusses on the graviceptive pathways (which integrate the vestibular, 
proprioceptive and visual inputs) and subsequently estimate the relative position of 
one’s body with respect to the absolute vertical (i.e. being the gravitational field of the 
earth)12–15. The result of the SVV test is almost exclusively determined by the otolithic 
function and balance, and also is a sensitive sign for brainstem dysfunction besides 
the peripheral vestibular otolithic imbalance12,16. The combination of both monocular 
and binocular static SVV measurements may give important insight into the nature 
of the SVV deviation. For instance patients with a monocular isolated vertical or 
oblique ocular motor palsy will very likely only show an abnormal static SVV deviation 
in the ipsilateral viewing condition; whereas patients with an ocular tilt reaction due 
to a brainstem infarction will very likely show abnormal static SVV deviations in at 
least two viewing conditions15. The cervical and ocular VEMP are easily applicable 
neurophysiological tests suitable for detailed evaluation of both the peripheral and 
central vestibular system. Careful interpretation of possible VEMP abnormalities can 
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be very helpful in localizing the vestibular abnormalities to the peripheral or central 
vestibular system17. The BAEP does not test the vestibular system, but the peripheral 
and central auditory systems; however, both the inner ear and the cochlear nerve are 
an integral part of the peripheral labyrinth and vestibulocochlear nerve. The BAEP is 
also able to detect and localize brainstem dysfunction. Therefore, the BAEP can be 
helpful in both localizing and determining the extent of the lesion in combination 
with the vestibular tests. (Video)nystagmography in combination with rotatory chair 
and caloric stimulation belong to the oldest and most widely used tests to determine 
the function of both the peripheral and central vestibular system, and oculomotor 
systems. However, these caloric and rotatory stimulation tests are mainly limited to 
the examination of the lateral semicircular canal, superior vestibular nerve and related 
central vestibular structures. So the combination of all tests described above (i.e. the 
vestibular testing battery) can give an insight into the function of both the peripheral 
(i.e. both the semicircular canals, otoliths, and vestibulocochlear nerve) and central 
vestibular apparatus. Also, abnormalities can be localized more easily to either the 
peripheral or central vestibular system when the vestibular battery tests are applied 
integrally.
The secondary aim is to test our hypothesis that vestibular system abnormalities are 
a risk factor for falling in PD patients. Finally, we want to determine the first two 
aims in a mixed group of AP patients. 
Methodology
Study Participants
Sixty-nine volunteers were included in this case-control study; 25 healthy controls 
(mean age 67, range 42-81 years, 15 men, 10 women), 30 PD patients (mean age 70, 
range 59-81 years, 26 men, 4 women, all fulfilling the UK Parkinson’s Disease Society 
Brain Bank criteria18), and 14 AP patients (mean age 68, range 52-81 years, 9 men, 
5 women, 6 multiple system atrophy, 3 progressive supranuclear palsy, and 5 vascular 
parkinsonism). The multiple system atrophy patients with predominant parkinsonism 
(MSA-P) all fulfilled the diagnostic criteria for probable MSA-P as proposed in the 
consensus statement by Gilman19. Supranuclear palsy patients (PSP) fulfilled the 
NINDS-SPSP criteria for possible PSP20. Vascular parkinsonism patients fulfilled the 
criteria of the Winikates and Jankovic vascular rating scale21. When patients took 
levodopa, they were tested during the subjective ON-state.
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The healthy controls and the patients did not have a relevant medical history (no 
relevant neurological, otological, ophthalmological diseases, and/or absence of 
moderate-to-severe cognitive problems) with the exception of PD or AP (in 
combination with a related cerebrovascular disorder in the vascular parkinsonism 
group). The controls were matched for age and gender to the PD and AP patients. 
All participants completed the study. The study was approved by the regional and 
local medical ethical committee (CMO Arnhem-Nijmegen, the Netherlands, number 
2012/393), was registered in the Dutch trial register (Nederlands Trial Register, NTR-
3928); all volunteers signed an informed consent. 
 
Clinical neurological tests and questionnaires
The participants were questioned about their medical history, medication, dizziness, 
gait and balance problems, prior falls and near falls, motor fluctuations, and freezing 
of gait. They underwent a detailed neurological and neurotological clinical examination 
with additional measurements for possible orthostatic hypotension (i.e. blood pressure 
measurement after lying supine for at least 15 minutes; followed by blood pressure 
measurements in a standing position after 1, 3, and 5 minutes). All PD and AP 
patients were tested during a regular medication on-state.
All participants completed: a) the 16 items activities-specific balance confidence scale 
(ABC-16), b) the dizziness handicap inventory (DHI), c) the Edinburgh handedness 
inventory, d) all subscales of the standardized unified Parkinson’s disease rating scale 
(UPDRS), e) the modified Hoehn and Yahr scale, f ) the Schwab and England activities 
of daily life (ADL) scale, and g) a standardized falls questionnaire22.
All participants received a Berg balance scale examination for quantitative balance 
assessment with additional pull-testing and functional reach testing for the assessment 
of the degree of postural imbalance. Partial postural imbalance was defined as a normal 
functional reach test in combination with an abnormal pull-test (i.e. sudden 
unexpected forceful backward shoulder pull without any specific prior instructions 
other than to remain standing upright23; the patient was able to recover balance in 
more than two backward steps). Complete postural imbalance was defined as an 
abnormal pull-test: the patient would have fallen down if the examiner had not been 
present behind the patient to catch him/her during the fall. Patients that are informed 
in more detail about this test tend to shift their centre of mass more anterior by leaning 
forwards in anticipation of the backward shoulder pull, which makes the test less 
reliable. For this reason patients were not informed in more detail prior to the test.
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Laboratory tests
Brainstem Auditory Evoked Potentials (BAEP)
BAEPs were recorded by using Ag/AgCl-surface electrodes, and abrasive gel was 
applied before electrode placement to ensure impedance levels below 2 kΩ, with a 
maximal side-to-side impedance difference of 1 kΩ. Acoustic stimuli consisted of 80 
dBnHL, +/- polarity, clicks. Each click lasted 0.1 ms and was delivered monaurally 
with a repetition rate of 9.8 Hz through a calibrated headphone (TDH49P acoustically 
shielded headphone, Oxford Medical Instruments, England), while 40 dBnHL white 
noise was delivered to the contralateral ear. The active electrodes were positioned 
bilaterally pre-auricular, the reference electrode at Cz, and the ground electrode was 
positioned at Fpz. BAEPs were recorded with a Medelec Synergy T-EP5 EMG/EP 
machine (Oxford Medical Instruments, Surrey, England); two averages of 1000 stimuli 
each (bandpass filtered 300-1000Hz, notch-filtered and without artifact rejection) 
were compared for reproducibility. The latencies of peaks I, II, III, IV, and V, and the 
interpeak latencies of I-III, III-V, I-IV were analyzed. 
Vestibular Evoked Myogenic Potentials (VEMP)
The methodology of both cervical and ocular VEMP testing have been described in 
detail previously24,17. All VEMPs were recorded using Ag/AgCl-surface electrodes; 
abrasive gel was applied before attaching the electrodes to ensure that the impedance 
levels were below 2kΩ, with a maximal side-to-side impedance difference of 1kΩ. The 
ground electrode was placed at Cz. For cervical VEMP recording the active electrodes 
were placed symmetrically over the upper middle part of the sternocleidomastoid 
muscle bellies with the reference electrode over the sternal manubrium. The patients 
were asked to sit upright and to push their chins downward against an inflated blood 
pressure cuff  (inflated to a baseline pressure of 60 mmHg), as proposed by Vanspauwen 
et al. (2006)25. A target pressure of 80 mmHg was chosen with a maximal variance of 
2 mmHg above or below this target pressure, which was visually monitored by both 
the examiner and the subject using the manometer. We interrupted the VEMP 
measurements every 30 seconds of contraction, with a pause of 30 seconds, to minimize 
the effects of muscle strain26. The peak latencies (in milliseconds, ms) of the p13 and 
n23 were measured, as well as the p13-n23 peak-to-peak amplitude (in microvolts, 
mcV). The active electrodes during the ocular VEMP recording were placed 
symmetrically over the middle part of the lower eyelids, on top of the inferior orbital 
edges, and the reference electrodes were placed 2 centimeters below them. During the 
ocular VEMP measurements, subjects were asked to sit upright and to look upwards 
at a fixed target (upward eye deviation of about 30 degrees). The peak latencies (in 
milliseconds, ms) of the n1, p1, n2, and p2 were measured, as were the n1-p1 and 
n2-p2 peak-to-peak amplitudes (in microvolts, mcV).
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The cervical and ocular VEMPs were elicited acoustically by means of short tone 
bursts with an acoustically shielded headphone (TDH49P acoustically shielded 
headphone, Oxford Medical Instruments, Surrey, England, rise/fall time: 1ms, plateau 
time 2ms, repetition rate 5Hz, frequency 500Hz, 100dB NHL). The cervical and 
ocular VEMPs were recorded with a Medelec Synergy T-EP5 EMG/EP machine 
(Oxford Medical Instruments, Surrey, England). All evoked responses were amplified 
(5000x), band-pass filtered (10-1000Hz), notch filtered, averaged, and were recorded 
without artifact rejection. For each trial two hundred acoustic stimuli were averaged. 
We checked three trials for reproducibility. 
Subjective Visual Vertical (SVV)
The SVV tests were performed in a completely darkened room. We assured that both 
the (corrected) vision and the visual field of the participants were sufficient to perform 
the test. The participants were sitting upright 2 metres from the viewing screen. The 
investigator operated the equipment in an adjacent room (VERTITEST-II, Difra 
Instrumentation, Eupen, Belgium). The subject was instructed to adjust the laser 
projected red line (1.6 metres long and 5 millimetres wide) to the gravitational vertical 
with a hand-held infrared remote controlled potentiometer (steps of 0.1˚/click and 
with an angle speed of 3.85˚/second when the button was pressed continuously) and 
to wait for 5 seconds at the chosen end position to reconsider and thereafter to vocally 
confirm this definitive position. After this definitive confirmation the line was taken 
away by the investigator and tilted to the new starting position before it was projected 
again to prevent the subject from being influenced. As a convention, deviations 
counter-clockwise from the absolute vertical were indicated by negative values and 
deviations clockwise from the absolute vertical were indicated by positive values. The 
deviations were measured with a precision of 0.1˚. The investigator tilted the laser 
projected red line at random to a preset angle that was either clockwise or counter-
clockwise with a random starting deviation between 20 and 25 degrees. A total of 
four measurements were obtained for every testing condition. The measurements were 
obtained under 3 different testing conditions in a random order: (i) both eyes viewing, 
(ii) right eye viewing, and (iii) left eye viewing. When all measurements in all the 
testing conditions were combined, a total of 12 static SVV results were obtained per 
subject. The lights were turned on for a few minutes after each viewing condition to 
check the head position and to prevent the SVV drift, resulting from being in the 
darkness for prolonged periods of time27. 
Videonystagmography, rotatory chair tests, and calorics
Nystagmography was performed by using a monocular high quality infrared video 
goggle system (NysStar, Difra instrumentation, Eupen, Belgium). First, the infrared 
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video goggle system was calibrated for both the participant’s vertical and horizontal 
eye movements. Then, normal eye movement functions were tested using a 
standardized testing battery (i.e. slow pursuit eye movements at different velocities 
both in the horizontal and vertical plane, random saccades with amplitudes of up to 
-15 to +15 degrees, optokinetic nystagmus at different stimulus velocities of 24/42/60° 
per second in both directions, and  eye movements during eccentric gaze both in dark 
and light conditions). After this, eye movements secondary to rotatory stimulation 
(MicroTorque, Difra instrumentation, Eupen, Belgium) were studied (i.e. nystagmus 
during sinusoidal rotatory chair testing in darkness, the effects of visual fixation, and 
a velocity step test). Caloric stimulation was performed by monaural irrigation of 
water at 27° and 44° Celsius using a standardized testing protocol. Both the degree 
of vestibular paresis  and the directional preponderance were calculated by means of 
the Jongkees’ formulas (mean slow component velocities: RC, right cold; LC, left 
cold; RW, right warm; LW, left warm caloric stimulation)
 - Vestibular paresis formula = ((RC+RW)-(LC+LW)) / (RC+LC+RW+LW) (normal 
value ≤ 25%)
 - Directional preponderance formula = ((RW+LC)-(LW+RC)) / (RC+LC+RW+LW) 
(normal value ≤ 30%)
Statistical analysis
The statistical database software SPSS version 23.0 (SPSS inc., USA) was used for 
statistical analyses. The Shapiro-Wilks test was applied to determine normality. Because 
of the limited sample size of our study and the results of the normality tests we used 
non-parametrical tests for further statistical analyses. The Kruskal-Wallis one-way 
analysis by ranks test was applied for comparison of the continuous non-parametrically 
distributed data of the three independent groups (controls, PD, and AP), the Mann-
Whitney-U test for a group to group comparison, and a significance level of 5 percent 
was used for all analyses. An ordinal logistic regression analysis was applied for 
comparison of the categorical variables. 
Results
Individual patient data concerning clinical characteristics, questionnaire outcomes, 
Berg balance scale results, and outcomes of the laboratory examinations are presented 
in tables 1, 2, and 3. The clinical parameters are summarized in table 4, and the 
laboratory examinations in table 5 and 6. The three groups did not differ significantly 
201804 proefschrift Jeroen Venhovens.indd   84 26-01-18   15:06
Neurovestibular analysis and falls in PD and AP: baseline study
C
ha
pt
er
 5
85
(especially with respect to age) and were thus adequately matched. Orthostatic 
hypotension, freezing of gait, and postural instability, as well as the number of falls 
per person each year, the risk for falling and fear of falling were significantly more 
common in the PD and AP groups in comparison with healthy individuals.
BAEP abnormalities occurred in PD and AP patients only (86% of the abnormal 
BAEP responses of both patient groups combined have interpeak III-V latency 
prolongation, some combined with peak V latency prolongation; 14% have absent 
BAEP responses. The mean latencies of the III-V BAEP intervals that are abnormal 
are 120% of the upper limit of normal (range 102-134% ULN; 20% > 130% ULN). 
Abnormal test results of the ocular and cervical VEMP were seen significantly more 
often in both patient groups. Delayed latencies were about four times more common 
in abnormal ocular VEMP measurements in comparison with absent responses, and 
delayed latencies were equally common as absent responses in abnormal cervical 
VEMP measurements. The mean latencies of the n1 ocular VEMP that are abnormal 
are 128% ULN (range 108-152% ULN; 56% > 130% ULN) and the mean latencies 
of the p13 cervical VEMP that are abnormal are 134% ULN (range 101-217% ULN; 
50% > 130% ULN). The mean VEMP n1/p13 latencies and n1-p1/p13-n23 
amplitudes did not differ significantly between the PD, AP, and the healthy control 
groups. The number of abnormal SVV results did not differ significantly between the 
groups. However, all abnormal SVV tests of healthy controls only showed abnormal 
results in one viewing condition, whereas 75% of the abnormal SVV tests of the PD 
group and 100% of the AP group showed abnormal results in two or more viewing 
conditions. The videonystagmography results show significantly more abnormal results 
in the patient groups with respect to saccade and optokinetic testing in comparison 
with the healthy controls. Saccadic slowing and increased saccade latency (a mean 
initiation time of more than 250 ms) are abnormal results that are equally present in 
both groups. Abnormal optokinetic test results exclusively showed unilateral decreased 
responses in two or more optokinetic stimulation velocities. Also, fixation suppression 
tests during sinusoidal rotatory stimulation in the patient groups were significantly 
more often abnormal, especially in the AP group. The other videonystagmography, 
rotatory chair, and caloric tests did not result in significantly more abnormal results 
between all three of the groups. 
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Table 1.
Individual clinical characteristics of patients with Parkinson’s disease and atypical Parkinsonism. 
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I II III IV V VI
Parkinson’s 
Disease
1 68 M 4,0 Right 1 2 18 1 2 80 51 0 72
2 60 M 2,0 Left 5 11 17 2 2,5 80 56 0 99
3 73 M 7,0 Symmetrical 2 13 19 0 3 90 56 0 91
4 60 M 2,0 Left 1 6 10 1 1,5 90 56 0 95
5 78 M 2,0 Left 1 9 10 1 1,5 90 56 28 73
6 73 M 2,0 Right 2 11 17 0 3 85 56 0 70
7 64 M 2,0 Right 1 5 14 2 1 95 56 0 78
8 59 F 4,0 Right 0 11 12 0 2 90 56 4 78
9 72 M 5,5 Right 1 15 9 1 2,5 95 56 0 86
10 80 M 1,5 Right 3 13 9 0 2 70 53 6 64
11 58 M 4,0 Left 0 3 10 4 1 95 56 0 73
12 66 M 4,5 Right 0 12 14 2 3 90 50 4 72
13 66 M 2,0 Right 0 7 7 0 1 95 56 0 98
14 70 M 5,0 Left 1 9 11 0 2,5 90 54 0 61
15 59 M 12,0 Left 1 15 15 4 2 90 55 22 58
16 75 F 10,0 Right 0 22 26 1 3 80 43 30 51
17 75 M 3,0 Right 2 8 14 0 2,5 90 54 0 68
18 59 M 2,0 Left 1 13 14 2 2 85 55 0 71
19 76 F 3,5 Right 1 13 13 2 2,5 90 48 0 38
20 76 M 6,0 Left 2 20 23 4 3 60 41 0 59
21 81 F 22,0 Symmetrical 3 26 34 1 4 40 30 0 70
22 75 M 8,0 Left 4 15 24 3 3 80 44 0 48
23 67 M 3,0 Right 2 9 14 2 2,5 90 56 0 99
24 71 M 5,0 Symmetrical 0 15 16 1 2 90 55 0 76
25 76 M 8,0 Left 2 14 24 9 2,5 75 53 0 75
26 65 M 6,0 Right 1 5 13 1 2 90 54 0 74
27 76 M 2,0 Right 1 6 12 1 1,5 90 53 10 68
28 69 M 3,0 Left 1 7 16 1 2,5 90 55 0 97
29 78 M 12,0 Left 0 25 27 8 2,5 70 48 0 58
30 65 M 2,0 Symmetrical 2 4 11 1 2 95 55 0 68
A
ty
pi
ca
l P
ar
ki
ns
on
is
m
MSA 31 73 F 2,5 Symmetrical 0 17 19 5 4 70 35 0 40
32 67 F 6,0 Symmetrical 4 21 20 6 3 60 44 38 58
33 69 M 3,0 Symmetrical 3 18 15 3 3 80 40 46 46
34 71 M 4,0 Symmetrical 3 29 24 2 4 60 26 0 39
35 57 M 9,5 Right 4 17 19 3 2 80 56 64 62
36 61 M 5,0 Symmetrical 0 22 30 0 4 75 35 2 43
PSP 37 71 F 1,5 Right 7 7 7 - 1 90 51 0 76
38 61 M 2,0 Symmetrical 0 5 11 - 3 90 51 0 75
39 74 M 3,0 Symmetrical 9 16 23 - 3 60 52 16 64
Vascular 40 71 F 2,0 Left 0 6 13 - 2,5 90 48 0 57
41 52 F 3,5 Right 0 0 0 - 2 100 56 18 98
42 76 M 6,5 Symmetrical 1 3 10 - 2,5 90 52 0 79
43 65 M 1,0 Left 4 1 14 - 3 80 53 0 92
44 81 M 3,0 Symmetrical 0 7 19 - 3 80 40 0 55
* Gender (male or female). ** disease duration (calculated from symptom onset in years). *** Unified Parkinson’s disease rating 
scale (UPDRS); part I (evaluation of mentation, behavior, and mood); part II (self-evaluation of the activities of daily life, ADL); 
part III (clinician-scored motor evaluation in the on-state); part IV (Parkinson’s disease therapy related complications); part V 
(Hoehn and Yahr staging of severity of Parkinson’s disease); part VI (Schwab and England ADL scale). Ω DHI (dizziness handicap 
inventory). π ABC-16 (fear of falling questionnaire).
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Table 2.
Individual clinical characteristics and test results of patients with Parkinson’s disease and atypical Parkinsonism
ID Fa
lls
*
O
rt
ho
**
FO
G
**
*
PI
**
**
Ve
st
 Ω
B
A
EP
 π
cV
EM
P
 α
oV
EM
P
 β
SV
V
 δ
VNG + calorisation φ 
C S O P N R F
Parkinson’s 
Disease
1 - - - - - -/- -/- -/A + - - - - - - -
2 - + + C - -/- -/- -/- + VP(r) - - - - - -
3 Y + - C - -/A -/- A/A - VP(l) - + + - - -
4 - - - P - -/- -/- -/- - - - - - - - -
5 - + - P - -/- -/- -/- - - - - - - - -
6 - - - C - -/D -/- -/A - - + - + - - -
7 - - - - - -/- -/D -/- - - - - - - - -
8 - - - - - -/- A/- -/D - - - - - - - -
9 - - - P - -/- -/- -/- - - - - + - - -
10 6M - - - - -/- D/- D/- + - - - + - + -
11 3M - - P - -/- D/D -/A - - - - - - - -
12 - - - C - -/D -/- D/A - VP(l) + + + - + +
13 - - - - - D/- -/- -/D - - - - - - - -
14 - - - P - -/- -/- -/- - - - - + - + -
15 - - - P - -/- -/- -/D - - - - - - - -
16 1M - - C + -/- D/- -/A + - - - + - - -
17 - - - P - -/- -/- -/- + - + + + - - -
18 - - - - - -/- -/- -/- - - + - + - + -
19 - - - P - D/- -/- -/D + - + - + - + -
20 W - + C - D/- -/- -/A + - + - + - - -
21 W - + C - -/- -/- D/A - - - - + - - +
22 1M - + C - -/- -/D D/A - - + - + - - -
23 6M + - P - D/- -/- -/A - - - - - - - -
24 - - - - - D/D -/D -/D + - + - - - - -
25 Y - + P - -/- D/- -/- + - + + + - - -
26 - - - P - D/- -/D -/- - - + - - - - -
27 - + - - - -/- -/- -/- + - - - + - - -
28 - - - P - -/- -/- -/- + VP(b) + - + - + -
29 W + + P - -/- A/D -/- - - + + - - - -
30 Y - - - - -/- A/- -/- + - + - + - - -
At
yp
ic
al
 P
ar
ki
ns
on
ism
MSA 31 1M + - C - -/- -/- A/A - - + + + - - +
32 3M + - C - -/- D/- -/A + - + + + - - +
33 W + + C - D/D -/- -/A - - + + + - + -
34 W + + C - -/A A/- -/- - DP(l) + - + - + -
35 - + - - + -/- -/D -/A - - + + + + - +
36 3M + - C - -/- D/D -/- - - + + + - - +
PSP 37 6M - - P - -/- D/- -/- + - + - + - - -
38 - - - C - D/D -/- -/- - - + - - - - -
39 - - - P - -/- -/- -/- - - + - + - + -
Vascular 40 1M + - C - -/- D/- D/- + - - - - - - -
41 6M - - - - -/- -/- -/A - VP(r) - + + - + +
42 Y - - P - D/D -/- -/- + - + - + - - -
43 6M - - P + -/- -/- -/A - VP(r) + - + - - -
44 - - - C - D/- D/D D/- - - - - - - - -
* Number of fall episodes during the last year (Y: once a year; 6M: once every six months; 3M: once every three months; 1M: monthly; W: weekly; D: daily). ** 
Orthostasis (ortho). *** Freezing of gait (FOG). **** Postural imbalance, PI (C: complete imbalance on pull testing without unaided recovery of balance; P: partial 
imbalance on pull testing with unaided recovery of balance requiring 2 or more backward steps). Ω Abnormalities during clinical bedside neurovestibular testing. 
π Brainstem Auditory Evoked Potentials (BAEP); Right/Left responses; A: absent response; D: delayed response; -: normal response. α cervical Vestibular Evoked 
Myogenic Potential (cVEMP). β Ocular Vestibular Evoked Myogenic Potential (oVEMP). δ Subjective Visual Vertical (SVV). φ Videonystagmography (VNG) and 
calorisation results; C(alorisation; VP: vestibular paresis (left/right/bilateral); DP: directional preponderance (left/right/bilateral)); S(accade testing); O(ptokinetics); 
smooth P(ursuit); spontaneous N(ystagmus) in dark and light conditions; R(otary) chair testing; F(ixation) suppression testing; +: abnormal; -: normal.
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Table 3.
Individual medication characteristics of patients with Parkinson’s disease and atypical Parkinsonism. 
ID Medication
Parkinson’s 
Disease
1 Levodopa/Benserazide 300/75mg + Trihexifenidyl 1mg daily
2 Levodopa/Benserazide 300/75mg daily
3 Levodopa/Benserazide 550/137.5mg daily
4 Levodopa/Benserazide 450/112.5mg daily
5 Levodopa/Benserazide 400/100mg daily
6 Levodopa/Benserazide 300/75mg daily
7 Levodopa/Benserazide 800/200mg + Ropinirol 8mg daily
8 Levodopa/Benserazide 800/200mg + Ropinirol 14mg daily
9 Levodopa/Benserazide 400/100mg daily
10 Levodopa/Benserazide 450/112.5mg daily
11 Levodopa/Benserazide 150/37.5mg daily
12 Levodopa/Benserazide 300/75mg daily
13 Levodopa/Benserazide 800/200mg daily
14 Levodopa/Benserazide 400/100mg daily
15 Levodopa/Benserazide 300/75mg + Pramipexol 1.5mg daily
16 Levodopa/Carbidopa/Entacapon 500/125/400mg + Pramipexol 1.5mg daily
17 Levodopa/Benserazide 300/75mg daily
18 Levodopa/Benserazide 450/112.5mg daily
19 Levodopa/Benserazide 600/150mg daily
20 Levodopa/Benserazide 300/75mg daily
21 Levodopa/Benserazide 300/75mg daily
22 Levodopa/Benserazide 900/175mg daily
23 Levodopa/Benserazide 400/100mg daily
24 Levodopa/Benserazide 550/137.5mg daily
25 Levodopa/Benserazide 400/100mg daily
26 Levodopa/Benserazide 600/150mg daily
27 Levodopa/Benserazide 300/75mg daily
28 Levodopa/Benserazide 450/112.5mg daily
29 Levodopa/Benserazide 900/175mg daily
30 Levodopa/Benserazide 150/37.5mg daily
At
yp
ic
al
 P
ar
ki
ns
on
ism
MSA 31 Levodopa/Benserazide 300/75mg daily
32 Levodopa/Benserazide 800/200mg + Ropinirol 8mg daily
33 -
34 Levodopa/Benserazide 150/37.5mg daily
35 -
36 -
PSP 37 -
38 -
39 -
Vascular 40 -
41 -
42 -
43 Levodopa/Benserazide 450/112.5mg daily
44 -
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The combined results of the vestibular testing battery were significantly more 
frequently abnormal in the patient groups in comparison to the healthy control group, 
93% in PD and 100% in AP compared to 60% in the healthy controls. One patient 
in the PD group only had abnormal slow eye movement abnormalities during 
videonystagmography testing, which could also be caused by a lesion outside the 
vestibular pathways. Therefore, 27 of the PD patients (90%) and 14 of the AP patients 
(100%) have vestibular abnormalities on laboratory examinations. Of these patients 
22 PD patients (79%) and 8 AP patients (57%) have no complaints of dizziness or 
vertigo. The vestibular deficits have a central profile in 21 of the 27 PD patients (78%) 
compared to 13 of the 14 AP patients (93%). Four PD patients (15%) and 1 AP 
patient (7%) have a vestibular testing profile that was non localizing. One PD patient 
(4%) has a testing profile suggestive of a peripheral vestibular problem.
The BAEP and both cervical and ocular VEMP test results of the symptomatic side 
in PD patients differed significantly when compared to healthy volunteers. The BAEP 
I-III and III-V interlatencies differed significantly on the symptomatic side of the PD 
patients (i.e. P = 0.012 and P = 0.019, respectively) in comparison to the healthy 
controls. The other BAEP parameters did not have significantly different results. Also, 
the cervical VEMP p13 latency and the ocular VEMP n1/p1 latencies had significantly 
different results on the symptomatic side in comparison to the healthy controls 
(cervical VEMP p13: P = 0.003; ocular VEMP n1: P = 0.017 and p1: P = 0.009). 
However, the comparison of BAEP and ocular VEMP results of the asymptomatic 
side of PD patients to the healthy controls or the side-to-side comparison within PD 
patients did not yield significantly different results; with exception of the p13 cervical 
VEMP latency comparison of the symptomatic side versus the asymptomatic side (P 
= 0.020). Also the other cervical and ocular VEMP variables did not differ significantly.
Figure 1 shows that neurovestibular test abnormalities are significantly more common 
in the patients with falling incidents versus the non-falling patients. Eleven of the 30 
PD patients fall at least once each year (37%); 3 patients have orthostasis (27%), 9 
have postural instability (82%), 5 have freezing of gait (45%), and 11 have laboratory 
signs of vestibular dysfunction (100%). If the number of patients with falling incidents 
was diminished with the number of falls due to one of the other causes mentioned 
above, 2 of the 11 PD patients (18%) only had laboratory signs of vestibular 
dysfunction. Ten of the 14 AP patients fall at least once each year (71%); of the falling 
patients 6 have orthostasis (60%), 2 have freezing of gait (20%), 9 have postural 
imbalance (90%), and 10 have laboratory signs of vestibular dysfunction (100%). 
Only 1 patient (10%) has laboratory signs of vestibular dysfunction as the cause for 
falling, when other causes as mentioned above were corrected. The mean levodopa 
dosage in falling PD patients was 510 mg/day (SD ±84 mg), and in non-falling PD 
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Table 4.
Group characteristics and comparison between the groups concerning the different clinical variables in 
the Parkinson’s disease,  atypical Parkinsonism, and healthy control groups. 
Pa
rk
in
so
n’
s 
D
is
ea
se
A
ty
pi
ca
l 
Pa
rk
in
so
ni
sm
H
ea
lt
hy
 
co
nt
ro
le
s
P
-v
al
ue
*
Number of patients 30 14 25 0.054
Gender (male/female) M: 26 / F: 4 M: 9 / F: 5 M: 15 / F: 10 0.056
Mean age (years old, SD) 70 (7) 68 (8) 67 (10) 0.609
Average disease duration (years, SD) 5,0 (4,5) 3,8 (2,3) - 0.373
Orthostasis (N, percentage) 6 (20) 7 (50) 0 (0) <0.001
Freezing of gait (N, percentage) 6 (20) 2 (14) 0 (0) 0.018
Postural instability:
 - Complete (N, percentage)
 - Partial (N, percentage)
 - None (N, percentage)
8 (27)
13 (43)
9 (30)
8 (57)
4 (29)
2 (14)
1 (4)
1 (4)
23 (92)
<0.001
Vestibular bedside examination 
(normal: N, percentage)
29 (97) 12 (86) 24 (96) 0.387
Handedness (average, SD) 29,0 (3,7) 27,9 (5,6) 28,4 (5,5) 0.728
ABC-16 fear of falling (average, SD) 72,9 (15,4) 63,1 (18,7) 82,3 (18,2) 0.006
UPDRS score (average, SD):
 - Subscore I
 - Subscore II
 - Subscore III
 - Subscore IV
 - Subscore V
 - Subscore VI
1,4 (1,2)
11,4 (6,0)
15,8 (6,3)
1,8 (2,2)
2,3 (0,7)
84,7 (12,0)
2,5 (2,9)
12,8 (8,4)
16,0 (7,7)
1,9 (2,0)
2,9 (0,8)
78,9 (12,7)
0,4 (1,2)
0,1 (0,3)
0,1 (0,4)
0 (0)
0 (0)
99,2 (2,8)
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
Berg Balance score (average, SD) 52,2 (5,9) 45,6 (9,2) 55,4 (1,6) <0.001
Dizziness Handicap Inventory (average, SD) 3,5 (8,3) 13,1 (21,2) 7,4 (16,6) 0.239
Falling patients (at least once in the last year, 
N, percentage)
11 (37) 10 (71) 3 (12) 0.001
Average number of falls last year :
 - All patients in total (average , SD)
 - Only falling patients (average, SD)
6,4 (15,8)
16,0 (22,1)
10,2 (18,1)
14,3 (20,3)
0,3 (0,9)
2,7 (1,2)
0.001
Fall injury (N, percentage):
 - No injury
 - Minor (e.g. cuts and bruises)
 - Intermediate (e.g. simple fractures)
 - Severe (e.g. fractures requiring surgery)
1 (9)
9 (82)
1 (9)
0 (0)
1 (10)
8 (80)
0 (0)
1 (10)
0 (0)
2 (67)
1 (33)
0 (0)
0.714
Treatment (N, percentage):
 - No treatment necessary
 - Self-treatment 
 - Outpatient doctor’s treatment
 - Hospital admission (no surgery)
 - Hospital admission for surgery
2 (18)
6 (55)
2 (18)
1 (9)
0 (0)
1 (10)
7 (70)
1 (10)
0 (0)
1 (10)
0 (0)
2 (67)
1 (33)
0 (0)
0 (0)
0.714
* The P-value is calculated by means of an ordinal regression calculation (in the categorical variables) 
and the Kruskal-Wallis one-way analysis of variance by ranks test (in the continuously distributed, 
independent, and non-parametrical variables). A significance level of 5 percent (i.e. P-value ≤0.05) was 
adopted for each analysis and significant P-value results are printed in bold.
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patients was 467 mg/day (SD ±39 mg), P = 0.779, obviously statistically not different. 
Nor the disease severity, according to the Hoehn and Yahr classification, of the falling 
PD patients was  statistically significant different from that in the non-falling patients; 
mean Hoehn and Yahr classification of the falling PD patients was 2.3 (SD ±0.6), 
and for the non-falling PD patients was 2.3 (SD ±0.9), P = 0.812.
Table 5.
Group characteristics and comparison between the groups concerning the different test results in the 
Parkinson’s disease,  atypical Parkinsonism, and healthy control groups. 
Parkinson’s 
Disease
Atypical 
Parkinsonism
Healthy 
controles
P-value*
Number of subjects 30 14 25 0.054
BAEP abnormal subjects (percentage) ** 9 (30) 5 (36) 0 (0) 0.072
cVEMP abnormal subjects (percentage) *** 12 (40) 7 (50) 2 (8) 0.005
oVEMP abnormal subjects (percentage) *** 16 (53) 8 (57) 2 (8) <0.001
SVV abnormal subjects (percentage) α 12 (40) 4 (29) 3 (12) 0.057
VNG + Calorisation abnormal 
(percentage):φ
 - Calorisation (percentage)
 - Saccade testing (percentage)
 - Optokinetics (percentage)
 - Smooth pursuit (percentage)
 - Spontaneous nystagmus (percentage)
 - Rotary chair testing (percentage)
 - Fixation suppression (percentage)
4 (13)
13 (43)
5 (17)
17 (57)
0 (0)
6 (20)
2 (7)
3 (21)
11 (79)
6 (43)
11 (79)
1 (7)
4 (29)
5 (36)
2 (8)
2 (8)
2 (8)
10 (40)
0 (0)
5 (20)
0 (0)
0.627
<0.001
0.035
0.058
0.197
0.795
0.002
Total neurovestibular testing  battery: 
oVEMP + cVEMP + VNG + calorisation + 
SVV, ≥ 1 abnormal test (percentage)
28 (93) 14 (100) 17 (60) 0.004
VEMP-testing only (cVEMP+oVEMP):
≥ 1 abnormal test  (percentage) 21 (70) 11 (79) 4 (16) <0.001
VEMP-testing (cVEMP+oVEMP) + SVV:
≥ 1 abnormal test (percentage) 25 (83) 12 (86) 6 (24) <0.001
* The P-value is calculated by means of an ordinal regression calculation (in the categorical variables) 
and the Kruskal-Wallis one-way analysis of variance by ranks test (in the continuously distributed, 
independent, and non-parametrical variables). A significance level of 5 percent (i.e. P-value 
≤0.05) was adopted for each analysis and significant P-value results are printed in bold. ** BAEP: 
Brainstem auditory Evoked Potentials. *** cVEMP: cervical Vestibular Evoked Myogenic Potentials, 
oVEMP: ocular Vestibular Evoked Myogenic Potentials. α SVV: Subjective Visual Vertical. φ VNG: 
videonystagmography. 
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Table 6.
Group characteristics, mean group results, and comparison between the groups concerning the different 
test results in the Parkinson’s disease,  atypical Parkinsonism, and healthy control groups.
Parkinson’s 
Disease
Atypical 
Parkinsonism
Healthy 
controles
P-value*
Number of subjects 30 14 25 0.054
BAEP** results: mean (SD)
- BAEP 1th peak latency (ms)
- BAEP 2th peak  latency (ms)
- BAEP 3th peak  latency (ms)
- BAEP 4th peak  latency (ms)
- BAEP 5th peak  latency (ms)
- BAEP interpeak I-III latency (ms)
- BAEP interpeak III-V latency (ms)
- BAEP interpeak I-V latency (ms)
1.54 (0.25)
2.43 (0.31)
3.56 (0.39)
4.71 (0.39)
5.69 (0.31)
2.03 (0.26)
2.13 (0.44)
4.16 (0.36)
1.44 (0.26)
2.35 (0.39)
3.61 (0.41)
4.77 (0.34)
5.74 (0.42)
2.18 (0.37)
2.13 (0.36)
4.31 (0.48)
1.54 (0.17)
2.50 (0.27)
3.70 (0.25)
4.78 (0.28)
5.61 (0.25)
2.15 (0.22)
1.90 (0.32)
4.07 (0.26)
0.867
0.760
0.335
0.557
0.361
0.145
0.068
0.412
Ocular VEMP***: mean (SD)
- n1 peak latency (ms)
- p1 peak latency (ms)
- n1p1 peak-to-peak amplitude (mcV)
13.7 (4.2)
20.8 (5.3)
7.1 (11.0)
11.8 (3.5)
19.4 (4.1)
4.4 (2.6)
11.5 (2.6)
17.5 (4.0)
3.6 (3.5)
0.067
0.021
0.057
Cervical VEMP***:  mean (SD)
- p13 peak latency (ms)
- n23 peak latency (ms)
- p13n23 peak-to-peak amplitude (mcV)
17.0 (3.6)
25.1 (4.2)
39.8 (45.1)
17.0 (2.8)
26.0 (5.0)
47.7 (66.4)
15.1 (2.1)
23.3 (3.0)
44.5 (49.0)
0.143
0.318
0.342
SVV α: mean (SD) 
- Binocular deviation (degrees)
- Monocular deviation OS (degrees)
- Monocular deviation OD (degrees)
- Counter-clockwise deviation (degrees)
- Clockwise deviation (degrees)
0.6 (2.4)
-0.3 (3.0)
0.4 (2.7)
-1.0 (2.8)
1.4 (3.1)
-0.3 (3.5)
0.6 (5.4)
0.1 (4.6)
-2.2 (4.5)
2.5 (5.2)
-0.3 (1.5)
-0.9 (1.8)
0.3 (1.8)
-1.5 (1.6)
1.6 (1.7)
0.552
0.234
0.918
0.310
0.438
* The P-value is calculated by means of the Kruskal-Wallis one-way analysis of variance by ranks test 
(in the continuously distributed, independent, and non-parametrical variables). A significance level of 
5 percent (i.e. P-value ≤0.05) was adopted for each analysis and significant P-value results are printed 
in bold. ** BAEP: Brainstem auditory Evoked Potentials. *** VEMP: Vestibular Evoked Myogenic 
Potentials. α SVV: Subjective Visual Vertical. 
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Discussion
In our study abnormal central vestibular function test results are very common, but 
mostly asymptomatic in both PD and AP patients. PD or AP patients with falling 
incidents also have significantly more abnormal vestibular test results compared to 
the non-falling patients. Apart from well-established causes of falls (freezing of gait, 
orthostasis, cognitive problems, and postural instability), approximately 10 to 18% 
of the patients have vestibular dysfunction as the only identifiable cause for falling. 
We acknowledge that we may have missed additional contributions of e.g. mild 
orthostasis, which can be variably present during clinical examination, and which can 
be missed during routine testing28. We were not able to exclude all possible and 
previously reported risk factors for falling in PD6, but we excluded the most relevant 
causes. Therefore, the present study is mostly exploratory and hypothesis generating, 
however it holds in our opinion sufficient evidence that vestibular system abnormalities 
are associated with falling in PD and AP patients. To our knowledge this finding has 
not been reported before; especially the recently published consensus-based overview 
concerning the risk factors and management of falls in PD did not specifically mention 
vestibular dysfunction as a contributing cause6.
Figure 1.
Sensitivity of the different neurovestibular tests in Parkinson’s disease and atypical Parkinsonism patients 
with and without fall episodes over the last year.
* VNG: videonystagmography, SVV: subjective visual vertical, VEMP: vestibular evoked myogenic 
potentials, Full battery: full neurovestibular test battery (VNG+calorisation, SVV, and VEMP testing), 
x≥1: at least one abnormal test result, x≥2: at least two abnormal test results. ** P-values were calculated 
by means of ordinal regression analysis, only significantly different results (P-value < 0.05) were shown.
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Pollak7 demonstrated vestibular involvement in 54 patients with PD; 37% had 
unilaterally absent cervical VEMPs elicited with air-conducted stimuli, and 7% had 
bilaterally absent responses; the mean latencies were not significantly different between 
groups. However, the patients and the control group were not adequately matched 
for age (PD group: 66 ± 10 years, control group: 46 ± 15 years, P < 0.001) and the 
level of sternocleidomastoid muscle contraction was neither standardized, nor 
corrected for afterwards. Therefore, possible cervical VEMP amplitude differences 
between the two groups would not have been reliable a priori29. Liao8 found abnormal 
air-conducted cervical VEMP p13-n23 amplitudes in 10 patients with PSP and 
concluded that the reduced vestibulospinal reflex could possibly contribute to the 
elevated fall risk in PSP patients. The patients and the control group were correctly 
matched for age, but the cervical VEMP amplitudes were not corrected for the force 
of sternocleidomastoid muscle correction nor were they standardized, and thus they 
were not optimally reliable as suggested by the authors. We could not find reduced 
cervical VEMP amplitudes in the PSP group in our study after age-matching and 
standardization for the applied force of muscle contraction. Recent studies by De 
Natale30,31 in groups of 33 and 24 PD patients in total showed significantly more 
abnormal individual masseter, ocular, and cervical VEMPs in comparison with an age 
matched control group (P < 0.001). At the group level the amplitudes of especially 
the masseter and ocular VEMPs were significantly smaller in comparison to the healthy 
control subjects, and the individual results showed a significant correlation with 
postural instability and REM sleep behavior disorder screening scores. The groups 
were adequately matched for age and the cervical VEMP amplitudes were corrected 
for the force of sternocleidomastoid muscle contraction. Therefore, the amplitude 
differences at the group level in their studies are reliable. These amplitude differences 
at the group level were not significantly different between the groups in our study, 
however we agree with the high level of individual VEMP abnormalities in the PD 
group in comparison to the control group. Pötter-Nerger9 concluded that cervical 
VEMP latencies and amplitudes did not differ significantly between PD patients and 
healthy controls at a group level. However, ocular VEMP latencies, especially in bone-
conducted stimuli at the symptomatic side were significantly prolonged, amplitudes 
on the other hand did not differ significantly. They adequately matched for age to the 
control group; the level of sternocleidomastoid muscle contraction was standardized. 
They concluded that the abnormal ocular VEMP latencies were probably caused by 
upper brainstem involvement, with the lower brainstem being relatively spared (hence 
the normal cervical VEMPs). Our study confirms the findings of Pötter-Nerger9 that 
ocular VEMP latencies are significantly prolonged at the symptomatic side in 
comparison to healthy controls. In addition, we found a significantly different result 
concerning cervical VEMP latencies at the symptomatic side. This difference 
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concerning the cervical VEMP latencies can possibly be explained by differences in 
population size (30 PD patients versus 13 in the study by Pötter-Nerger9), since 
smaller differences between groups are easier to be detected in a larger study 
population. Therefore, we disagree with the conclusion of the previous authors that 
especially otolith-ocular projections on the symptomatic side in the upper brainstem 
of PD patients are more vulnerable to neurodegeneration in comparison to the lower 
brainstem structures; the otolith-cervical projections through the medial vestibulospinal 
tract on the symptomatic side are functionally involved (this is the same side as the 
patient’s rigidity, resting tremors, and bradykinesia; as the vestibulospinal tract fibers 
descent from the vestibular nuclei at the ipsilateral side). Not only the otolith-ocular 
projections of the symptomatic side of the upper brainstem are especially vulnerable 
to neurodegeneration, but also the other brainstem projections such as the auditory 
brainstem pathways seem to be affected, which is illustrated especially by the prolonged 
BAEP III-V interlatencies. In the peripheral nervous system, considerable prolonged 
latencies are associated with demyelination. The same principle holds true for 
prolonged latencies of BAEP components in multiple sclerosis and other demyelinating 
disorders of the central nervous system. Whether the substantial delay encountered 
in components of the cervical and ocular VEMP, in both PD and AP patients, is 
caused by demyelination is rather speculative, although still a subject for further 
research, possibly with secondary axonal degeneration in the more advanced stages29. 
Primary axonal neurodegeneration is probably less likely to be an explanation for the 
prolonged latencies without relevant amplitude reduction, which is found in our 
group of PD and AP patients. 
Our study has limitations. The size of the patient groups is rather small due to strict 
in-/exclusion criteria. The AP group was particularly small and also heterogeneous, 
so these results must be interpreted cautiously and as hypothesis-generating for further 
research. Also, the lengthy and cumbersome nature of neurovestibular testing is 
demanding for elderly patients, and especially for AP patients. Some symptoms (such 
as mild orthostasis) are fluctuating phenomena; so we are unable to fully exclude all 
other possible risk factors as a cause for falling. Finally, patients were tested during a 
subjective on state, so we cannot exclude that dopaminergic medication affected some 
of our findings. Recently, Pötter-Nerger et al. performed cervical and ocular VEMP 
studies in PD patients during both the subjective ON- and OFF-state9. Both the 
latencies and amplitudes of the cervical and ocular VEMPs did not show effects of 
dopaminergic modulation. However, in an earlier study Pötter-Nerger et al. 
demonstrated that PD patients have significantly lower cervical VEMP amplitudes 
in comparison with healthy controls both during the subjective ON- and OFF-state32. 
The amplitudes of the PD patients, however, were significantly higher during the 
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subjective ON-state in comparison to the OFF-state indicating that levodopa partially 
restores the decreased vestibular nuclear excitability32. Our patients were tested during 
the subjective ON-state. Based upon the literature referenced above it seems likely 
that levodopa did not have any influence or would possibly partially decrease vestibular 
testing abnormalities. Therefore, our study may even show some underestimation of 
vestibular abnormalities. 
To conclude, we found a high prevalence of abnormal vestibular test results in both 
PD and AP patients; specifically in the symptomatic side of the brainstem in PD 
patients. The quantitative extent of the electrophysiological abnormalities may suggest 
a predominant demyelinating component in the neurodegenerative process. The 
vestibular system abnormalities were associated with falling in both groups. 
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Abstract
Objectives
Our primary aim was to determine whether neurovestibular laboratory tests can 
predict future falls in patients with either Parkinson’s disease (PD) or atypical 
parkinsonism (AP). 
Methods
We included 25 healthy subjects, 30 PD patients (median Hoehn and Yahr stage 
2.5, range 1-4), and 14 AP patients (5 multiple system atrophy, 3 progressive 
supranuclear palsy, and 5 vascular parkinsonism) in a case-control study design 
(all matched for age and gender). At baseline, all subjects underwent clinical 
neurological and neurotological assessments, cervical and ocular vestibular evoked 
myogenic potentials (cervical and ocular VEMPs), brainstem auditory evoked 
potentials (BAEPs), subjective visual vertical measurements (SVV), and video 
nystagmography (VNG) with caloric and rotary test stimulation. After one year 
follow-up, all subjects were contacted by telephone for an interview concerning 
their fall frequency based upon their fall diaries and balance confidence (according 
to the ABC-16 questionnaire); only one was lost to follow-up (attrition bias of 
only 1.4%).
Results
Cervical and ocular VEMPs combined with clinical tests for postural imbalance 
predict future fall incidents in both PD and AP groups with a sensitivity of 100%. 
A positive predictive value (PPV) of 68.2% was achieved, if only one VEMP test 
was abnormal, and a PPV of 83.3% when both VEMP tests were abnormal. The 
fall frequency both at baseline and after one year was significantly higher and the 
balance confidence scale (ABC-16) was significantly lower in both the PD and 
AP groups compared to healthy controls.
Conclusions
Cervical and ocular VEMP testing can predict the risk of future fall incidents in 
PD and AP patients with postural imbalance in the absence of freezing of gait. 
Obviously, at this moment we cannot predict whether the knowledge of this 
increased risk will subsequently result in effective strategies to diminish or even 
prevent falling. 
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Introduction
Falls are highly prevalent in patients with Parkinson’s disease (PD) or atypical 
parkinsonism (AP). Approximately 70% of PD patients have at least one fall episode 
annually1. Fall incidents often lead to social isolation which may result in a reduced 
quality of life, because fall incidents can cause a fear of renewed fall episodes, possibly 
resulting in a self-imposed restriction of daily activities2–4.
We previously showed that vestibular dysfunction is an independent risk factor for 
the occurrence of falls in PD and AP patients4. The results of vestibular tests mainly 
reflect central neurological vestibular dysfunction, even though these patients usually 
do not complain of vertigo or dizziness4. Patients with PD or AP who had experienced 
prior falls had more abnormal vestibular test results compared to non-falling patients. 
After exclusion of the well-established causes of falls (e.g. orthostasis, freezing of gait, 
cognitive problems and postural instability) 10-18% of the falling PD and AP patients 
had vestibular system abnormalities as the only identifiable cause for falling4. We 
therefore concluded that vestibular system dysfunction, as established with 
neurovestibular laboratory tests, is an independent and relevant risk factor for falling 
in PD and AP.
The primary aim of this prospective study was to determine whether neurovestibular 
laboratory tests have predictive value for the occurrence of future falls in PD and AP 
patients and, if so, to determine their sensitivity, specificity, and positive predictive 
values. The secondary aim was to determine the fall frequency and balance confidence 
in both PD and AP after one year of follow-up, as compared with an age- and gender-
matched healthy control group.
Methodology
Study Participants
Previously we described the methodology and baseline measurements of our study 
cohort4. Now we present the data after one year follow-up (median 12 months, range 
12-14 months). The neurovestibular laboratory tests conducted at baseline were: a) 
cervical and ocular vestibular evoked myogenic potentials (VEMPs), b) subjective 
visual vertical (SVV), and c) video nystagmography (VNG) with additional caloric- 
and rotatory chair stimulation. The study was approved by the regional and local 
medical ethical committee (CMO Arnhem-Nijmegen, the Netherlands, number 
2012/393) and was registered as well in the Dutch trial register (Nederlands Trial 
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Register, NTR-3928). All volunteers signed an informed consent. Healthy controls 
and patients did not have a relevant medical history (i.e. no relevant neurological, 
otological, ophthalmological diseases, and/or absence of moderate-to-severe cognitive 
problems) with the exception of PD or AP (in combination with a related 
cerebrovascular disorder in the vascular parkinsonism group). Controls were matched 
for age and gender with the PD and AP patients. Sixty-nine volunteers were included 
in the baseline case-control study. Only one patient with multiple system atrophy 
with predominant parkinsonism (MSA-P) was lost to follow-up, resulting in an 
attrition bias of only 1.4%. 
Sixty-eight volunteers completed the follow-up study; 25 healthy controls (mean age 
67, range 42-81, 15 men), 30 PD patients (mean age 70, range 59-81, 26 men, all 
fulfilling the UK Parkinson’s Disease Society Brain Bank criteria5, median Hoehn and 
Yahr stage 2.5, range 1-4), and 13 atypical parkinsonism (AP) patients (mean age 68, 
range 52-81, 8 men, 5 multiple system atrophy, 3 progressive supranuclear palsy, and 
5 vascular parkinsonism). The MSA-P patients all fulfilled the diagnostic criteria for 
probable MSA-P as proposed in the consensus statement by Gilman6. Supranuclear 
palsy patients (PSP) all fulfilled the NINDS-SPSP criteria for possible PSP7. Vascular 
parkinsonism patients all fulfilled the criteria of the Winikates and Jankovic vascular 
rating scale8.
Follow-up by telephone interview
All participants were contacted by telephone for an interview one year after the 
baseline measurements. At the end of the baseline examinations, they were asked to 
keep track of their fall incidents during the following year by means of a fall diary. 
During the telephone interview, they were questioned about their fall frequency during 
the previous year, their fear of falling according to the ABC-16 questionnaire (16-items 
activities-specific balance confidence scale), acquired injuries related to fall incidents, 
and whether they had received medical treatment for  such injuries.
Statistical analysis
The statistical database software SPSS version 23.0 (SPSS inc., USA) was used for 
statistical analyses. The Shapiro-Wilks test was applied to determine whether 
parametrical tests were applicable. Because of this test result and due to the limited 
sample size of our study we had to apply non-parametrical tests for further statistical 
analyses. The Kruskal-Wallis one-way analysis by ranks test was applied for 
comparison of the continuous non-parametrically distributed data of the three 
independent groups (controls, PD, and AP), the Mann-Whitney-U test for a group 
to group comparison, and a significance level of 5 percent was used for all analyses. 
201804 proefschrift Jeroen Venhovens.indd   104 26-01-18   15:06
Neurovestibular analysis and falls in PD and AP: one-year follow-up study
C
ha
pt
er
 6
105
An ordinal logistic regression analysis was applied for comparison of the categorical 
variables. We did not perform a multivariate regression analysis of the data due to 
the limited sample size.
Results
We refer to table 1 for the PD and AP patients’ individual data concerning the one-
year follow-up results in relation to the baseline measurements, and to table 2 for the 
group characteristics. Both tables were adapted from our baseline study4. 
From our data in table 2 and additional group-to-group comparisons it may be 
inferred that PD and AP patients fall statistically significantly more often in 
comparison to age- and gender-matched healthy control subjects at baseline (PPD-controls 
= 0.037; PAP-controls <0.001). In addition, the percentage of falling AP patients 
compared to healthy controls during the follow-up year was statistically significantly 
higher (PPD-controls = 0.571; PAP-controls = 0.034). Also, the percentage of falling AP 
patients was higher than the PD patients, however the difference was only statistically 
significant at baseline (Pbaseline-PD-PA = 0.032; Pfollow-up-PD-PA = 0.090). The PD patients 
and the AP patients have a statistically significantly higher fall frequency at baseline 
in comparison to controls (Baseline: PPD-controls = 0.035; PAP-controls = 0.001); and both 
also have a higher fall frequency during follow-up, however it is only the difference 
between the AP patients and controls that is statistically significant (Follow-up: PPD-
controls  = 0.394; PAP-controls = 0.032). AP patients have a higher frequency of falling in 
comparison to the PD patients, however only the baseline measurements were 
statistically significant (Pbaseline-PD-PA = 0.039; Pfollow-up-PD-PA = 0.116). Also, the increase 
in fall frequency was especially striking in the AP group in comparison to both the 
PD patients and controls, however the difference is not statistically significant between 
the groups (P = 0.164). The number of fall incidents did increase in the AP and PD 
groups when comparing the baseline and follow-up measurements, however the 
difference is not statistically significant (Pbaseline-follow-up-AP = 0.257; Pbaseline-follow-up-PD = 
0.705). The increase in the healthy control group, however, is statistically significant 
(Pbaseline-follow-up-control = 0.046)
The 16-items activities-specific balance confidence scale (ABC-16) differed significantly 
between the groups in total both at baseline (Ptotal = 0.006; PPD-controls = 0.028; PAP-
controls = 0.004; PPD-AP = 0.096); and during follow-up one year later (Ptotal = 0.001; 
PPD-controls = 0.022; PAP-controls = 0.001; PPD-AP = 0.018). Moreover, the difference was 
statistically significant between the groups when only the non-falling patients were 
considered both at baseline (Ptotal = 0.010; PPD-controls = 0.014; PAP-controls = 0.009; 
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Table 1.
ID Fa
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EM
P
oV
EM
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V
 
VNG + calorisation φ
C S O P N R F
Parkinson’s 
Disease
1 -/- - - - - 72/57 -/- -/A + - - - - - - -
2 -/- + + C - 99/100 -/- -/- + VP(r) - - - - - -
3 Y/- + - C - 91/90 -/- A/A - VP(l) - + + - - -
4 -/- - - P - 95/80 -/- -/- - - - - - - - -
5 -/- + - P - 73/76 -/- -/- - - - - - - - -
6 -/- - - C - 70/64 -/- -/A - - + - + - - -
7 -/- - - - - 78/74 -/D -/- - - - - - - - -
8 -/- - - - - 78/68 A/- -/D - - - - - - - -
9 -/- - - P - 86/90 -/- -/- - - - - + - - -
10 6M/- - - - - 64/59 D/- D/- + - - - + - + -
11 3M/3M - - P - 73/65 D/D -/A - - - - - - - -
12 -/- - - C - 72/65 -/- D/A - VP(l) + + + - + +
13 -/- - - - - 98/99 -/- -/D - - - - - - - -
14 -/- - - P - 61/64 -/- -/- - - - - + - + -
15 -/- - - P - 58/71 -/- -/D - - - - - - - -
16 1M/1M - - C + 51/31 D/- -/A + - - - + - - -
17 -/- - - P - 68/63 -/- -/- + - + + + - - -
18 -/- - - - - 71/73 -/- -/- - - + - + - + -
19 -/6M - - P - 38/36 -/- -/D + - + - + - + -
20 W/W - + C - 59/54 -/- -/A + - + - + - - -
21 W/W - + C - 70/66 -/- D/A - - - - + - - +
22 1M/W - + C - 48/46 -/D D/A - - + - + - - -
23 6M/- + - P - 99/95 -/- -/A - - - - - - - -
24 -/- - - - - 76/61 -/D -/D + - + - - - - -
25 Y/3M - + P - 75/68 D/- -/- + - + + + - - -
26 -/- - - P - 74/75 -/D -/- - - + - - - - -
27 -/- + - - - 68/70 -/- -/- + - - - + - - -
28 -/- - - P - 97/93 -/- -/- + VP(b) + - + - + -
29 W/W + + P - 58/82 A/D -/- - - + + - - - -
30 Y/- - - - - 68/80 A/- -/- + - + - + - - -
At
yp
ic
al
 P
ar
ki
ns
on
ism
MSA 31 1M/1M + - C - 40/20 -/- A/A - - + + + - - +
32 3M/1M + - C - 58/45 D/- -/A + - + + + - - +
33 W/D + + C - 46/0 -/- -/A - - + + + - + -
34 W/D + + C - 39/29 A/- -/- - DP(l) + - + - + -
35 -/- + - - + 62/57 -/D -/A - - + + + + - +
36# 3M/# + - C - 43/# D/D -/- - - + + + - - +
PSP 37 6M/W - - P - 76/58 D/- -/- + - + - + - - -
38 -/- - - C - 75/79 -/- -/- - - + - - - - -
39 -/- - - P - 64/43 -/- -/- - - + - + - + -
Vascular 40 1M/1M + - C - 57/59 D/- D/- + - - - - - - -
41 6M/- - - - - 98/96 -/- -/A - VP(r) - + + - + +
42 Y/- - - P - 79/80 -/- -/- + - + - + - - -
43 6M/3M - - P + 92/71 -/- -/A - VP(r) + - + - - -
44 -/- - - C - 55/28 D/D D/- - - - - - - - -
Adapted from Venhovens et al. (Venhovens et al., 2016). Individual clinical characteristics and test results of patients with Parkinson’s 
disease and atypical Parkinsonism. * Number of fall episodes during the last year (fall frequency at baseline / fall frequency during 
one-year follow-up; Y: once a year; 6M: once every six months; 3M: once every three months; 1M: monthly; W: weekly; D: daily). ** 
Orthostasis (ortho). *** Freezing of gait (FOG). **** Postural imbalance, PI (C: complete imbalance on pull testing without unaided 
recovery of balance; P: partial imbalance on pull testing with unaided recovery of balance requiring 2 or more backward steps). Ω 
Abnormalities during clinical bedside neurovestibular testing. µ ABC-16 questionnaire (16-items specific confidence of balance scale 
at baseline / ABC-16 score after one-year follow-up). Evoked potentials: Right/Left responses; A: absent response; D: delayed response; 
-: normal response. φ Videonystagmography (VNG) and calorisation results; C(alorisation; VP: vestibular paresis (left/right/bilateral); 
DP: directional preponderance (left/right/bilateral)); S(accade testing); O(ptokinetics); smooth P(ursuit); spontaneous N(ystagmus) in 
dark and light conditions; R(otary) chair testing; F(ixation) suppression testing; +: abnormal; -: normal. # Loss to follow-up.
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PPD-AP = 0.116); and during follow-up one year later (Ptotal = 0.009; PPD-controls = 0.010; 
PAP-controls = 0.004; PPD-AP = 0.081). However, only the change in ABC-16 scores 
between the baseline measurements and after one year follow-up was statistically 
significant in the total group (Ptotal = 0.028; PPD-controls = 0.022; PAP-controls = 0.001; 
PPD-AP = 0.018). However, the ABC-16 results of the falling patients were similar in 
the groups. The fall related injuries both at baseline or during follow-up and their 
treatments did not differ significantly.
Discussion
Laboratory examinations, and especially the vestibular evoked myogenic measurements, 
VEMPs (an abnormal VEMP result, defined as having at least one abnormal result 
at both the cervical and/or ocular VEMP tests combined) have a sensitivity of 100% 
to predict the occurrence of falls, at the cost of a low PPV of 46.8% (15 of the 32 
patients will fall during follow-up). The presence of freezing of gait is also a strong 
predictor for the occurrence of falls (seven out of eight patients will fall, yielding a 
PPV of 87.5%). However, the sensitivity for detecting patients at risk for future falls 
is limited as only seven out of 15 patients will be detected (46.6%). The sensitivity 
for detecting patients at risk for falling is very high concerning the clinical testing for 
the presence of postural instability (100%), but the PPV is only 46.9%. 
Therefore, there is no single clinical or laboratory test (that is independent of clinical 
tests) with a high positive predictive value and a high sensitivity for detecting 
patients with a high risk for falling. Both kinds of tests are needed to make a 
screening test that is useful in clinical practice in order to detect all patients at risk, 
however to also prevent a large number of false positive results which would lower 
the diagnostic value. 
However, when both tests are used in combination (i.e. to use VEMP testing for 
additional screening for future fall incidents in those patients who at least have partial 
postural imbalance) the sensitivity will still remain 100% (fifteen out of the fifteen 
patients will be detected); and the PPV will subsequently be 68.2% when only the 
ocular or the cervical VEMP is abnormal (15 out of the 22 patients with positive 
results will fall during the year follow-up), or 83.3% when both VEMP tests are 
abnormal (5 out of 6 patients with positive results will fall during the follow-up year; 
with 5 out of 15 falling patients having abnormal results in both VEMP tests). 
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Table 2.
Adapted from Venhovens et al. (Venhovens et al., 2016). 
Parkinson’s 
Disease
Atypical 
Parkinsonism
Healthy 
controles
P-value*
Number of subjects (N) 30 14** 25 0.054
Number of falling patients:
-  Baseline (N, percentage)
-  One year follow-up (N, percentage)
11 (37)
8 (27)
10 (71)
7 (54)
3 (12)
5 (20)
<0.001
0.043
Average number of falls/year (baseline):
-  All patients in total (average, SD)
-  Only falling patients (average, SD)
6,4 (15,8)
16,0 (22,1)
10,2 (18,1)
14,3 (20,3)
0,3 (0,9)
2,7 (1,2)
<0.001
Average number of falls/year (one-year follow-up):
-  All patients in total (average, SD)
-  Only falling patients (average, SD)
7,7 (3,3)
28,8 (8,8)
63,2 (37,4)
117,4 (64,2)
0,9 (0,5)
4,4 (2,0)
0.032
Change in number falls/year (absolute, percentage)
-  All patients in total (absolute, percentage)
-  Only falling patients (absolute, percentage)
+1,3 (+21,1)
+9,8 (+51,3)
+53,0 (+518,7)
+103,1 (+721,0)
+0,6 (+175,0)
+1,7 (+65,0)
0.164
ABC-16 fear of falling, Baseline:
-  All patients in total (average, SD)
-  Only falling patients (average, SD)
-  Only non-falling patients (average, SD)
72,9 (2,8)
59,0 (4,6)
78,0 (2,8)
64,7 (5,1)
57,9 (6,4)
72,2 (6,3)
82,3 (3,6)
60,8 (9,4)
87,7 (3,0)
0.006
0.914
0.010
ABC-16 fear of falling , Follow-up  after one-year:
-  All patients in total (average, SD)
-  Only falling patients (average, SD)
-  Only non-falling patients (average, SD)
70,5 (3,1)
56,0 (6,2)
75,8 (2,9)
51,2 (7,5)
38,8 (8,4)
63,8 (10,5)
80,3 (3,6)
53,8 (7,9)
87,0 (2,4)
0.001
0.190
0.009
Change in ABC-16:
-  All patients in total (absolute, percentage)
-  Only falling patients (absolute, percentage)
-  Only non-falling patients (absolute, percentage)
-2,4 (-3,3)
-3,0 (-5,1)
-2,2 (-2,8)
-13,5 (-20,9)
-19,1 (-33,0)
-8,4 (-11,6)
-2,0 (-2,4)
-7,0 (-11,5)
-0,7 (-0,8)
0.028
0.156
0.506
Fall injury, Baseline (N, percentage):
-  No injury
-  Minor (e.g. cuts and bruises)
-  Intermediate (e.g. simple fractures)
-  Severe (e.g. fractures requiring surgery)
1 (9)
9 (82)
1 (9)
0 (0)
1 (10)
8 (80)
0 (0)
1 (10)
0 (0)
2 (67)
1 (33)
0 (0)
0.714
Fall injury, Follow-up after one-year (N, percentage):
-  No injury
-  Minor (e.g. cuts and bruises)
-  Intermediate (e.g. simple fractures)
-  Severe (e.g. fractures requiring surgery)
0 (0)
7 (88)
0 (0)
1 (12)
0 (0)
6 (86)
1 (14)
0 (0)
1 (20)
3 (60)
0 (0)
1 (20)
0.414
Treatment, Baseline (N, percentage):
-  No treatment necessary
-  Self-treatment 
-  Outpatient doctor’s treatment
-  Hospital admission (no surgery)
-  Hospital admission for surgery
2 (18)
6 (55)
2 (18)
1 (9)
0 (0)
1 (10)
7 (70)
1 (10)
0 (0)
1 (10)
0 (0)
2 (67)
1 (33)
0 (0)
0 (0)
0.714
Treatment , One-year follow-up (N, percentage):
-  No treatment necessary
-  Self-treatment 
-  Outpatient doctor’s treatment
-  Hospital admission (no surgery)
-  Hospital admission for surgery
0 (0)
7 (88)
0 (0)
0 (0)
1 (12)
0 (0)
5 (72)
1 (14)
1 (14)
0 (0)
1 (20)
2 (40)
1 (20)
0 (0)
1 (20)
0.427
Group characteristics and comparison between the groups concerning the different test results in the Parkinson’s disease, atypical 
Parkinsonism, and healthy control groups. * The P-value is calculated by means of an ordinal regression calculation (in the categorical 
variables) and the Kruskal-Wallis one-way analysis of variance by ranks test (in the continuously distributed, independent, and non-
parametrical variables). A significance level of 5 percent (i.e. P-value ≤0.05) was adopted for each analysis and significant P-value 
results are printed in bold. ** Fourteen patients completed the baseline examinations and one patient was lossed to follow-up.
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Cervical and ocular VEMP testing combined with the clinical evaluation for postural 
instability gives additional information concerning the future fall risk of PD and AP 
patients compared to clinical evaluation of postural instability alone. However, the 
presence of freezing of gait is such a strong predictor for future falls in both PD and 
AP patients (PPV 87.5%; all the falling patients with freezing of gait also had abnormal 
VEMPs and postural instability) that VEMP testing in these patients does not have 
any additional value. Therefore, cervical and ocular VEMP testing seems to give 
additional information concerning the future fall risk in selected PD and AP patients 
(those patients who have postural instability in the absence of freezing of gait). 
However, one could speculate whether this additional information (possible increase 
of the PPV from 46.9% to 68.2-83.3%) will aid in guiding future fall prevention 
therapies (for instance through physical therapy) as PD and AP patients with postural 
imbalance already have a high risk for falling. Recently, a practical consensus-based 
overview concerning the risk factors and management of falls in PD was published 
emphasizing the multifaceted origin of the falls and the need for a personalized 
approach9. 
Decreasing the risk of falling is important, as fall incidents will result in a lowered 
subjective balance confidence (as can be concluded from the data in table 2.), 
secondarily resulting in  self-imposed restrictions in daily life, ultimately leading to 
social isolation2,3. Moreover, patients with parkinsonism are more at risk for fall-related 
injuries, such as hip fractures secondarily leading to a higher morbidity, mortality, 
and health care costs in comparison to individuals without Parkinsonism3,10. 
Our study also has some important limitations, which we also mentioned earlier4. 
The first limitation relates to the small sample size; this was explained by the strict 
inclusion/exclusion criteria and the lengthy nature of the neurovestibular testing, 
which is especially demanding for elderly and AP patients. Therefore, the results from 
this study need to be interpreted cautiously and as hypothesis-generating for further 
research, especially in the heterogeneous AP group. We advocate further research 
concerning the additional value of VEMP testing for predicting the risk of falling in 
larger PD and AP groups. The second limitation is, that the volunteers may have had 
a bias concerning the recollection of their falling incidents. We tried to overcome this 
issue by asking the volunteers to keep track of their fall incidents by keeping 
personalized fall diaries. However, mal-compliance could bias the results possibly 
leading to an underestimation of the true fall incidence. Therefore, we questioned the 
volunteers about their fall frequency instead of the absolute number of falls, to 
minimize the effects of mal-compliance and recollection bias. 
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To conclude, we found a high prevalence in the number of falling patients and fall 
incidents in our follow-up study after one year in both PD and AP patients. After 
one year, especially the frequency of the fall incidents in the AP group increased in 
comparison to the PD and control group, which was not statistically significant 
(probably as a result of the small group size) as the other groups did also show a less 
pronounced increase in the number of fall incidents. The risk of future falls in PD 
and AP patients can be predicted better when patients with postural imbalance on 
clinical testing are additionally tested by means of cervical and ocular VEMP testing 
(with the exclusion of patients with freezing of gait). However, it remains unclear if 
the increase in future fall risk (possible PPV increase from 46.9% to 68.2-83.3%) will 
aid in the different utilization of fall prevention strategies as PD and AP patients with 
postural imbalance already have a high risk of falling.
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As mentioned earlier, this thesis is divided into two parts which will be discussed 
separately. The first part covers technical and practical issues of neurovestibular 
laboratory examinations, with an emphasis on vestibular evoked myogenic potentials 
(VEMP) and static subjective visual vertical testing (SVV). The second part offers a 
detailed overview of a study concerning neurovestibular analysis in persons with 
Parkinson’s disease (PD) or atypical parkinsonism (AP), both at baseline and after 
one-year follow-up. Each part begins with a brief summary of the respective 
chapter(s), followed by a general discussion and some thoughts on the perspectives 
for future research.
PART ONE
Neurovestibular laboratory testing – practical and technical issues
Vestibular evoked myogenic potentials (VEMP)
Summary chapters 2 and 3
Over the past two decades, vestibular evoked myogenic potential (VEMP) testing 
has come into use as a test suitable for detailed neurophysiological assessment of 
both the central and peripheral vestibular system. VEMP testing can be divided 
into a cervical and an ocular response. The cervical VEMP test assesses the integrity 
of the vestibulo-spinal reflex arc beginning at the saccular afferents to ultimately 
evoke an inhibitory motor response in the ipsilateral sternocleidomastoid muscle 
(by subsequently travelling through the ipsilateral inferior vestibular nerve, 
vestibular nuclei, medial vestibulospinal tract, cervical motor neurons, and the 
accessory nerve)1–5. The ocular VEMP test assesses the integrity of the vestibulo-
ocular reflex arc most likely beginning at the utricular afferents (however, it is 
debated extensively in literature whether the precise origin is predominately the 
utriculus or a combination of both the utriculus and the sacculus) to ultimately 
evoke an excitatory motor response in the contralateral inferior oblique external 
eye muscle (by subsequently travelling through the ipsilateral superior vestibular 
nerve, vestibular nuclei, medial longitudinal fasciculus, and contralateral 
oculomotor nucleus and nerve)1–10. We refer to figure 1, chapter 2, for a schematic 
representation of the complex neurophysiological pathways concerning the 
vestibulo-ocular and vestibulo-spinal reflex arcs and to figure 2, chapter 2, for an 
example of typical normal VEMP responses5. Chapter 2 gives a detailed overview 
 
201804 proefschrift Jeroen Venhovens.indd   114 26-01-18   15:06
Summary, general discussion, and perspectives for future research
C
ha
pt
er
 7
115
 
concerning VEMP abnormalities in different central neurological disorders, the  
interpretation of these results, and possible clinical applications. This was achieved 
through critical assessment of the available literature; the level of diagnostic 
evidence was subsequently estimated. The general level of diagnostic evidence 
according to the Oxford centre of evidence-based medicine mainly exists of level 
4 evidence with exceptions reaching a maximum of level 2b evidence (for Multiple 
Sclerosis, vestibular schwannomas, PD, and vertebrobasilar stroke) leaving the total 
diagnostic evidence concerning VEMPs in central neurological disorders to be 
limited at this moment. However, VEMP abnormalities are seen rather often in 
central neurological disorders and careful interpretation of these abnormalities may 
give important localizing information, but mostly are not disease specific. We refer 
to table 1, chapter 2, for a detailed description of VEMP abnormalities at different 
anatomical localizations5. In Chapter 3 a prospective ocular and cervical VEMP 
study is described concerning the intra-, interobserver, and the test re-test reliability 
in twenty healthy volunteers. The intra- and interobserver reliability, which is an 
important aspect of clinical VEMP judgement, concerning the three experienced 
clinical neurophysiologists is excellent for both ocular and cervical VEMP studies. 
The group results concerning the first test and the re-test were similar and did not 
differ significantly. However, the individual results showed relevant variability. 
Despite this individual variability, the results of all volunteers remained within 
normal limits. The raw ocular and cervical VEMP peak-to-peak amplitudes were 
the most reliable test re-test parameters, followed by cervical VEMP latencies. The 
ocular VEMP latencies showed a poor test re-test reliability11. 
VEMP abnormalities are seen rather often in patients with either peripheral or central 
neurovestibular disorders, as well as in other central neurological disorders5,12. Careful 
interpretation of these abnormalities may give important localizing information 
concerning the side and the origin of the lesions within the central or peripheral 
vestibular system, which is the main strength of VEMP testing. However, VEMP 
testing performed for suspected peripheral vestibular disorders should be interpreted 
with great care when the patient has a concomitant central neurological disorder and 
vice versa. Chapter 2 gives additional information regarding the anatomical 
localization of VEMP abnormalities. In addition, I have to stress that the level of 
diagnostic evidence according to the Oxford centre of evidence-based medicine is 
currently rather limited to a general level 4 evidence with exceptions reaching a 
maximum of level 2b evidence (for Multiple Sclerosis, vestibular schwannomas, PD, 
and vertebrobasilar stroke). Therefore, in my opinion the primary indication for 
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VEMP testing in relationship to neurovestibular disorders should at this moment be 
patients whose neurovestibular complaints cannot be reliably localized to or within 
the central or peripheral neurovestibular system clinically, neither with (video)
nystagmography and additional caloric stimulation, nor with brain magnetic resonance 
imaging (MRI)5. There is however, one exception being the diagnostic work-up of a 
patient with a suspected superior semicircular canal dehiscence syndrome (SCDS), 
in which decreased ipsilateral cervical VEMP stimulation thresholds and especially 
increased contralateral ocular VEMP amplitudes are a very sensitive sign, which can 
help in identifying the pathological side. The main cause of this phenomenon is 
supposed to be the increased sound and pressure sensitivity of the ipsilateral labyrinth 
in comparison to the contralateral side13,14.
In general, VEMP abnormalities are not considered to be disease specific and thus do 
not give additional information concerning the nature of the lesion. However, one 
could speculate whether careful interpretation of the VEMP abnormalities can give 
insight into the pathophysiological hallmark of the disorder (whether the lesion is 
primary demyelinating, axonal, or a combination of both), similar to for example 
peripheral neuropathies. Demyelinating peripheral neuropathies are defined by a 
severe reduction in nerve conduction velocities, conduction blocks, increased temporal 
dispersion, severely delayed F-waves, and/or severely delayed distal nerve conduction 
latencies. Moreover, axonal peripheral neuropathies are defined by reduced amplitudes 
in the presence of relatively spared nerve conduction velocities15,16. 
To our knowledge, there are currently no reliable neurophysiological criteria to 
differentiate primary demyelinating or axonal disorders in relationship to nerve 
conduction studies by means of evoked potentials for central nervous system disorders. 
For example, optic neuritis in Multiple Sclerosis (which pathophysiologically has a 
primary demyelinating hallmark) typically causes asymmetric severe latency delays of 
the ipsilateral visual evoked potential (VEP) measurements with relatively spared 
amplitudes. Moreover, optic neuropathies caused by external compression, ischemia, 
metabolic disturbances, and neurodegenerative disorders tend to cause less pronounced 
latency delays and possibly a larger reduction in amplitudes in comparison to VEP 
abnormalities caused by optic neuritis17,18. However, brainstem auditory evoked 
potential (BAEP) abnormalities in Multiple Sclerosis patients are very aspecific, mainly 
causing peak IV and V abnormalities followed by latency prolongation of the I-V 
interpeak and especially the III-V interpeak latencies. The abnormalities described 
above, however, are not typical for demyelinating disorders and can be found in 
numerous other disorders, for instance brainstem gliomas, spinocerebellar 
degeneration, and hydrocephalus19. The VEMP results in Multiple Sclerosis patients 
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mainly show increased latencies followed by absent responses. However, delayed 
latencies were also reported in patients with Alzheimer’s disease, in patients with 
migraine, and in a few patients with vertebrobasilar stroke (most had absent responses 
followed by diminished amplitudes)5. 
To conclude on a hypothetical and purely speculative basis, on could argue, based 
upon all the arguments mentioned above, that severe asymmetrically prolonged VEMP 
latencies (more than 130 percent of the upper limit of normal) with relatively spared 
amplitudes and wave morphology may be caused by demyelinating lesions (analogous 
to VEP abnormalities in optic neuritis and nerve conduction abnormalities in 
demyelinating peripheral neuropathies). However, one could also state the opposite: 
that evoked potential measurements (and especially the BAEP and VEMP) do at this 
moment not allow this pathophysiological differentiation concerning the underlying 
aetiology based upon the numerous BAEP and VEMP case-reports in different 
disorders, which show that delayed latencies can also be found in numerous other 
conditions, which do not have a primary demyelinating hallmark (e.g. vertebrobasilar 
stroke and migraine). However, these reports do not contain detailed descriptions 
concerning the extend of the latency prolongation, which is expected to be more 
severe in demyelinating lesions compared to axonal lesions. Further clarification 
concerning this pathophysiological differentiation based upon evoked potential 
measurements for central neurological disorders seems interesting for further research. 
Not only could this pathophysiological differentiation be helpful diagnostically, if 
possible at all this differentiation could aid in unravelling the underlying 
pathophysiology of different central nervous system disorders (e.g. neurodegenerative 
disorders) and to follow their progression over time. To begin with, a similar study-
design which was used in the peripheral polyneuropathy study by Tankisi et al.15, 
comparing amplitudes and nerve conduction velocities in different medical disorders 
with a well-known pathophysiological hallmark, could be followed (however, adapted 
for VEMP and BAEP measurements in central nervous system disorders).
In Chapter 3, an important aspect of clinical VEMP judgement is described, being 
the intra- and interrater reliability, which was excellent in our study11. This study also 
demonstrates that experienced clinical neurophysiologists / neurologists with limited 
experience in the judgement of individual VEMP recordings could be reliably trained 
to judge individual examinations in a very short time (45 minutes).  
The VEMP test re-test study demonstrates an individual variability, however all results 
remained within normal limits, so this does not seem to be relevant for healthy 
subjects. One could speculate whether this is also the case for patients with abnormal 
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test results (whether their test results remained abnormal if these patients were re-
tested). The ocular and especially the cervical VEMP peak-to-peak amplitudes seem 
to be the most reliable test re-test parameters, followed by the cervical VEMP latencies. 
The ocular VEMP latencies on the other hand show a poor test re-test reliability. 
Standardization of the cervical VEMP amplitudes by means of standardizing the level 
of Sternocleidomastoid muscle contraction during the measurements, also is an 
important aspect of performing VEMP testing (for instance with a pressure gauge to 
assure that the pre-defined target level of force is applied consistently, as described by 
Vanspauwen et al.20,21). An alternative method for standardization of the cervical 
VEMP amplitudes is to correct them by using the rectified mean pre-stimulus 
electromyographic background signal. Unfortunately, at this moment well-defined 
methods for standardization of the ocular VEMP amplitudes do not exist. Nguyen et 
al.22 described an interesting method which they used for standardization of their 
ocular VEMP amplitudes, which to our knowledge has not been studied extensively 
in literature elsewhere. The authors used vertical saccades to correct their electrode 
placement. The recording electrodes were replaced when the inter eye amplitude 
caused by the vertical saccades was greater than 25 percent. The ocular VEMP test 
re-test study by Nguyen et al.22 showed a more reliable ocular VEMP amplitude in 
comparison to our study (moderate-to-good reliability in our study compared to an 
excellent reliability in the study by Nguyen et al.22). However, unfortunately the overall 
poor reliability of the ocular VEMP latencies did not improve with these 
standardization procedures. These standardization methods for the ocular VEMP are 
possibly effective and should certainly be investigated further.   
Static subjective visual vertical (SVV)
Summary chapter 4
Graviception is the perception of a person’s orientation relative to the gravitational 
force, which can be measured by means of the (static) subjective visual vertical 
(SVV). These graviceptive pathways integrate multimodal sensory input (i.e. 
vestibular, proprioceptive, and visual input) and subsequently estimate the relative 
position of one’s body with respect to the absolute vertical: the gravitational field 
of the Earth23–27. The static SVV results are almost exclusively determined by the 
otolith function and balance, as these are the main receptors in the peripheral 
vestibular system sensitive to gravitational forces (i.e. linear accelerations). 
However, neurovestibular lesions located more proximally both in the peripheral  
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and central vestibular system can obviously also cause abnormal static SVV results 
by disrupting the corresponding gravitational pathways secondarily resulting in  
an otolithic imbalance. Static SVV abnormalities for instance are a sensitive sign 
of brainstem dysfunction25,28. We refer to chapter 4 concerning the static SVV 
testing methodology. A technical prospective static SVV study in 44 healthy 
volunteers concerning the effects of different preset angle deviations and the test 
re-test variability is described in chapter 4. The static SVV results were significantly 
biased toward the side of the preset angle (Wilcoxon test, P ≤ 0.001), however 
not by the preset angle deviation itself (when deviations of 10, 20 and 30 degrees 
were compared). The test re-test results of the healthy volunteers were stable at a 
group level without significant differences, however individually they showed 
relevant variability with an overall poor reliability. However, all individual results 
remained within normal limits. The last aim of this study was to explore and 
further construct a robust static SVV testing protocol incorporating both 
monocular and binocular measurements. 
The final aim of the research described in Chapter 4 was to explore and construct a 
robust static SVV testing protocol incorporating both binocular and monocular 
measurements. The literature is severely hampered by the lack of a uniform testing 
protocol, resulting in a marked heterogeneity, which makes generalization of SVV 
findings in literature very difficult. At this moment, most studies in literature only 
perform binocular measurements, however the performance of both binocular and 
monocular measurements combined, gives additional information concerning the 
underlying localization of the lesion. Excellent research performed by Dieterich and 
Brandt25,28–30 showed that 94% of 111 patients with acute brainstem infarctions have 
a direction specific pathological binocular static SVV tilt. The binocular static SVV 
tilt is ipsiversive in peripheral unilateral vestibular disorders or pontomedullary lesions 
below the crossing of the graviceptive pathways. The binocular static SVV tilt is 
contraversive in pontomesencephalic brainstem lesions and indicates involvement of 
the medial longitudinal fasciculus (MLF), interstitial nucleus of Cajal (INC), and/or 
the rostral interstitial nucleus of the MLF. However, about 64% of the patients with 
lesions in the vestibular subnuclei of the thalamus and 44% of the patients with lesions 
in the vestibular cortex (i.e. insular, superior temporal, and transverse temporal gyri) 
too, showed binocular pathologic static SVV tilts, which mainly were contraversive 
and some were ipsiversive. Yet, it is not only central or peripheral neurovestibular 
disorders that cause pathologic deviations of the static SVV tilt. Pathologic static SVV 
tilts also occurred in 67% of the patients with vertical external eye muscle paresis of 
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peripheral origin due to ipsilateral third and fourth cranial nerve palsies. The 
pathologic static SVV tilts, however, were only monocular and confined to the paretic 
eye in the acute stage up till three months. Thereafter, the monocular static SVV tilt 
gradually transferred to the non-paretic eye as a result of compensation mechanisms29. 
The main difference between the pathologic static SVV tilts in supranuclear and 
infranuclear ocular motor disorders, is that infranuclear abnormalities are strictly 
confined to the paretic eye in the acute setting and non-paretic eye in the chronic 
phase after three months. Therefore, binocular static SVV tilts were normal in all 
patients with infranuclear ocular motor disorders in contrast with supranuclear lesions 
which were abnormal in 94% of the brainstem strokes, all showing pathological 
binocular SVV tilts. Also, bilateral fourth cranial nerve palsies could be localized by 
means of static SVV testing, which showed bilateral pathologic monocular tilts with 
an opposite direction and normal binocular static SVV tilts. Moreover, pathologic 
SVV tilts in supranuclear lesions are always directed towards the same side25,29. 
Therefore, additional static SVV testing incorporating both monocular and binocular 
measurements gives additional important diagnostic information. 
We also demonstrated that static SVV tilts are biased in the direction of the preset 
angle, but are not influenced by the deviation of the preset angle (for deviations larger 
than 10 degrees). Our findings are in concordance with earlier studies24,31, however 
preset angle deviations smaller than 8 degrees had less influence on the final static 
SVV results. In our study and in literature pathologic static SVV tilts between the 10 
and 20 degrees were frequently encountered. Therefore, I would advise to use a preset 
angle deviation of 20 degrees and to divide counter-clockwise and clockwise preset 
angles equally when performing repeated measurements (because of the bias of the 
static SVV result in the direction of the preset angle). Both of the recommendations 
were incorporated in the final static SVV testing protocol, as well as the combination 
of monocular and binocular measurements. 
Analogous to VEMP testing, static SVV testing in healthy volunteers also showed an 
individual test re-test variability, which was stable at a group level without significant 
differences. All the results of the healthy volunteers, however, remained within normal 
limits. One could wonder, if the same is true for patients with pathologic SVV tilts. 
However, pathologic SVV tilts tend to normalize over time, for instance in brainstem 
strokes25,28 and to gradually transfer from the paretic eye in the acute phase to the non-
paretic eye after a time period of three months in infranuclear ocular motor disorders29. 
We would advise further research concerning the test re-test variability in patients with 
pathological static SVV tilts, but to keep the time between the tests very short (for instance 
a few days at the most) because of the dynamic nature of the pathological static SVV tilts. 
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The application of static SVV testing outside specialized tertiary dizziness clinics is 
also hampered by the high costs of the specialized equipment. Interestingly, Zwergal 
et al.32 studied a low-cost, easily performed, and reliable bedside static SVV test by 
using a selfmade modified bucket, see figure 1. The conversion of the bucket takes 
less than one hour and costs less than 5 dollars. The authors compared the bucket-test 
with conventional static SVV testing by using a hemispheric dome and they found 
an excellent inter- and intra-test reliability (Pearson correlation coefficients respectively 
0.89-0.90 and 0.92) both in healthy subjects and in patients with acute neurovestibular 
disorders. Brodsky et al.33 recently repeated the bucket version of the static SVV test 
in paediatric patients with suspected neurovestibular disorders, however the authors 
modified the original bucket test by using a smartphone with a subjective vertical 
application which costs about 18 dollars. The authors also compared the smartphone-
based bucket version of the static SVV test with conventional static SVV testing while 
using a hemispheric dome and found a moderate correlation (Pearson correlation 
coefficient 0.43). However, despite the moderate correlation with conventional static 
SVV testing smartphone-based bucket static SVV testing seems to be a useful screening 
test for acute neurovestibular disorders with a sensitivity of 75%, specificity of 100%, 
positive predictive value of 100%, and negative predictive value of 92%. However, 
as promising as these new methods seem, further research with additional comparisons 
of the (smartphone-assisted) bucket version with the conventional static SVV test is 
needed in larger groups in order to confirm the earlier research reports.
Figure 1.
Bucket version of the SVV test, adapted from Zwergal et al. (2009)32
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PART TWO
Neurovestibular analysis and falls in Parkinson’s disease and atypical 
parkinsonism. A baseline study and one-year follow-up study
Summary chapter 5
Recurrent falls are a major problem in PD patients, and even more so in patients 
with AP. About 50% of the PD patients have recurrent fall episodes, and 
approximately 70% fall (at least once) annually34–37. PD patients have a 2.2-fold 
increase in fractures overall, and a 3 to 4-fold increase in hip fractures compared 
to a healthy age-matched population. Moreover, PD patients with hip fractures 
have higher overall mortality rates, and higher rates of surgical and post-operative 
complications38. Recently, a practical consensus-based overview concerning the 
risk factors for falling in PD patients was published39. However, vestibular function 
abnormalities were not addressed as an individual risk factor, which is surprising 
as the vestibular system is one of the key systems in maintaining balance by 
integrating multimodal sensory information (i.e. vestibular, proprioceptive, and 
visual sensory input) and by secondarily adjusting the outgoing motor response 
by means of the vestibulospinal reflexes37. Chapter 5 shows the results of a case-
control study in which the vestibular system function in 25 healthy age-matched 
volunteers, 30 PD, and 14 AP patients (6 patients with multiple system atrophy, 
3 with progressive supranuclear palsy, and 5 with vascular parkinsonism) was 
systematically investigated and compared to an age and gender-matched healthy 
control group37. Ninety percent of PD patients (27 of 30) and 100% of AP 
patients (all 14) showed signs of neurovestibular dysfunction, mainly with a 
central vestibular dysfunction profile, on laboratory examinations (i.e. VEMP, 
SVV, videonystagmography with additional caloric and rotatory chair stimulation). 
Moreover, vestibular testing abnormalities were correlated with an increased risk 
of falling when fallers among PD and AP patients were compared with non-fallers 
(P ≤ 0.001). 
Abnormal neurovestibular laboratory function test results are seen remarkably often 
in both PD and AP patients (90% of the PD patients and 100% of the AP patients). 
About 66% of the patients with mild Parkinson’s disease had abnormal neurovestibular 
laboratory function test results in comparison to 96% and 100% of the patients with 
moderate and severe Parkinson’s disease respectively (however, only 1 patient with 
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severe Parkinson’s disease was included). Therefore, abnormal neurovestibular 
laboratory test results are very common in early Parkinson’s disease, however, they 
seem to increase in advancing stages of the disorder. Also, patients with atypical 
Parkinsonism were clinically more affected in comparison to the patients with 
Parkinson’s disease (respectively Hoehn and Yahr stages 2.9±0.8 and 2.3±0.7; P = 
0.0152). Persons with vestibular and or other neurological disorders (i.e. other than 
Parkinson’s disease or atypical parkinsonism) in their medical history were excluded 
from the study. Moreover, none of the patients had relevant actual complaints or signs 
during the neurological and neuro-otological examinations suggestive of other 
vestibular disorders. We were obviously not able to exclude all other (central) 
neurovestibular disorders, mainly because the absence of current cerebral imaging 
studies. However, we did not have any clues suggestive of other neurovestibular 
disorders in the absence of relevant current medical complaints or abnormalities 
during neurological and neurovestibular clinical testing.
These abnormal neurovestibular function test results mainly have a central vestibular 
dysfunction profile in 78-93% of the PD and AP patients, whereas only one PD 
patient (4%) had a profile suggestive of a peripheral vestibular disorder (the other 
vestibular dysfunction profiles were non-localizing). Also, 57-79% of the AP and PD 
patients did not have complaints of dizziness or vertigo. However, one can question 
whether these central neurovestibular laboratory testing abnormalities are truly 
asymptomatic. Indeed, 10-18% of the AP and PD patients with falls had 
neurovestibular testing abnormalities as the only identifiable risk factor for falling 
(after exclusion of orthostatic hypotension, postural instability, freezing of gait, and 
moderate-to-severe cognitive problems)37. However, we acknowledge that we were 
not able to exclude all possible and previously reported risk factors for falling in PD39, 
but we did exclude the most relevant causes. Also, we may have missed additional 
contributions of, for example, mild orthostatic hypotension which can be variably 
present during clinical examination, and which can be missed during routine testing40. 
However, neurovestibular testing abnormalities were strongly correlated with an 
increased risk of falling when PD and AP patients were compared with non-falling 
patients (P≤0.001). Therefore, it was concluded that central neurovestibular 
dysfunction on vestibular laboratory testing is highly prevalent in both PD and AP 
patients compared to healthy volunteers, and is strongly associated with an increased 
risk of falling, which has not been reported earlier in the literature37. I acknowledge 
that the studied groups in the study were small, and also had a heterogeneous 
population (especially in the AP group, where subgroups were small). Therefore, the 
results must be interpreted cautiously and as hypothesis-generating for future research 
in larger groups. Moreover, it is currently unknown whether these strongly associated 
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neurovestibular laboratory abnormalities are directly associated with falling or a 
secondary epiphenomenon, for instance as a result of deconditioning. Also, 
dopaminergic medication does not seem to be the cause of these abnormalities as 
Pötter-Nerger demonstrated that levodopa may partially decrease vestibular testing 
abnormalities41,42. However, the central vestibular system is one of the key systems for 
maintaining balance by integrating multimodal sensory input (i.e. the visual, 
peripheral vestibular, and proprioceptive input) and by subsequently adjusting the 
outgoing motor response by means of the vestibulospinal reflexes. Therefore, one 
could argue, purely speculative and based upon theoretical physiological evidence, 
that vestibular dysfunction is causally linked to falling as a possible cause and not an 
epiphenomenon.
These central vestibular testing abnormalities in PD patients mostly consisted of 
abnormal evoked potential test results (VEMPs and BAEPs), which showed significant 
prolongation of the latencies (p13, n1, and interpeak III-V latencies) on the 
symptomatic brainstem side compared to healthy volunteers (0.003 ≤ P ≤ 0.019). 
However, comparison of these latencies at the asymptomatic side of PD patients with 
those of healthy volunteers, or a side-to-side comparison within PD patients, did not 
yield significantly different results, with the exception of the p13 cervical VEMP 
latency side-to-side comparison (P = 0.020). These results point to an asymmetrical 
brainstem involvement in the neurodegenerative process, mainly affecting the 
symptomatic brainstem side, and subsequently traveling along with the affected fibre 
tracts (i.e. the affected brainstem side is ipsilateral to the patient’s resting tremors, 
rigidity, and bradykinesia at the pontomedullary junction below the level of the 
vestibular nuclei; and the affected fibre tracts cross over to the contralateral brainstem 
side above the level of the vestibular nuclei along with the decussation of the medial 
longitudinal fasciculus). There is just one prior study by Pötter-Nerger et al.41, which 
only shows asymmetrical abnormalities of the ocular VEMP tests involving the 
symptomatic brainstem side, whereas the cervical VEMP tests did not show these 
asymmetrical abnormalities. However, the differences between Pötter-Nerger et al.41’s 
study and ours can possibly be explained by the difference in population size (i.e. 30 
PD patients in our study versus 13 patients in the study by Pötter-Nerger et al.41), as 
small differences between groups are more easily detected in a larger study population. 
Our study demonstrates that not only the central vestibular brainstem pathways are 
affected at the symptomatic brainstem side, but also that the central auditory brainstem 
pathways seem to be affected, which is illustrated by the prolonged III-V BAEP 
interlatencies at the symptomatic brainstem side. As discussed earlier, the main BAEP 
and VEMP abnormalities in our study consisted of severely prolonged cervical VEMP 
p13 latency, ocular VEMP n1 latency, and BAEP III-V inter-latency prolongations 
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(i.e. p13 mean latency prolongation of 134% upper limit of normal (ULN); n1 mean 
latency prolongation of 128% ULN; mean III-V BAEP inter-latency prolongation 
of 120% ULN) with preserved amplitudes37. As discussed in paragraph 1.1 of this 
chapter, asymmetrically severely prolonged evoked potential latencies combined with 
relatively preserved amplitudes can theoretically be caused by a primary demyelinating 
neurodegeneration. However, the pathophysiological distinction between axonal and 
demyelinating central nervous system pathologies based upon evoked potential 
measurements is purely speculative and has to our knowledge not been studied earlier 
in literature. At this moment, clear neurophysiological criteria for this 
pathophysiological differentiation in central nervous system disorders are lacking, in 
contrast to the neurophysiological criteria that are present for this differentiation of 
the peripheral neuropathies. Further research concerning this pathological 
differentiation between axonal and demyelinating central nervous system disorders, 
based upon evoked potential measurements seems interesting, as this gives important 
insights into the pathophysiological hallmark of the underlying disease. 
Parkinson’s disease is defined pathophysiologically by the presence of abnormal alpha-
synuclein protein aggregations in neurons and glial cells, and by progressive 
neurodegeneration of selected brain regions (e.g. cholinergic pedunculopontine 
nucleus, dopaminergic substantia nigra and ventral tegmental area). These protein 
aggregates are called: a) Lewy bodies in neuronal perikarya, b) Lewy neuritis in 
neuronal processes, and c) coiled bodies in affected oligodendrocytes43,44. Also, 
multiple system atrophy (MSA) – one of the forms of atypical parkinsonism – is 
characterized by neuronal and glial alpha-synuclein aggregates, however, it is generally 
believed that neurons in MSA also have inclusions within their brainstem nuclei in 
contrast to PD44. Seidel et al.43 demonstrated Lewy bodies and Lewy neuritis in all 
cranial nerve nuclei, premotor oculomotor, precerebellar, and vestibular nuclei for 
the first time in PD patients; this contrasted with the general belief that such 
abnormalities were limited to MSA patients. Moreover, Lewy neuritis and coiled 
bodies were demonstrated in all brainstem fibre tracts. These abnormalities may be 
the result of a transneuronal disease spread along the anatomical pathways due to 
disturbed intra-axonal transport processes43. When we combine both the 
neuropathological and neurophysiological research data in PD patients, a transneuronal 
disease progression along the anatomical pathways, asymmetrically affecting the 
brainstem seems most likely (i.e. brainstem fibre tracts ipsilateral to the patient’s 
clinically most affected side at the medullopontine junction, and contralateral to the 
patient’s clinically most affected side above the motor decussation at the pontine and 
pontomesencephalic junction). However, asymmetrical brainstem degeneration 
spreading along with the brainstem fibre tracts below the level of the substantia nigra 
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in the mesencephalon has not yet been confirmed in neuropathological studies and 
seems an interesting topic for future research. The neuropathological brainstem 
abnormalities suggest a neurodegenerative process with a primary axonal hallmark43, 
however the electrodiagnostic evoked potential abnormalities (i.e. severely delayed 
latencies with relatively spared amplitudes) suggest an important demyelinating 
neurodegenerative component. However, recent experimental evidence in different 
animal models suggests that synaptic dysfunction is an early and important feature 
in PD45, which might also (partially) explain the evoked potential abnormalities found 
in VEMP and BAEP testing (apart from the possible concomitant primary axonal 
and or demyelinating features of the disorder). Future neuropathological brainstem 
studies in PD should therefore also focus on the myelination of affected brainstem 
fibre tracts containing Lewy neuritis and coiled bodies, with the primary question 
whether concomitant demyelination is an important part of the neurodegenerative 
process. Obviously, more studies are needed concerning the process of synaptic 
transmission to confirm whether the synaptic dysfunction, which is found in animal 
PD models, is present in PD patients.
Summary chapter 6
The one-year follow-up results of the case-control study described above in 
paragraph 2 of this chapter, and which is discussed in chapter 5 in more detail, 
are discussed in Chapter 6. All 25 healthy volunteers, 14 AP, and 30 PD patients 
were contacted for a telephone interview one-year following the baseline 
examinations, and only 1 AP (MSA) patient was lost to follow-up (attrition bias 
of only 1.4%). All participants were questioned about their fall frequency based 
upon their fall diaries, and their subjective balance confidence (according to the 
ABC-16 questionnaire). The results were compared to the baseline results. The 
primary aim was to determine whether neurovestibular laboratory tests (collected 
at baseline) can predict future falls in PD and AP patients. Cervical and ocular 
VEMPs combined with clinical tests for postural imbalance were the best 
predictors of future fall incidents, both in PD and AP groups, with a sensitivity 
of 100%. The positive predictive value was 68.2% when only one VEMP test was 
abnormal, and 83.3% when both VEMP tests were abnormal. The fall frequency 
at baseline and after one year was significantly higher and the balance confidence 
scale (ABC-16) was significantly lower in both the PD and AP groups compared 
to healthy controls. Therefore, abnormal VEMP tests are associated with an 
increased risk of future fall incidents in PD and AP patients with postural 
imbalance in the absence of freezing of gait46.
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A screening test is only useful in clinical practice when it has both a high sensitivity 
and a positive predictive value (PPV). Knowing that freezing of gait is a common risk 
factor for falls47,48, we examined the association between freezing at baseline and the 
subsequent risk of falls. In our study, assessment of freezing of gait (by qualitative 
assessment of straight walking in combination with the assessment of rapid clockwise 
and count-clockwise turning) was the clinical test with the highest PPV (namely 
87.5%), but the sensitivity was only 46.9% (as only 7 of the 15 falling patients were 
detected). This makes testing for freezing of gait by itself inadequate for screening 
purposes, since half of the potential fallers are missed. Moreover, clinical testing for 
postural imbalance (using the retropulsion test) had a sensitivity of 100% for detection 
of falling among PD and AP patients, but the PPV was only 46.9%. So again, this 
clinical test is, by itself, unsuitable for screening purposes because about half of the 
patients with abnormal results will not fall in the following year. However, the 
combination of both cervical and ocular VEMP testing, combined with clinical testing 
for postural imbalance, seemed to be the optimal combination (yielding a sensitivity 
of 100% for detecting patients at risk of future falling, with a PPV of 68.2% for one 
abnormal VEMP test and a PPV of 83.3% when both VEMP tests are abnormal). 
However, the presence of freezing of gait is such a strong, but insensitive, predictor 
for future falls in both AP and PD patients that VEMP testing in these patients does 
not have any additional value (i.e. all patients with freezing of gait also had postural 
imbalance and abnormal VEMPs). Therefore, I concluded that cervical and ocular 
VEMP testing can possibly give additional information concerning the future fall risk 
in selected PD and AP patients (i.e. those patients with postural imbalance in the 
absence of freezing of gait)46. However, these results, as discussed above, must be 
interpreted cautiously as the studied groups contained small numbers of patients, 
with a heterogeneous population in the AP patient group.
One can speculate whether this additional information will aid in guiding future fall 
prevention therapies as PD and AP patients with postural imbalance already have a 
high risk for falling. Multiple meta-analyses and Cochrane reviews of physiotherapy 
in PD reported short-term statistically significant, but clinically modest positive effects 
concerning balance-related activity performance and improvement of gait. However, 
there was no significant evidence concerning the reduction of the risk of falling49–52. 
Moreover, one Cochrane review49 compared the different physical therapies and 
concluded that a formal qualitative comparison was not possible because of the 
heterogeneity of the studied techniques, small sample sizes of the studied groups, 
methodological flaws, and risk of publication bias. Therefore, there is no evidence to 
choose or advise one form of physical therapy over another, as was concluded by the 
authors49. High-quality prospective studies with large study groups and long-term 
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follow-up are needed to assess the effect of physiotherapy in PD and AP concerning 
the reduction of the risk of falling, and to assess which form of physical therapy is 
superior in achieving this goal. Such studies should follow evidence-based guidelines 
for physiotherapy strategies in PD53,54, and the interventions should ideally be delivered 
by therapists experienced in the management of patients with PD55,56.
A recent single-case study described the motor and non-motor effects of repeated 
caloric vestibular stimulation in a patient with PD57. The motor performance and the 
non-motor scores (i.e. Montreal cognitive assessment, hospital depression scale, and 
Epworth sleepiness scale) improved significantly during repeated caloric vestibular 
stimulation and persisted during follow-up 5 months after stimulation. Moreover, 
these improvements were not seen during the first phase of the study which consisted 
of sham-stimulation. Moreover, recent studies in PD patients provide preliminary 
evidence that (stochastic) galvanic vestibular stimulation can possibly significantly 
reduce postural instability, improve corrective postural responses, improve anterior 
bending posture, and is, above all, safe for short term use58–62. These studies, however, 
consist of single case-reports or small case series without further evidence, and should 
therefore in my opinion be considered as proof-of-concept evidence. Obviously, large 
scale randomized controlled double-blinded trials are needed in PD and AP patients 
to demonstrate whether (stochastic) galvanic vestibular or repeated caloric stimulation 
is able to clinically and statistically significantly reduce fall episodes and/or to improve 
motor and non-motor symptoms.
At this moment, I do not advise to perform VEMP testing in PD or AP patients as 
it does not have any treatment consequences. However, vestibular laboratory testing 
(i.e. VEMP, SVV, and or videonystagmography with caloric and rotatory chair 
stimulation) might be helpful in elucidating the underlying physiological changes 
secondary to repeated vestibular stimulation as mentioned earlier. 
Highlights of the most important findings
 - Abnormal VEMP and SVV laboratory test results can give important clues to the 
localization of the underlying neurovestibular problem, but are not disease specific. 
 - Approximately 90% of PD patients and 100% of AP patients have abnormal 
neurovestibular laboratory test results, with a predominantly central neurovestibular 
dysfunction profile.
 - In PD patients, it is mainly the symptomatic brainstem side that is 
electrophysiologically affected, compared to healthy volunteers (i.e. the affected 
brainstem side is ipsilateral to the patient’s resting tremors, rigidity, and bradykinesia 
at the pontomedullary junction below the level of the vestibular nuclei; and the 
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affected fibre tracts cross over to the contralateral brainstem side above the level of 
the vestibular nuclei along with the decussation of the medial longitudinal 
fasciculus)
 - PD and AP patients with laboratory signs of neurovestibular dysfunction have a 
statistically significant increased risk of falling.
 - Cervical and ocular VEMP testing in combination with clinical testing for postural 
imbalance can predict future fall incidents in PD and AP patients (sensitivity of 
100%, PPV of 68.2% with one abnormal VEMP test, and a PPV of 83.3% when 
both VEMP tests are abnormal). 
201804 proefschrift Jeroen Venhovens.indd   129 26-01-18   15:06
Chapter 7
130
References
1. Curthoys, I. S. A critical review of the neurophysiological evidence underlying clinical vestibular 
testing using sound, vibration and galvanic stimuli. Clin. Neurophysiol. 121, 132–144 (2010).
2. Eleftheriadou, A. & Koudounarakis, E. Vestibular-evoked myogenic potentials eliciting: An 
overview. European Archives of Oto-Rhino-Laryngology 268, 331–339 (2011).
3. Rosengren, S. M., Welgampola, M. S. & Colebatch, J. G. Vestibular evoked myogenic potentials: 
Past, present and future. Clin. Neurophysiol. 121, 636–651 (2010).
4. Rosengren, S. & Kingma, H. New perspectives on vestibular evoked myogenic potentials. Curr. 
Opin. Neurol. 26, 74–80 (2013).
5. Venhovens, J., Meulstee, J. & Verhagen, W. Vestibular Evoked Myogenic Potentials (VEMPs) in 
Central Neurological Disorders. Clin. Neurophysiol. 127, 40–49 (2016).
6. Colebatch, J. G. Sound conclusions? Clin. Neurophysiol. 121, 124–126 (2010).
7. Curthoys, I. S. A balanced view of the evidence leads to sound conclusions. A reply to J.G. Colebatch 
‘Sound conclusions?’. Clin. Neurophysiol. 121, 977–8 (2010).
8. Papathanasiou, E. S. Ocular vestibular evoked myogenic potentials (OVEMPs): saccule or utricle? 
Clin. Neurophysiol. 123, 216 (2012).
9. Papathanasiou, E. S. & Papacostas, S. S. Vestibular evoked myogenic potentials: the fuzzy picture 
of different stimulation types is beginning to come into focus. Clin. Neurophysiol. 124, 1926–7 
(2013).
10. Todd, N. The ocular vestibular evoked myogenic potential (OVEMP), ten years old. Clin. 
Neurophysiol. 125, 439–41 (2014).
11. Venhovens, J., Meulstee, J. & Verhagen, W. I. M. Ocular and Cervical Vestibular Evoked Myogenic 
Potentials (VEMPs) in healthy volunteers: the intra-, interobserver, and the test re-test reliability. 
J. Vestib. Res. 25, 161–7 (2015).
12. Brantberg, K. Vestibular evoked myogenic potentials (VEMPs): Usefulness in clinical neurotology. 
Seminars in Neurology 29, 541–547 (2009).
13. Yew, A. et al. Characteristics and management of superior semicircular canal dehiscence. J. Neurol. 
Surg. B. Skull Base 73, 365–70 (2012).
14. Zuniga, M. & Janky, K. Ocular vs. cervical VEMPs in the diagnosis of superior semicircular canal 
dehiscence syndrome. Otol. Neurotol.  Off. Publ. Am. Otol. Soc. Am. Neurotol. Soc. [and] Eur. Acad. 
Otol. Neurotol. Neurotol. 34, 121–126 (2013).
15. Tankisi, H., Pugdahl, K., Johnsen, B. & Fuglsang-Frederiksen, A. Correlations of nerve conduction 
measures in axonal and demyelinating polyneuropathies. Clin. Neurophysiol. 118, 2383–2392 
(2007).
16. Chung, T., Prasad, K. & Lloyd, T. E. Peripheral neuropathy. Clinical and electrophysiological 
considerations. Neuroimaging Clinics of North America 24, 49–65 (2014).
17. Nuwer, M. R. Fundamentals of evoked potentials and common clinical applications today. 
Electroencephalography and Clinical Neurophysiology 106, 142–148 (1998).
18. Lascano, A. M., Lalive, P. H., Hardmeier, M., Fuhr, P. & Seeck, M. Clinical evoked potentials in 
neurology: a review of techniques and indications. J. Neurol. Neurosurg. Psychiatry jnnp-2016-
314791 (2017). doi:10.1136/jnnp-2016-314791
19. O.N., M. Brainstem auditory evoked potentials. J. Clin. Neurophysiol. 11, 319–342 (1994).
20. Vanspauwen, R., Wuyts, F. L. & Van De Heyning, P. H. Validity of a new feedback method for the 
VEMP test. Acta Otolaryngol. 126, 796–800 (2006).
21. Vanspauwen, R., Wuyts, F. L. & Van De Heyning, P. H. Vestibular evoked myogenic potentials: 
Test-retest reliability and normative values obtained with a feedback method for the 
sternocleidomastoid muscle contraction. J. Vestib. Res. Equilib. Orientat. 19, 127–135 (2009).
22. Nguyen, K. D., Welgampola, M. S. & Carey, J. P. Test-retest reliability and age-related characteristics 
of the ocular and cervical vestibular evoked myogenic potential tests. Otol. Neurotol. 31, 793–802 
(2010).
23. Venhovens, J., Meulstee, J. & Verhagen, W. I. M. Static Subjective Visual Vertical in Healthy 
Volunteers: The Effects of Different Preset Angle Deviations and Test-Retest Variability. 
Neuroophthalmology. 40, 113–119 (2016).
201804 proefschrift Jeroen Venhovens.indd   130 26-01-18   15:06
Summary, general discussion, and perspectives for future research
C
ha
pt
er
 7
131
24. Baccini, M., Paci, M., Del Colletto, M., Ravenni, M. & Baldassi, S. The assessment of subjective 
visual vertical: comparison of two psychophysical paradigms and age-related performance. Atten. 
Percept. Psychophys. 76, 112–22 (2014).
25. Brandt, T. & Dieterich, M. Vestibular syndromes in the roll plane: topographic diagnosis from 
brainstem to cortex. Ann. Neurol. 36, 337–47 (1994).
26. Tarnutzer,  a a, Bockisch, C., Straumann, D. & Olasagasti, I. Gravity dependence of subjective 
visual vertical variability. J. Neurophysiol. 102, 1657–1671 (2009).
27. Yelnik, A. P. et al. Perception of verticality after recent cerebral hemispheric stroke. Stroke 33, 
2247–2253 (2002).
28. Dieterich, M. & Brandt, T. Ocular torsion and tilt of subjective visual vertical are sensitive brainstem 
signs. Ann. Neurol. 33, 292–299 (1993).
29. Dieterich, M. & Brandt, T. Ocular torsion and perceived vertical in oculomotor, trochlear and 
abducens nerve palsies. Brain 116, 1095–1104 (1993).
30. Brandt, T., Dieterich, M. & Danek, A. Vestibular cortex lesions affect the perception of verticality. 
Ann. Neurol. 35, 403–412 (1994).
31. Pagarkar, W., Bamiou, D.-E., Ridout, D. & Luxon, L. M. Subjective visual vertical and horizontal: 
effect of the preset angle. Arch. Otolaryngol. Head. Neck Surg. 134, 394–401 (2008).
32. Zwergal, A. et al. A bucket of static vestibular function. Neurology 72, 1689–1692 (2009).
33. Brodsky, J. R., Cusick, B. A., Kawai, K., Kenna, M. & Zhou, G. Peripheral vestibular loss detected 
in pediatric patients using a smartphone-based test of the subjective visual vertical. Int. J. Pediatr. 
Otorhinolaryngol. 79, 2094–2098 (2015).
34. Wood, B. H., Bilclough, J. A., Bowron, A. & Walker, R. W. Incidence and prediction of falls in 
Parkinson’s disease: a prospective multidisciplinary study. J. Neurol. Neurosurg. Psychiatry 72, 721–
725 (2002).
35. Bloem, B. & Bhatia, K. in Clinical disorders of balance, posture and gait. (ed. Bronstein AM, Brandt 
T, Nutt JG, W. M.) 173–206 (Arnold: London, 2004).
36. Grimbergen, Y. A. M., Munneke, M. & Bloem, B. R. Falls in Parkinson’s disease. Curr. Opin. Neurol. 
17, 405–415 (2004).
37. Venhovens, J., Meulstee, J., Bloem, B. R. & Verhagen, W. I. M. Neurovestibular analysis and falls 
in Parkinson’s disease and atypical parkinsonism. Eur. J. Neurosci. 43, 1636–46 (2016).
38. Critchley, R. J., Khan, S. K., Yarnall, A. J., Parker, M. J. & Deehan, D. J. Occurrence, management 
and outcomes of hip fractures in patients with Parkinson’s disease. Br. Med. Bull. 115, 135–42 
(2015).
39. van der Marck, M. A. et al. Consensus-based clinical practice recommendations for the examination 
and management of falls in patients with Parkinson’s disease. Parkinsonism and Related Disorders 
20, 360–369 (2014).
40. Thijs, R. D., Bloem, B. R. & Dijk, J. G. Falls, faints, fits and funny turns. J. Neurol. 256, 155–167 
(2009).
41. Pötter-Nerger, M., Govender, S., Deuschl, G., Volkmann, J. & Colebatch, J. G. Selective changes 
of ocular vestibular myogenic potentials in Parkinson’s disease. Mov. Disord. 30, 584–9 (2015).
42. Pötter-Nerger, M., Reich, M. M., Colebatch, J. G., Deuschl, G. & Volkmann, J. Differential effect 
of dopa and subthalamic stimulation on vestibular activity in Parkinson’s disease. Mov. Disord. 27, 
1268–75 (2012).
43. Seidel, K. et al. The brainstem pathologies of Parkinson’s disease and dementia with Lewy bodies. 
Brain Pathol. 25, 121–35 (2015).
44. Dickson, D. W. Parkinson’s disease and parkinsonism: neuropathology. Cold Spring Harb. Perspect. 
Med. 2, (2012).
45. Schirinzi, T. et al. Early synaptic dysfunction in Parkinson’s disease: Insights from animal models. 
Mov. Disord. 0, 1–12 (2016).
46. Venhovens, J., Meulstee, J., Bloem, B. R. & Verhagen, W. I. M. Neurovestibular dysfunction and 
falls in Parkinson’s disease and atypical Parkinsonism: a prospective one year follow-up study. Artic. 
Submitt.
47. Bloem, B. R., Hausdorff, J. M., Visser, J. E. & Giladi, N. Falls and freezing of gait in Parkinson’s 
disease: A review of two interconnected, episodic phenomena. Mov. Disord. 19, 871–884 (2004).
48. Okuma, Y. Freezing of gait and falls in Parkinson’s disease. J. Parkinsons. Dis. 4, 255–60 (2014).
201804 proefschrift Jeroen Venhovens.indd   131 26-01-18   15:06
Chapter 7
132
49. Tomlinson, C. L. et al. Physiotherapy for Parkinson’s disease: a comparison of techniques. Cochrane 
database Syst. Rev. CD002815 (2014). doi:10.1002/14651858.CD002815.pub2
50. Tomlinson, C. L. et al. Physiotherapy versus placebo or no intervention in Parkinson’s disease. 
Cochrane database Syst. Rev. CD002817 (2013). doi:10.1002/14651858.CD002817.pub4
51. Tomlinson, C. et al. Physiotherapy intervention in Parkinson’s disease: systematic review and meta-
analysis. Bmj 345, e5004 (2012).
52. Allen, N. E., Sherrington, C., Paul, S. S. & Canning, C. G. Balance and falls in Parkinson’s disease: 
a meta-analysis of the effect of exercise and motor training. Mov. Disord. 26, 1605–15 (2011).
53. Keus, S. H. J., Munneke, M., Nijkrake, M. J., Kwakkel, G. & Bloem, B. R. Physical therapy in 
Parkinson’s disease: evolution and future challenges. Mov. Disord. 24, 1–14 (2009).
54. Radder, D. L. M. et al. Physical therapy and occupational therapy in Parkinson’s disease. Int. J. 
Neurosci. 1–14 (2017). doi:10.1080/00207454.2016.1275617
55. Bloem, B. R. & Munneke, M. Revolutionising management of chronic disease: the ParkinsonNet 
approach. BMJ 348, g1838–g1838 (2014).
56. de Vries, N. M., Sturkenboom, I. H. & Bloem, B. R. Physiotherapy and Occupational Therapy 
and Mild to Moderate Parkinson Disease. JAMA Neurol. 73, 893–4 (2016).
57. Wilkinson, D., Podlewska, A. & Sakel, M. A durable gain in motor and non-motor symptoms of 
Parkinson’s Disease following repeated caloric vestibular stimulation: A single-case study. 
NeuroRehabilitation 38, 179–82 (2016).
58. Samoudi, G., Jivegård, M., Mulavara, A. P. & Bergquist, F. Effects of Stochastic Vestibular Galvanic 
Stimulation and LDOPA on Balance and Motor Symptoms in Patients With Parkinson’s Disease. 
Brain Stimul. 8, 474–80
59. Rizzo-Sierra, C. V, Gonzalez-Castaño, A. & Leon-Sarmiento, F. E. Galvanic vestibular stimulation: 
a novel modulatory countermeasure for vestibular-associated movement disorders. Arq. 
Neuropsiquiatr. 72, 72–7 (2014).
60. Kataoka, H. et al. Can Postural Instability Respond to Galvanic Vestibular Stimulation in Patients 
with Parkinson’s Disease? J. Mov. Disord. 9, 40–3 (2016).
61. Okada, Y. et al. Galvanic vestibular stimulation may improve anterior bending posture in Parkinson’s 
disease. Neuroreport 26, 405–10 (2015).
62. Pal, S., Rosengren, S. M. & Colebatch, J. G. Stochastic galvanic vestibular stimulation produces a 
small reduction in sway in Parkinson’s disease. J. Vestib. Res. 19, 137–42 (2009).
201804 proefschrift Jeroen Venhovens.indd   132 26-01-18   15:06
Summary, general discussion, and perspectives for future research
C
ha
pt
er
 7
133
201804 proefschrift Jeroen Venhovens.indd   133 26-01-18   15:06
201804 proefschrift Jeroen Venhovens.indd   134 26-01-18   15:06
Nederlandse samenvatting, algemene discussie en  
perspectieven voor toekomstig wetenschappelijk onderzoek
Chapter 8
201804 proefschrift Jeroen Venhovens.indd   135 26-01-18   15:06
Chapter 8
136
Deze thesis is verdeeld in twee delen welke apart van elkaar zullen worden 
bediscussieerd. Het eerste deel omvat technische en praktische problemen van 
neurovestibulaire onderzoeken met de nadruk op vestibulaire geëvoceerde potentialen 
(VEMP) en de statische subjectieve visuele verticaliteit (SVV). Het tweede deel geeft 
een gedetailleerd overzicht van een wetenschappelijke studie met betrekking tot 
neurovestibulaire onderzoeken bij personen met de ziekte van Parkinson (PD) en 
atypische parkinsonisme (AP) – zowel de baseline resultaten als na een follow-up duur 
van één jaar. Ieder deel begint met een korte samenvatting van het betreffende 
hoofdstuk en wordt gevolgd een algemene discussie en perspectieven voor toekomstig 
wetenschappelijk onderzoek.
DEEL EEN
Neurovestibulaire testen – praktische en technische problemen
Vestibulair geëvoceerde potentialen (VEMP)
Samenvatting hoofdstukken 2 en 3
Vestibulair geëvoceerde potentialen testen (VEMP) kwamen ongeveer twee 
decades geleden in gebruik als testen welke geschikt zijn voor gedetailleerde 
neurofysiologische beoordeling van het centrale en perifere vestibulaire systeem. 
VEMP testen kunnen worden onderverdeeld in een cervicale en oculaire respons. 
De cervicale VEMP test beoordeelt de integriteit van de vestibulospinale reflexboog 
welke begint bij de sacculus om uiteindelijk een inhibitoir motore respons te 
veroorzaken in de ipsilaterale sternocleidomastoïdeus spier (door vervolgens via 
de ipsilaterale inferieure vestibulaire zenuw, vestibulaire kernen, mediale 
vestibulospinale tractus, cervicale spinale motore neuronen en de nervus 
accessorius te reizen)1-5. De oculaire VEMP test beoordeelt de integriteit van de 
vestibulo-oculaire reflexboog welke meest waarschijnlijk begint in de utriculus 
(over de precieze origine wordt echter uitgebreid gedebatteerd in de literatuur en 
met name of de exacte origine voornamelijk de utriculus is of een combinatie van 
de utriculus en de sacculus) om uiteindelijk een excitatoire motore respons te 
veroorzaken in de contralaterale musculus obliquus inferior (door vervolgens via 
de ipsilaterale superieure vestibulaire zenuw, vestibulaire kernen, fasciculus 
longitudinalis medialis, contralaterale nucleus oculomotorius en nervus 
oculomotorius te reizen)1-10. Voor een schematische representatie van deze  
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complexe neurofysiologische baansystemen5 van de vestibulo-oculaire en  
vestibulospinale reflexbogen verwijzen we gaarne naar figuur 1, hoofdstuk 2. Voor 
een voorbeeld met betrekking tot de normale cervicale en oculaire VEMP 
responsen verwijzen we u gaarne naar figuur 2, hoofdstuk 2. Hoofdstuk 2 geeft 
een gedetailleerd overzicht van de VEMP afwijkingen in verschillende centraal 
neurologische aandoeningen, de interpretatie van deze VEMP responsen en 
mogelijke klinische toepassingen. Hiervoor werd de beschikbare wetenschappelijke 
literatuur kritisch beoordeeld en vervolgens werd op basis van deze gegevens het 
niveau van diagnostische evidentie ingeschat. Het algemene niveau van 
diagnostische evidentie volgens het Oxford centrum voor evidence-based medicine 
bestaat voornamelijk uit een graad 4 evidentie voor het gebruik van VEMP testen 
voor centraal neurologische aandoeningen met enkele uitzonderingen welke een 
maximum graad van 2b bereiken (voor Multiple Sclerosis, vestibulaire 
schwannomen, ziekte van Parkinson en herseninfarcten in het vertebrobasilaire 
stroomgebied). Hierbij blijft de totale diagnostische evidentie met betrekking tot 
VEMP afwijkingen in centraal neurologische aandoeningen erg beperkt op het 
moment. VEMP afwijkingen worden regelmatig gezien in centraal neurologische 
aandoeningen en gedetailleerde interpretatie van de resultaten kan belangrijke 
lokaliserende informatie geven, echter de afwijkingen zijn meestal wel aspecifiek 
met betrekking tot de onderliggende ziekte. Voor een gedetailleerde beschrijving 
van de te verwachten VEMP afwijkingen voor aandoeningen op verschillende 
anatomische lokalisaties verwijzen we gaarne naar tabel 1, hoofdstuk 2. In 
hoofdstuk 3 wordt een prospectieve oculaire en cervicale VEMP studie beschreven 
met betrekking tot de intra-, interbeoordelaar en test her-test betrouwbaarheid 
in twintig gezonde studie deelnemers. De intra- en interbeoordelaar 
betrouwbaarheid, welke een belangrijk aspect is van klinische VEMP beoordeling, 
betreffende de drie ervaren klinische neurofysiologen is zeer goed voor zowel de 
oculaire als cervicale VEMP responsen. De groepsresultaten met betrekking tot 
de test en de her-test waren vergelijkbaar en er was geen significant verschil tussen 
de groepen. De individuele resultaten, echter vertoonden wel een relevante 
variabiliteit waarbij alle resultaten wel binnen de normale grenzen bleven. De 
oculaire en cervicale VEMP amplitudes waren de meest betrouwbare test her-test 
parameters gevolgd door de cervicale VEMP latenties. De oculaire VEMP latenties 
vertoonden een matige test her-test betrouwbaarheid11.
VEMP afwijkingen worden regelmatig gezien bij patiënten met zowel centrale als 
perifere neurovestibulaire aandoeningen en overige centraal neurologische 
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aandoeningen5,12. Gedetailleerde interpretatie van deze afwijkingen kan mogelijks 
belangrijke lokaliserende informatie geven met betrekking tot de zijde en origine van 
de laesie binnen het centrale en perifere vestibulaire systeem (wat de voornaamste 
kracht van VEMP testen is). De uitslagen van VEMP testen bij verdenking op een 
perifeer vestibulaire problematiek moeten echter met grote zorg worden geïnterpreteerd 
wanneer er bij een patiënt sprake is van een centraal neurologische aandoening en 
vice versa. Hoofdstuk 2 geeft aanvullende informatie met betrekking tot de mogelijke 
anatomische lokalisaties van VEMP afwijkingen. De diagnostische graad van evidence-
based medicine voor het gebruik van VEMP testen voor centraal neurologische 
aandoeningen is momenteel erg beperkt tot een algemene graad 4 evidentie met enkele 
uitzonderingen welke een maximum graad van 2b bereiken (voor Multiple Sclerosis, 
vestibulaire schwannomen, ziekte van Parkinson en herseninfarcten in het 
vertebrobasilaire stroomgebied). De primaire indicatie voor het uitvoeren van VEMP 
testen is daardoor in mijn opinie enkel patiënten wier neurovestibulaire klachten niet 
betrouwbaar kunnen worden gelokaliseerd in het centrale of perifere vestibulaire 
systeem noch met MRI-cerebrum, noch met videonystagmografie met calorisatie5. 
Een uitzondering is de diagnostische work-up van een patiënt met een verdenking op 
een superieure semicirculair kanaal dehiscentie syndroom (SCDS) waarbij er 
ipsilateraal verminderde cervicale VEMP stimulatie drempels zijn en voornamelijk 
toegenomen contralaterale oculaire VEMP amplitudes. Deze VEMP afwijkingen zijn 
een sensitief teken bij het lokaliseren van de aangedane zijde. De voornaamste oorzaak 
van dit fenomeen is waarschijnlijk een toegenomen geluid en drukgevoeligheid van 
het ipsilaterale labyrint in vergelijking met de contralaterale zijde13,14.
VEMP afwijkingen zijn in het algemeen niet ziekte specifiek en geven daardoor geen 
additionele informatie met betrekking tot de etiologie van de onderliggende ziekte. 
Men kan er echter over speculeren of gedetailleerde interpretatie van de VEMP 
afwijkingen geen inzicht kan geven in de onderliggende pathofysiologische 
kenmerken van de ziekte (of de onderliggende ziekte primair demyeliniserend, 
axonaal of een combinatie van beiden is) vergelijkbaar met bijvoorbeeld perifere 
neuropathieën. Demyeliniserende perifere neuropathieën kenmerken zich door een 
forse reductie van de zenuwgeleidingssnelheden, conductie blokkades, toegenomen 
temporale dispersie, fors vertraagde F-waves en/of fors vertraagde distale 
zenuwgeleidingstijden. Daarentegen worden axonale perifere neuropathieën 
gekenmerkt door afgenomen amplitudes in de aanwezigheid van relatief gespaarde 
zenuwgeleidingssnelheden15,16.
Op dit moment zijn er geen betrouwbare neurofysiologische criteria voor geëvoceerde 
potentialen welke de differentiatie tussen primair demyeliniserende en axonale 
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aandoeningen in het centrale zenuwstelsel mogelijk maken. Neuritis optica in Multiple 
Sclerosis bijvoorbeeld (welke zich pathofysiologisch kenmerkt door primaire 
demyelinisatie) veroorzaakt typisch asymmetrisch sterk verlengde latenties van de 
ipsilaterale visueel geëvoceerde potentialen meting (VEP) met relatief gespaarde 
amplitudes. Opticus neuropathieën ten gevolge van externe compressie, ischemie, 
metabole ontregelingen en neurodegeneratieve aandoeningen echter veroorzaken 
meestal minder uitgesproken latentie verlengingen en een meer uitgesproken reductie 
van de VEP amplitude17,18. Afwijkingen met betrekking tot de auditieve hersenstam 
geëvoceerde potentialen (BAEP) in Multiple Sclerosis patiënten zijn daarentegen erg 
aspecifiek en veroorzaken voornamelijk top IV en V afwijkingen gevolgd door 
verlenging van de intertop I-V en voornamelijk III-V latenties. De bovenbeschreven 
BAEP afwijkingen zijn echter niet typisch voor demyeliniserende aandoeningen en 
worden ook gevonden in vele andere centraal neurologische aandoeningen zoals 
hersenstam gliomen, spinocerebellaire degeneratieve aandoeningen en hydrocephalus19. 
De VEMP resultaten in Multiple Sclerosis patiënten tonen voornamelijk toegenomen 
latenties gevolgd door afwezige responsen. Toegenomen latenties worden echter ook 
beschreven in patiënten met de ziekte van Alzheimer, migraine en met een 
vertebrobasilair herseninfarct (bij de laatste aandoening hadden de meeste patiënten 
afgenomen amplitudes)5.
Concluderend kan men op hypothetische en puur speculatieve basis beargumenteren 
dat sterk asymmetrisch toegenomen VEMP latenties (meer dan 130 procent van de 
bovenste limiet van de normaalwaarden) met relatief gespaarde amplitudes en golf 
morfologie mogelijks worden veroorzaakt door demyeliniserende aandoeningen 
(vergelijkbaar met de VEP afwijkingen in neuritis optica en zenuwgeleidingsbevindingen 
in perifere neuropathieën). Omgekeerd kan eveneens worden beweerd dat geëvoceerde 
potentialen metingen op dit moment (en voornamelijk de BAEP en VEMP testen) 
geen pathofysiologische differentiatie toelaten met betrekking tot de onderliggende 
aandoening. Dit is gebaseerd op de BAEP en VEMP case-beschrijvingen in de literatuur 
bij verschillende aandoeningen welke geen primair demyeliniserend kenmerk hebben 
(zoals vertebrobasilaire herseninfarcten en migraine). De bovenvermelde case-
beschrijvingen in de literatuur bevatten helaas geen gedetailleerde beschrijvingen met 
betrekking tot de mate van latentietijd toename van de geëvoceerde potentialen waarbij 
de verwachting is dat deze veel meer uitgesproken zijn bij demyeliniserende 
aandoeningen in vergelijking met axonale aandoeningen. Verdere verduidelijking van 
deze pathofysiologische differentiatie voor centraal neurologische aandoeningen 
gebaseerd op geëvoceerde potentialen metingen lijkt een interessant onderzoeksgebied 
voor toekomstig onderzoek. Deze pathofysiologische differentiatie lijkt niet enkel nuttig 
voor diagnostische doeleinden, eveneens kan deze differentiatie behulpzaam zijn voor 
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het ontrafelen van de onderliggende pathofysiologische mechanismen in verschillende 
centraal neurologische aandoeningen welke tot op heden niet volledig bekend zijn 
(zoals bijvoorbeeld verschillende neurodegeneratieve aandoeningen) en om hun 
progressie over het beloop van de tijd te volgen. Eenzelfde studie opzet kan hiervoor 
worden toegepast als werd gebruikt door de auteurs Tankisi et al.15 in hun studie naar 
perifere polyneuropathieën waarbij de geleidingssnelheden en amplitudes werden 
bepaald in aandoeningen met goed bekende pathofysiologische kenmerken, echter dan 
toegepast voor VEMP en BAEP metingen in centraal neurologische aandoeningen.
In hoofdstuk 3 wordt de intra- en interbeoordelaar betrouwbaarheid van VEMP 
beoordeling besproken welke zeer goed was in onze studie11. De studie toont eveneens 
aan dat ervaren klinisch neurofysiologen en neurologen met beperkte ervaring in de 
beoordeling van individuele VEMP curven in een korte tijd (ongeveer 45 minuten) 
kunnen worden getraind om deze beoordelingen betrouwbaar uit te voeren. De VEMP 
test her-test studie toont aan dat er een individuele variabiliteit is in de resultaten, echter 
dat deze allen binnen de normale grenzen blijven waarbij deze variabiliteit niet relevant 
lijkt te zijn voor gezonde proefpersonen. Men kan hier echter over speculeren of dit ook 
het geval is voor patiënten met abnormale test resultaten en of deze ook afwijkend blijven 
indien patiënten opnieuw getest worden. De oculaire en met name de cervicale VEMP 
amplitudes lijken de meest betrouwbare test her-test parameters te hebben, gevolgd door 
de cervicale VEMP latenties. De oculaire VEMP latenties vertonen echter een matige test 
her-test betrouwbaarheid. Standaardisatie van de cervicale VEMP amplitudes door de 
mate van sternocleidomastoideus spiercontractie te controleren gedurende de VEMP 
meting is eveneens een belangrijk aspect van het uitvoeren van VEMP metingen 
(bijvoorbeeld door een bloeddruk cuff en manometer te gebruiken waarbij een vooraf 
gekozen spierkracht kan worden aangehouden en gecontroleerd  gedurende de meting 
zoals omschreven door de auteurs Vanspauwen et al.20,21). Een alternatieve methode 
hiervoor is om de cervicale VEMP amplitudes te corrigeren door het ruwe pre-stimulus 
EMG achtergrond signaal te gebruiken. Op dit moment zijn er helaas geen goed 
omschreven en gestandaardiseerde methoden om de oculaire VEMP amplitudes te 
corrigeren. Nguyen et al.22 beschreven in hun studies een interessante methode om de 
oculaire VEMP amplitudes te standaardiseren welke tot onze kennis tot op heden nog 
niet uitvoerig bestudeerd is in de literatuur. De auteurs gebruikten verticale saccades 
voorafgaande de meting om de plaatsing van de elektroden te corrigeren. Indien het 
verschil tussen de amplitudes van de saccades tussen de beide ogen meer dan 25 procent 
bedroeg werden de elektrodes qua plaatsing gecorrigeerd. De oculaire VEMP test her-test 
studie van Nguyen et al.22 vertoonden een betere betrouwbaarheid (namelijk een zeer goede 
betrouwbaarheid) van de oculaire VEMP amplitudes in vergelijking met onze studie welke 
slechts matig tot goed was. Helaas verbeterde de algemeen matige betrouwbaarheid van 
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de oculaire VEMP latenties niet met de bovenvermelde standaardisatie procedures. De 
bovenvermelde standaardisatie procedures voor de oculaire VEMP amplitudes lijken om 
de bovenstaande redenen effectief te zijn en daarom zeker de moeite waard om door middel 
van verder wetenschappelijk onderzoek verder uit te zoeken.
Statische subjectieve visuele verticaliteit (SVV)
Samenvatting hoofdstuk 4
Graviceptie is de mogelijkheid van een persoon om de oriëntatie relatief tot de 
zwaartekracht in te schatten welke kan worden gemeten door de (statische) 
subjectieve visuele verticaliteit (SVV). De graviceptieve baansystemen zorgen voor 
een multimodale sensore integratie van de vestibulaire, proprioceptieve en visuele 
input en bepaald aan de hand hiervan de relatieve positie van het lichaam ten 
opzichte van de absolute verticaliteit (zijnde het zwaartekrachtsveld van de 
aarde23-27). De resultaten van de statische SVV worden voornamelijk bepaald door 
de otoliet functie en balans waarbij dit de voornaamste receptoren in het perifere 
vestibulaire systeem zijn die gevoelig zijn voor de zwaartekracht (zijnde lineaire 
versnellingen). Neurovestibulaire laesies meer proximaal gelokaliseerd in zowel 
het perifere en centrale vestibulaire systeem kunnen natuurlijk ook afwijkingen 
in de statische SVV resultaten veroorzaken door verstoring van de graviceptieve 
baansystemen welke secundair resulteren in een otoliet dysbalans. Bijvoorbeeld 
statische SVV afwijkingen zijn een sensitief teken van hersenstam dysfunctie25,28. 
Voor het uitvoeren van de statische SVV testen verwijzen we naar hoofdstuk 4, 
methodologie paragraaf. In hoofdstuk 4 wordt een studie beschreven met 44 
gezonde proefpersonen met betrekking tot de effecten van verschillende 
uitgangshoek deviaties en zijden en de test her-test variabiliteit. De statische SVV 
resultaten worden beïnvloed door de zijde van de uitgangshoek (Wilcoxon test, 
P ≤ 0.001), echter niet door de grote van de hoek zelf (uitgangshoeken van 10, 
20 en 30 graden werden vergeleken). De test her-test resultaten van de gezonde 
proefpersonen waren vergelijkbaar op groepsniveau, echter vertoonden een 
relevante variabiliteit op individueel niveau met matige betrouwbaarheid. Alle 
individuele resultaten bleven echter binnen de normale grenzen ondanks deze 
variabiliteit. Het laatste doel van de studie was om een robuust statisch SVV 
protocol te exploreren en verder uit te bouwen waarbij zowel monoculaire als 
binoculaire metingen werden gebruikt. Het statische SVV studie protocol staat 
uitvoerig beschreven in hoofdstuk 4. 
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Het laatste doel van de studie in hoofdstuk 4 was om een praktisch statisch SVV 
protocol te exploreren en uit te bouwen met hierin zowel monoculaire als binoculaire 
metingen. Op dit moment is het vergelijken van literatuurbevindingen omtrent de 
statische SVV erg moeizaam gezien het ontbreken van een eenduidig test protocol 
waarbij veel auteurs de testen op verschillende manieren uitvoeren. Tevens worden 
op dit moment in de wetenschappelijke literatuur bijna alleen maar binoculaire 
metingen uitgevoerd, echter de toevoeging van monoculaire metingen gecombineerd 
met de binoculaire geeft additionele informatie met betrekking tot de mogelijke 
onderliggende lokalisatie van de laesie. Dieterich en Brandt25,28-30 toonden aan dat 94% 
van de 111 patiënten met acute hersenstam herseninfarcten een kant specifieke 
pathologische binoculaire statische SVV afwijking heeft. De binoculaire statische SVV 
afwijking is ipsiversief in perifere unilaterale vestibulaire aandoeningen en 
pontomedullaire laesies (onder het niveau waar de graviceptieve baansystemen kruisen 
naar de contralaterale zijde). De binoculaire statische SVV afwijkingen zijn 
contraversief in pontomesencephale aandoeningen en geeft betrokkenheid van de 
fasciculus longitudinalis medialis (FLM), interstitiële nucleus van Cajal (INC) en/of 
rostrale interstitiële nucleus van de FLM aan. Ongeveer 64% van de patiënten met 
laesies waarbij de vestibulaire subnuclei van de thalamus betrokken zijn en 44% van 
de patiënten met laesies in de vestibulaire cortex (insulaire, superieure temporale en 
transverse temporale gyri) vertonen binoculaire pathologische statische SVV 
afwijkingen welke voornamelijk contraversief zijn. Niet enkel centrale of perifere 
neurovestibulaire aandoeningen veroorzaken pathologische statische SVV deviaties. 
Pathologische statische SVV deviaties worden ook teruggevonden in 67% van de 
patiënten met verticale externe oogspierparesen ten gevolge van ipsilaterale IIIe en 
IVe hersenzenuw (respectievelijk nervus oculomotorius en nervus trochlearis) 
verlammingen. De pathologische statische SVV afwijkingen waren echter enkel 
monoculair en beperkt tot het aangedane oog in het acute stadium tot 3 maanden 
erna. Daarna gaan de pathologische monoculaire statische SVV afwijkingen geleidelijk 
over naar het contralaterale niet-aangedane oog ten gevolge van compensatie 
mechanismen29. Het grote verschil tussen de supranucleaire en infranucleaire 
oculomotore aandoeningen is dat statische SVV afwijkingen in infranucleaire 
aandoeningen beperkt zijn tot het aangedane oog in de acute setting en overgaan naar 
het niet-aangedane oog in de chronische setting na 3 maanden. De binoculaire 
statische SVV resultaten zijn normaal in alle patiënten met infranucleaire oculomotore 
aandoeningen in tegenstelling tot de patiënten met supranucleaire aandoeningen 
waarbij tot 94% van de patiënten met een herseninfarct van de hersenstam afwijkende 
binoculaire statische SVV resultaten vertoonden.  Tevens kan een bilaterale nervus 
trochlearis parese worden gelokaliseerd middels statische SVV testen welke een 
bilaterale monoculaire statische SVV tilt vertoonden met tegengestelde richting in 
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combinatie met een normale binoculaire statische SVV meting. Pathologische statische 
SVV afwijkingen in supranucleaire laesies zijn namelijk altijd gericht naar dezelfde 
zijde25,29. Samenvattend geven additionele statische SVV testen waarbij zowel 
monoculaire als binoculaire metingen worden gecombineerd, dus belangrijke 
additionele diagnostische informatie.
In onze studie toonden we eveneens aan dat statische SVV metingen werden beïnvloed 
in de richting van de uitgangshoek, echter niet door de grootte van de hoek zelf (voor 
deviaties van de hoek groter dan 10 graden). Onze bevindingen zijn in overeenstemming 
met eerder gepubliceerde studies in de wetenschappelijke literatuur24,31, echter 
uitgangshoek deviaties kleiner dan 8 graden hebben geleidelijk minder invloed op de 
uiteindelijke  statische SVV resultaten. In onze studie en in de literatuur worden 
statische SVV afwijkingen tussen de 10 en 20 graden frequent gezien. Daardoor wordt 
geadviseerd om een uitgangshoek met een begindeviatie van 20 graden te nemen en 
om de uitgangshoeken met de richting van de klok en daartegen in gelijk maar wel 
ad random te verdelen bij herhaalde metingen (ten gevolge van de bias van de 
resultaten in de richting van de uitgangshoek). Beide aanbevelingen zijn geïncorporeerd 
in het uiteindelijke voorstel voor het statische SVV test protocol.
Vergelijkbaar met de VEMP testen vertoonden ook de statische SVV testen bij de 
gezonde vrijwilligers een individuele test her-test variabiliteit die stabiel was op 
groepsniveau zonder statistisch significante verschillen. De resultaten van alle gezonde 
vrijwilligers bleven echter binnen de normale grenzen zowel in de test als her-test 
metingen. Men kan zich echter afvragen of dit ook geldt voor patiënten met afwijkende 
statische SVV metingen. Statische SVV metingen neigen echter te normaliseren over 
het beloop van de tijd bijvoorbeeld bij herseninfarcten in de hersenstam25,28 en gaan 
geleidelijk over van het paretische oog bij infranucleaire oculomotore aandoeningen 
in de acute fase naar de contralaterale zijde na een periode van 3 maanden29. Daardoor 
adviseren we toekomstig onderzoek naar de test her-test variabiliteit bij patiënten met 
afwijkende statische SVV metingen, echter om de periode tussen de testen zeer kort 
te houden met een maximum van enkele dagen gezien het dynamische karakter van 
de statische SVV afwijkingen.
De toepassing van statische SVV testen buiten gespecialiseerde derdelijns 
duizeligheidsklinieken wordt bemoeilijkt door de hoge kosten van gespecialiseerde 
apparatuur. Zwergal et al.32 bestudeerden een draagbare emmer-versie van de statische 
SVV test welke zelf gemaakt kan worden tegen lage kosten, zie figuur 1 van dit 
hoofdstuk. De conversie van een huis-tuin-en-keuken emmer duurt minder dan een 
uur en kost ongeveer 5 US dollars. De auteurs vergeleken deze emmer-versie van de 
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statische SVV test met de conventionele statische SVV test en vonden een zeer goede 
inter- en intra-test betrouwbaarheid (Pearson correlatie coëfficiënten van respectievelijk 
0.89-0.90 and 0.92) zowel in gezonde proefpersonen als in patiënten met acute 
neurovestibulaire aandoeningen. Brodsky et al.33 onderzochten recent een smartphone 
versie van de statische SVV emmer-versie bij pediatrische patiënten met een verdenking 
op een neurovestibulaire aandoening. Deze subjectieve verticaliteit applicatie op de 
smartphone koste ongeveer 18 US dollars en werd vergeleken met de conventionele 
statische SVV test. Een matige Pearson correlatie coëfficiënt van 0.43 werd gevonden, 
echter ondanks de matige correlatie was de SVV een nuttige screeningsmethode voor 
acute neurovestibulaire aandoeningen in kinderen (sensitiviteit 75%, specificiteit 
100%, positief voorspellende waarde van 100% en negatief voorspellende waarde van 
92%). Ondanks de veelbelovende resultaten van de bovenstaande onderzoeken is 
verder onderzoek in grotere groepen aangewezen waarbij de (smartphone-
ondersteunende) emmer-versie van de statische SVV test wordt vergeleken met 
conventioneel statisch SVV onderzoek om de bovenstaande bevindingen te bevestigen.
Figuur 1
Emmer-versie van de statische SVV test, bewerking van Zwergal et al. (2009)32 
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DEEL TWEE
Neurovestibulaire analyse en vallen bij personen met de ziekte van 
Parkinson en atypische parkinsonismen. De resultaten van de baseline 
studie en 1-jaars follow-up.
Samenvatting hoofdstuk 5
Terugkerende valepisoden zijn een groot probleem bij personen met de ziekte van 
Parkinson en nog meer uitgesproken bij personen met atypische parkinsonismen. 
Ongeveer 50% van personen met de ziekte van Parkinson vallen regelmatig en 
ongeveer 70% valt minimaal eens per jaar34-37. Personen met de ziekte van 
Parkinson hebben 2.2x meer kans op fracturen in het algemeen en 3-4x meer kans 
op heupfracturen in vergelijking met een gezonde groep proefpersonen met 
dezelfde leeftijd. Tevens hebben personen met de ziekte van Parkinson over het 
algemeen hogere mortaliteitskansen en hogere risico’s op peri- en postoperatieve 
complicaties gedurende de behandeling van deze fracturen38. Onlangs werd een 
praktische consensusafspraak gepubliceerd met betrekking tot de risico factoren 
voor vallen bij personen met de ziekte van Parkinson en adviezen voor de 
behandeling hiervan39. Vestibulaire dysfunctie werd echter niet besproken als een 
van de mogelijke oorzaken voor het vallen wat verassend is, aangezien het 
vestibulaire systeem onmisbaar is in het bewaren van de balans door multimodale 
sensore input te verwerken (zijnde de perifeer vestibulaire, proprioceptieve en 
visuele input) en om vervolgens de motore respons bij te sturen door middel van 
de vestibulospinale reflexen37. Hoofdstuk 5 toont de resultaten van een case-
control studie waarbij de functie van het vestibulaire systeem bij 25 gezonde 
proefpersonen systematisch werd onderzocht en vergeleken met 30 personen met 
de ziekte van Parkinson en 14 personen met atypische parkinsonismen (6 personen 
met multipele systeem atrofie, 3 met progressieve supranucleaire verlamming en 
5 met vasculair parkinsonisme)37. Ongeveer 90% van de personen met de ziekte 
van Parkinson (27 van de 30) en 100% van de personen met atypische 
parkinsonismen (alle 14) vertoonden bij het neurofysiologisch onderzoek tekenen 
van vestibulaire dysfunctie met voornamelijk een centraal vestibulair dysfunctie 
profiel (bij de VEMP, SVV en videonystagmografie metingen met additionele 
calorische stimulatie en draaistoelonderzoek). Daarnaast waren neurofysiologische 
afwijkingen bij de vestibulaire metingen sterk geassocieerd met een toegenomen 
risico voor vallen (wanneer de resultaten van vallende personen met de ziekte van 
Parkinson en atypische parkinsonismen werden vergeleken met de resultaten van 
niet vallende personen, P ≤ 0.001).
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Afwijkende neurovestibulaire functie testen worden opvallend vaak in zowel personen 
met de ziekte van Parkinson en atypische parkinsonismen gezien (90% van de 
personen met de ziekte van Parkinson en 100% bij atypische parkinsonismen). 
Ongeveer 66% van de patiënten met een milde vorm van de ziekte van Parkinson 
heeft afwijkende functie testen, waarbij deze testen bij 96% en 100% afwijkend zijn 
bij patiënten met een respectievelijk een matige tot ernstige vorm van de ziekte. 
Daarbij kan worden geconcludeerd dat afwijkende neurovestibulaire functie testen 
vaak worden aangetroffen bij personen met een mild stadium van de ziekte van 
Parkinson, maar dat de afwijkingen toenemend aanwezig zijn bij meer gevorderde 
stadia van de ziekte. Tevens waren de personen met atypische parkinsonismen ernstiger 
aangedaan in vergelijking met personen met de ziekte van Parkinson (respectievelijk 
Hoehn en Yahr stadia 2.9±0.8 en 2.3±0.7; P = 0.0152). Personen met neurovestibulaire 
en/of andere neurologische aandoeningen (anders dan de ziekte van Parkinson of 
atypische parkinsonismen) in hun voorgeschiedenis werden geëxcludeerd. Tevens had 
geen van de proefpersonen relevante medische klachten anamnestisch danwel 
symptomen bij klinisch neurologisch en neuro-otologisch onderzoek welke suggestief 
waren voor een andere onderliggende neurovestibulaire stoornis. Logischerwijs konden 
niet alle bestaande andere (centrale) neurovestibulaire stoornissen middels deze 
onderzoeken worden geëxcludeerd, voornamelijk door de afwezigheid van recente 
cerebrale MRI beeldvormende studies. Gezien echter het ontbreken van relevante 
klachten anamnestisch danwel symptomen bij neurologisch en neuro-otologisch 
onderzoek waren hiervoor op klinische gronden geen aanwijzingen.
De abnormale neurovestibulaire functie testen hadden voornamelijk een centraal 
vestibulair dysfunctie profiel in 78-93% van de personen met respectievelijk de ziekte 
van Parkinson en atypische parkinsonismen. Slechts één persoon met de ziekte van 
Parkinson (4%) had een profiel suggestief voor een perifere vestibulaire aandoening 
waarbij de overige profielen niet lokaliserend waren. Tevens hadden 57-79% van de 
personen met respectievelijk atypische parkinsonismen en de ziekte van Parkinson 
anamnestisch geen klachten van duizeligheid of vertigo. Men kan zich echter afvragen 
of de gevonden neurovestibulaire functie afwijkingen bij deze groep inderdaad 
asymptomatisch zijn. Ongeveer 10-18% van de personen met atypische 
parkinsonismen en de ziekte van Parkinson hebben neurovestibulaire functie 
afwijkingen bij neurofysiologische testen als de enige identificeerbare oorzaak voor 
vallen (na exclusie van orthostatische hypotensie, posturale instabiliteit, freezing of 
gait en matige-tot-ernstige cognitieve problemen)37. Helaas konden niet alle overige 
mogelijke oorzaken voor vallen behoudens de vestibulaire dysfunctie bij de 
bovenstaande patiënten worden uitgesloten (zoals bijvoorbeeld milde orthostatische 
hypotensie welke wisselend aanwezig kan zijn bij routine testen)39,40, echter wel de 
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overige meest relevante oorzaken. Daarnaast zijn vestibulaire afwijkingen bij 
neurofysiologische testen sterk gecorreleerd met een verhoogd risico voor vallen 
wanneer vallende personen met de ziekte van Parkinson en atypische parkinsonismen 
werden vergeleken met niet-vallende personen (P≤0.001). Uit de bovenstaande 
gegevens werd geconcludeerd dat neurovestibulaire dysfunctie zich uitende in 
afwijkende neurofysiologische vestibulaire testen veel voorkomen bij personen met 
de ziekte van Parkinson en atypische parkinsonismen en sterk geassocieerd zijn met 
een verhoogd valrisico (wat tot op heden niet eerder in de wetenschappelijke literatuur 
werd gerapporteerd)37. Met betrekking tot de bovenstaande studie moet worden 
gemeld dat de bestudeerde patiënten groepen relatief klein en heterogeen zijn (met 
name met betrekking tot de atypische parkinsonismen). De resultaten van deze studie 
moeten daarom voorzichtig worden geïnterpreteerd en voornamelijk worden gezien 
als hypothese genererend voor toekomstig onderzoek waarbij bevestiging van de 
resultaten in grotere patiëntengroepen wordt geadviseerd. Daarbij is het momenteel 
niet bekend of de sterk geassocieerde neurovestibulaire test afwijkingen direct een 
causaal verband hebben met vallen danwel een epifenomeen zijn (bijvoorbeeld door 
deconditionering ten gevolge van het vallen). Dopaminerge medicatie lijkt echter 
geen goede verklaring te zijn voor de gevonden neurovestibulaire test afwijkingen 
aangezien studies door de auteurs Pötter-Nerger et al.41,42 aantoont dat levodopa 
mogelijks vestibulaire test afwijkingen partieel verbeterd. Het centrale vestibulaire 
systeem is echter een van de belangrijke systemen in het behoudt van balans door de 
integratie van multimodale sensore informatie (perifeer vestibulaire, visuele en 
proprioceptieve input) en om vervolgens de uitgaande motore respons te moduleren 
middels de vestibulospinale reflexen. Op basis van de bovenstaande redenering kan 
men puur hypothetisch gebaseerd op theoretische fysiologische evidentie concluderen 
dat vestibulaire dysfunctie causaal verantwoordelijk is voor vallen als een mogelijke 
oorzaak en niet gebaseerd is op een epifenomeen. 
De centrale vestibulaire test afwijkingen in personen met de ziekte van Parkinson 
bestaan voornamelijk uit afwijkende geëvoceerde potentialen testen (VEMPs en 
BAEPs), welke significant verlengde latenties (p13, n1 en inter-top III-V latenties) 
lieten zien aan de symptomatische zijde van de hersenstam in vergelijking met gezonde 
proefpersonen (0.003 ≤ P ≤ 0.019). Vergelijking van de meetresultaten van de 
asymptomatische zijde van personen met de ziekte van Parkinson en gezonde 
proefpersonen of de kant-tot-kant vergelijkingen binnen de personen met de ziekte 
van Parkinson lieten geen significant afwijkende waarden zien met uitzondering van 
de p13 latentie van de cervicale VEMP kant-tot-kant vergelijking (P = 0.020). Deze 
resultaten wijzen op een asymmetrische hersenstam betrokkenheid in het 
neurodegeneratieve proces welke voornamelijk de aangedane zijde betreft en vervolgens 
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via de aangedane zenuwvezelbanen mee verloopt (de aangedane hersenstam zijde is 
ipsilateraal ten opzichte van de patiënt zijn rusttremoren, rigiditeit en bradykinesie 
op het niveau van de pontomedullaire overgang onder het niveau van de vestibulaire 
kernen; de aangedane zenuwvezelbanen kruisen naar de contralaterale hersenstam 
zijde boven het niveau van de vestibulaire kernen samen met de decussatio van de 
fasciculus longitudinalis medialis). Pötter-Nerger et al.41 laten enkel asymmetrische 
afwijkingen van de oculaire VEMP testen zien aan de symptomatische hersenstam 
zijde waarbij de cervicale VEMP deze asymmetrische afwijkingen niet liet zien. Het 
voornaamste verschil tussen de studie door Pötter-Nerger et al.41 en onze studie is de 
grootte van de populatie (30 personen met de ziekte van Parkinson in onze studie 
versus 13 personen in de studie van Pötter-Nerger et al.41). Kleinere verschillen tussen 
groepen worden namelijk sneller gedetecteerd in grotere studie populaties. Onze studie 
demonstreert eveneens dat niet enkel centrale vestibulaire banen zijn aangedaan aan 
de symptomatische zijde van de hersenstam, maar dat dit tevens geldt voor de centrale 
auditieve banen wat wordt geïllustreerd door latentie verlenging van de BAEP inter-
top III-V latenties aan de symptomatische zijde.
Zoals eerder vermeld bestaan de BAEP en VEMP afwijkingen in onze studie 
voornamelijk uit sterk verlengde cervicale VEMP p13 latenties, oculaire VEMP n1 
latenties en BAEP inter-top III-V latenties (p13 134%, n1 128% en III-V inter-top 
latenties 120% van de bovenste limiet van normaal) met relatief gespaarde amplitudes37. 
Zoals bediscussieerd in paragraaf 1.1 van dit hoofdstuk worden op theoretische 
gronden asymmetrisch sterk verlengde geëvoceerde potentialen latenties met relatief 
gespaarde amplitudes mogelijks verklaard door primair demyeliniserende 
aandoeningen. Het pathofysiologisch onderscheid tussen axonale en demyeliniserende 
centraal neurologische neurodegeneratieve aandoeningen gebaseerd op de resultaten 
van geëvoceerde potentialen metingen is puur speculatief en tot zover onze kennis 
reikt nog niet eerder bestudeerd. Op dit moment zijn er dan ook geen neurofysiologische 
criteria voor deze pathofysiologische differentiatie voor aandoeningen van het centrale 
zenuwstelsel, zoals deze er bijvoorbeeld wel zijn voor de differentiatie van perifere 
neuropathieën. Meer wetenschappelijk onderzoek met betrekking tot deze differentiatie 
tussen axonale en  demyeliniserende centrale zenuwstelsel aandoeningen gebaseerd 
op geëvoceerde potentialen metingen lijken dan ook interessant omdat dit belangrijke 
inzichten kan geven in de onderliggende pathofysiologische mechanismen van centrale 
zenuwstelsel aandoeningen waarvan dit tot op heden niet goed bekend is.
De ziekte van Parkinson is pathofysiologisch gedefinieerd bij de aanwezigheid van 
abnormale alfa-synucleïne eiwit aggregaties in neuronen en gliale cellen; en door de 
aanwezigheid van neurodegeneratie van specifieke hersenregio’s (cholinerge 
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pedunculopontiene nucleus, dopaminerge substantia nigra en de ventrale tegmentale 
area). Deze eiwit aggregaties worden als volgt genoemd: a) Lewy bodies in neuronale 
perikarya, b) Lewy neurieten in de axonen en dendrieten, c) coiled bodies in 
aangedane oligodendrocyten43,44. Tevens wordt multisysteem atrofie (MSA, een vorm 
van atypisch parkinsonisme) gekarakteriseerd door neuronale en gliale alfa-synucleïne 
aggregaten, echter waarbij er in het algemeen wordt aangenomen dat deze eveneens 
in contrast tot de ziekte van Parkinson ook aanwezig zijn in hersenstam nucleï44. 
Seidel et al.43 demonstreerden met hun neuropathologische studie dat Lewy bodies 
en neurieten eveneens aanwezig zijn in alle hersenstam craniale zenuwkernen, 
premotore, oculomotore, precerebellaire en vestibulaire nucleï bij patiënten met de 
ziekte van Parkinson. Dit was in contrast met de algemene aanname dat deze 
afwijkingen beperkt waren tot personen met MSA. Daarbij werden er in de 
bovenvermelde studie ook Lewy neurieten en coiled bodies aangetroffen in alle 
hersenstam zenuwvezelbanen. Deze afwijkingen zijn mogelijks het resultaat van een 
transneuronale ziekte verspreiding via de anatomische baansystemen ten gevolge van 
verstoorde intra-axonale transport mechanismen43. Wanneer we de neuropathologische 
en neurofysiologische wetenschappelijke kennis van de ziekte van Parkinson tot op 
heden combineren, lijkt een transneuronale ziekteprogressie via de anatomische 
zenuwvezelbanen het meest waarschijnlijk welke de hersenstam asymmetrisch aantast 
aan de symptomatische zijde van de patiënt. Asymmetrische aantasting van de 
hersenstam onder het niveau van het mesencefalon (substantia nigra) is tot op heden 
nog niet bevestigd middels neuropathologische studies en lijkt een interessant gebied 
voor toekomstig onderzoek. De afwijkingen welke neuropathologisch worden 
gevonden suggereren een neurodegeneratief proces met een primair axonaal 
kenmerk43, echter de neurofysiologische afwijkingen (fors verlengde latenties met 
relatief gespaarde amplitudes) passen beter bij een primair demyeliniserende 
neurodegeneratieve component. Recent dierexperimenteel onderzoek in verschillende 
diermodellen suggereren dat synaptische dysfunctie eveneens een vroeg en belangrijke 
component is in de ziekte van Parkinson45, welke eveneens de neurofysiologische 
afwijkingen ten dele kan verklaren. Toekomstige neuropathologische hersenstam 
studies bij de ziekte van Parkinson zouden daardoor tevens gefocust moeten zijn op 
de myelinisatie van aangedane zenuwvezelbanen welke Lewy neurieten en coiled 
bodies bevatten met de primaire vraag of begeleidende demyelinisatie een belangrijk 
kenmerk van de neurodegeneratie bij deze aandoening is. Natuurlijk zijn er ook meer 
toekomstige studies in mensen noodzakelijk omtrent de analyse naar mogelijke 
synaptische dysfunctie bij de ziekte van Parkinson, welke bij diermodellen werd 
teruggevonden.
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Samenvatting hoofdstuk 6
De één-jaar follow-up resultaten van de case-control baseline studie, zoals 
hierboven beschreven in paragraaf 2 van dit hoofdstuk en welke in hoofdstuk 5 
in meer detail zijn bediscussieerd, worden weergegeven in hoofdstuk 6. Alle 25 
gezonde vrijwilligers, 14 personen met atypische parkinsonismen en 30 personen 
met de ziekte van Parkinson werden telefonisch benaderd voor een interview één 
jaar volgend op de baseline onderzoeken. Slechts 1 patiënt met een atypisch 
parkinsonisme (MSA) kon niet meer telefonisch worden bereikt ondanks 
herhaaldelijke oproepen en was daarom lossed to follow-up (attrition bias van 
slechts 1,4%). Alle deelnemers werden ondervraagd met betrekking tot hun val 
frequentie gebaseerd op de valkalenders en over hun subjectief vertrouwen in de 
eigen balans (middels de ABC-16 vragenlijst). De resultaten na één jaar follow-up 
werden met de baseline resultaten vergeleken. De voornaamste onderzoeksvraag 
was of neurovestibulaire laboratorium testen (verricht bij aanvang van het 
onderzoek) toekomstige valepisoden bij personen met de ziekte van Parkinson en 
atypische parkinsonismen  kunnen voorspellen. Cervicale en oculaire VEMP 
testen in combinatie met klinische testen voor posturale instabiliteit zijn de beste 
voorspellers van toekomstige valepisoden met een sensitiviteit van 100%, positief 
voorspellende waarde van 68,2% bij slechts één afwijkende VEMP test en 83,3% 
wanneer beide VEMP testen afwijkend zijn. De valfrequentie zowel bij baseline 
als na één jaar follow-up was statistisch significant hoger en het subjectieve 
vertrouwen in de eigen balans (volgens de ABC-16 vragenlijst) was statistisch 
significant lager bij zowel Parkinson patiënten en patiënten met atypische 
parkinsonismen in vergelijking met gezonde vrijwilligers. Concluderend kan men 
stellen dat afwijkende VEMP testen geassocieerd zijn met een toegenomen risico 
op toekomstige valepisoden bij Parkinson patiënten en patiënten met atypische 
parkinsonismen met posturale instabiliteit in de afwezigheid van freezing of gait46.
 
Een screenings test is enkel bruikbaar in de klinische praktijk wanneer deze zowel een 
hoge sensitiviteit heft, als een positief voorspellende waarde. Wetende dat freezing of 
gait een grote risicofactor voor toekomstige valepisoden is47,48, bestudeerden we de 
associatie tussen freezing bij de baseline metingen en het toekomstige valrisico. In 
onze studie bleek de sensitiviteit van freezing of gait slechts 46,9% (slechts 7 van de 
15 vallende patiënten warden gedetecteerd), echter waarbij dit symptoom wel de 
hoogste positief voorspellende waarde had van namelijk 87,5% (bij kwalitatieve 
beoordeling van freezing middels het beoordelen van rechtdoor lopen en vlug en bloc 
draaien in beide richtingen). Voornamelijk de zeer beperkte sensitiviteit maakt het 
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testen van freezing of gait en zich een slechte screeningstest voor toekomstige 
valepisoden (aangezien ruim de helft van de potentieel vallende patiënten zal worden 
gemist). Het klinisch testen van de houdingsreflexen voor posturale instabiliteit 
(middels de retropulsietest) heeft een sensitiviteit van 100% voor toekomstige 
valepisoden in Parksinon patiënten en patiënten met atypische parkinsonismen, echter 
de positief voorspellende waarde is slechts 46,9%. Dus het testen van de 
houdingsreflexen alleen is niet bruikbaar als een screeningstest aangezien de helft van 
de patiënten met afwijkende houdingsreflexen het komende jaar niet zal vallen. De 
combinatie van zowel de cervicale en oculaire VEMP testen met klinische testen van 
de posturale stabiliteit lijken de ideale combinatie voor een screeningstest (met een 
sensitiviteit van 100% en positief voorspellende waarde van 68,2% wanneer slechts 
één VEMP test afwijkend is en van 83,3% wanneer beide VEMP testen afwijkend 
zijn) voor het voorspellen van toekomstige valepisoden bij Parkinson patiënten en 
patiënten met atypische parkinsonismen. De aanwezigheid van freezing of gait is 
echter zo’n sterke, maar insensitieve, voorspeller voor vallen dat aanvullende VEMP 
testen bij Parkinson patiënten en patiënten met atypische parkinsonismen met het 
symptoom freezing geen toegevoegde waarde hebben (alle patiënten met freezing of 
gait hadden eveneens posturale instabiliteit en afwijkende VEMP testen). 
Concluderend kan worden gesteld dat cervicale en oculaire VEMP testen aanvullende 
informatie kunnen geven over het toekomstige valrisico in geselecteerde personen met 
de ziekte van Parkinson en atypische parkinsonisme (namelijk bij personen zonder 
de aanwezigheid van freezing of gait)46. De bovenstaande resultaten moeten echter 
voorzichtig worden geïnterpreteerd aangezien de patiënten groepen kleine aantallen 
bevatten met voornamelijk een heterogene populatie in de patiënten groep met 
atypische parkinsonismen.
Men kan er echter over speculeren of deze additionele informatie met betrekking tot 
het toekomstige valrisico bij personen met de ziekte van Parkinson of met atypische 
parkinsonismen zal resulteren in andere val preventieve maatregelen aangezien 
patiënten met een verstoorde posturale stabiliteit reeds een hoog valrisico hebben. 
Meerdere meta-analyses en Cochrane reviews met betrekking tot het effect van 
fysiotherapie bij Parkinson patiënten rapporteren enkel korte-termijn statistisch 
significante, maar klinisch bescheiden, positieve effecten ten aanzien van balans-
gerelateerde taken en verbetering van het looppatroon. Er is echter geen 
wetenschappelijke evidentie dat het valrisico eveneens afneemt onder deze therapie46-52. 
Eén Cochrane review49 vergeleek de verschillende vormen van fysiotherapie en 
concludeerde dat een formele kwalitatieve vergelijking van de therapieën niet mogelijk 
is gezien de uitgesproken heterogeniteit van de studies, kleine patiënten aantallen, 
methodologische tekortkomingen en het risico van publicatie bias. Daardoor is er 
201804 proefschrift Jeroen Venhovens.indd   151 26-01-18   15:06
Chapter 8
152
geen wetenschappelijke evidentie om één vorm van fysiotherapie te verkiezen boven 
een andere. Prospectieve studies met een hoge kwaliteit en lange follow-up zijn daarom 
nodig om het effect van fysiotherapie bij zowel personen met de ziekte van Parkinson 
of met atypische parkinsonismen te beoordelen met betrekking tot de afname van het 
valrisico en om te beoordelen welke vorm van therapie superieur is om dit te bereiken 
boven een andere. Deze studies zouden evidence-gebaseerde richtlijnen voor 
fysiotherapie bij de ziekte van Parkinson moeten volgen en zouden idealiter moeten 
worden uitgevoerd door therapeuten met ervaring in behandeling van personen met 
de ziekte van Parkinson53-56.
Een recente case-studie beschreef de motore en niet-motore effecten van herhaalde 
calorische vestibulaire stimulatie bij een patiënt met de ziekte van Parksinon47. De 
motore en niet-motore scores (Montreal cognitieve beoordeling, MOCA; ziekenhuis 
depressie schaal, depressie deel van de HADS vragenlijst; en de Epworth slaperigheids 
score) verbeterden allen duidelijk zowel gedurende de herhaalde calorische stimulatie 
en na 5 maanden follow-up na het staken hiervan. Deze verbeteringen werden niet 
gezien gedurende de eerste fase van de studie welke bestond uit placebo stimulatie. 
Tevens laten andere recente studies bij personen met de ziekte van Parkinson voorlopig 
bewijs zien dat (stochastische) galvanische vestibulaire stimulatie mogelijks posturale 
instabiliteit verbetert, correctieve posturale responsen versterkt, voorover gebogen 
houding corrigeert en boven alles veilig is voor gebruik op de relatief korte termijn58-62. 
Deze studies bestaan echter uit kleine case-studies of kleine case-series. Naar onze 
mening zouden deze studies gezien moeten worden als proof-of-concept bewijs en 
zouden deze herhaald moeten worden in grotere dubbel blind gerandomiseerde studies 
om hun toegevoegde therapeutische waarde in de preventie van valepisoden en 
verbetering van zowel motore als non-motore symptomen bij personen met de ziekte 
van Parkinson als atypische parkinsonismen definitief vast te leggen.
Op dit moment is er geen bewijs om standaard VEMP testen uit te voeren bij personen 
met de ziekte van Parkinson of met atypische parkinsonismen aangezien het geen 
therapeutische consequenties heeft. Vestibulaire laboratorium testen (VEMP, SVV 
en/of videonystagmografie met calorisatie en draaistoelstimulatie) kunnen echter wel 
erg behulpzaam zijn in wetenschappelijke studies in het ophelderen van de 
onderliggende fysiologische veranderingen secundair aan bijvoorbeeld herhaalde 
calorische therapeutische stimulatie of stochastische vestibulaire stimulatie zoals 
hierboven beschreven in de mogelijke preventie van valepisoden. 
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2AFC Two-alternative forced choice method
ABC-16 16 items activities-specific balance confidence scale
AC-cVEMP  Air-conducted cervical vestibular evoked myogenic potentials
AC-oVEMP  Air-conducted ocular vestibular evoked myogenic potentials
ADJ Method of adjustment
ADL Activities of daily living
AICA Anterior inferior cerebellar artery
AP Atypical parkinsonism
AVS Acute vestibular syndrome
BAEP  Brainstem auditory evoked potentials
BCV-cVEMP  Bone-conducted cervical vestibular evoked myogenic potentials
BCV-oVEMP  Bone-conducted ocular vestibular evoked myogenic potentials
CCA Cortical cerebellar atrophy
CT Computed tomography
cVEMP Cervical vestibular evoked myogenic potentials
dBNHL Decibels above normale adult hearing level
DHI Dizziness handicap inventory
DWI Diffusion weighted imaging
EDSS Expanded disability status scale
EMG Electromyography
ENG Electronystagmography
HINTS Head impulse, nystagmus, and skew deviation testing
ICC Intraclass correlation coefficient
ICHD-III  International classification of headache disorders, 3th edition
INC Interstitial nucleus of Cajal
INO Internuclear ophthalmoplegia
LC Left cold
LW Left warm
mcV Microvolts
MJD Machado-Jospeh disease
MLF Medial longitudinal fasciculus
mmHg pressure in millimetres Mercury
MRI Magnetic resonance imaging
ms milliseconds  
MS Multiple Sclerosis
MSA Multi system atrophy
MSA-p MSA with predominant parkinsonism
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List of abbreviations
OPCA Olivo-ponto-cerebellar atrophy
oVEMP Ocular vestibular evoked myogenic potentials
PD Parkinson’s disease
PICA Posterior inferior cerebellar artery
PPV Positive predictive value
PSP Progressive supranuclear palsy
RC Right cold
REM Rapid eye-movement sleep
RW Right warm
SCDS Superior semicircular canal dehiscence syndrome
SCM Sternocleidomastoid muscle
SHV Subjective haptic vertical
SSCNS Superficial siderosis of the central nervous system
SVV Subjective visual vertical
ULN Upper limit of normal
UPDRS Unified Parkinson’s disease rating scale
VEMP Vestibular evoked myogenic potentials
VEP Visual evoked potentials
VM Vestibular migraine
VNG Videonystagmography
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Professor dr. Bas Bloem (Radboud Universiteit, Nijmegen), graag wil ik je hartelijk 
bedanken dat je mijn promotor wilde zijn. Jouw gedrevenheid, enthousiasme en 
creatieve out-of-the-box ideeën waardeer ik zeer. Dr. Wim Verhagen en dr. Jan 
Meulstee (Canisius-Wilhelmina ziekenhuis, Nijmegen), jullie waren als copromotoren 
mijn directe begeleiders en daardoor de drijvende kracht achter dit proefschrift. Altijd 
to-the-point, kritisch, constructief, secuur en zeer snel in het terugsturen van jullie 
commentaar, altijd leidend tot een duidelijke verbetering van de manuscripten. Hierbij 
kon ik me geen betere begeleiding wensen. Beste Wim, naast jouw begeleiding als 
copromotor wil ik je ook heel erg bedanken voor jouw goed vervulde rol als opleider. 
Jouw recente verkiezing tot opleider van het jaar is dan ook niets minder dan verdiend. 
Naast de overdracht van algemeen neurologische en met name neurovestibulaire 
medische kennis, heb je als rolmodel mij ook duidelijk ondersteund in mijn 
persoonlijke ontwikkeling tot medisch specialist. Tot op heden profiteer ik hier nog 
dagelijks van en kijk ik met een zeer goed gevoel terug op mijn opleiding tot medisch 
specialist. Beste Jan, dank voor het delen van jouw uitgebreide klinisch 
neurofysiologische kennis. Deze gedegen kennis maakt me niet alleen een betere 
klinisch neurofysioloog, maar ik ben er tevens van overtuigd dat dit me ook een betere 
klinisch neuroloog maakt. Naast het medisch inhoudelijke deel van het vak kijk ik 
ook met een goed gevoel terug op zowel onze persoonlijke gesprekken alsmede op de 
gesprekken over onze gedeelde hobbie, zijnde de astrofysica. Na het afronden van dit 
promotieonderzoek kom ik graag een keer langs om jouw observatorium te komen 
bewonderen en onze gesprekken voort te zetten. 
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Zonder de ondersteuning van de laboranten en secretaresse van de afdeling klinische 
neurofysiologie uit het Canisius-Wilhelmina ziekenhuis te Nijmegen was dit onderzoek 
eveneens niet mogelijk geweest. Dank jullie voor de praktische ondersteuning, 
constructieve blik op de technische uitvoering van het onderzoek, maar vooral ook 
voor de aangename en erg gezellige samenwerking.
De manuscriptcommissie bestaande uit professor dr. Henri Marres (Radboud 
Universiteit Nijmegen), professor dr. Jelte Bos (Vrije Universiteit, Amsterdam) en 
professor dr. Sander Geurts (Radboud Universiteit, Nijmegen) wil ik hartelijk 
bedanken voor de bereidheid dat ik u mijn proefschrift ter beoordeling mocht 
voorleggen. Naast de manuscriptcommissie zou ik graag professor emeritus dr. Luc 
Crevits (Universiteit Gent, België), professor dr. Floris Wuyts (Universiteit Antwerpen, 
België), professor dr. Henk Berendse (Vrije Universiteit, Amsterdam) en dr. Bart van 
de Warrenburg (Radboud Universiteit, Nijmegen) als overige leden van de 
promotiecommissie (naast de leden eerder vermeld in de manuscriptcommissie) bij 
voorbaat willen bedanken voor hun kritische beschouwing van mijn proefschrift. In 
het bijzonder zou ik hierbij zeer graag professor emeritus dr. Luc Crevits willen 
bedanken. Beste Luc, de basis van dit proefschrift en mijn neurovestibulaire interesse 
werden beide al zeer vroeg tijdens mijn opleiding geneeskunde bij u gelegd. Graag 
wil ik u nogmaals zeer hartelijk bedanken voor de mogelijkheden die u me heeft 
geboden om me zowel klinisch medisch als wetenschappelijk te ontwikkelen op uw 
afdeling neurologie aan de Universiteit Gent. Vooral uw scherpe kritische blik, oog 
voor details, zeer uitgebreide klinisch neurologische kennis, maar voornamelijk ook 
uw zeer vriendelijke en rustige bejegening waren en zijn voor mij een voorbeeld. 
Graag zou ik direct van de gelegenheid gebruik willen maken om alle stafleden, (oud) 
arts-assistenten, verpleegkundigen, secretaresses en het ondersteunend personeel van 
de afdeling neurologie uit het Canisius-Wilhelmina ziekenhuis te Nijmegen willen 
bedanken voor de samenwerking, collegialiteit en zeer goede sfeer tijdens mijn 
opleiding tot neuroloog.
Mijn collega neurologen uit het Albert Schweitzer ziekenhuis, waar ik tegenwoordig 
werkzaam ben, wil ik graag bedanken voor hun collegialiteit, vriendelijkheid, 
vertrouwen en geduld. We hebben samen een drukke praktijk, maar omdat we allen 
tezamen onze schouders eronder zetten, maken vele handen het werk een stuk lichter 
en leuker. Ik kijk uit naar onze langdurige samenwerking, waarbij er naast het medisch 
inhoudelijke aspect, gelukkig ook aandacht is voor humor en de persoon achter de 
dokter. Dank jullie voor de fijne samenwerking. Naast natuurlijk de neurologen dragen 
de physician assistants, arts-assistenten, doktersassistenten, KNF-laboranten, 
secretaresses, verzorgenden en verpleegkundigen in belangrijke mate bij aan de fijne 
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werkomgeving. Dankzij jullie ga ik iedere dag met een glimlach aan het werk waarvoor 
heel hartelijk bedankt.
Beste Mischa en Monique Vreeburg, jullie steun als paranimfen betekent veel voor 
me. Sinds we elkaar kennen, vanaf onze studie scheikunde aan de Universiteit Utrecht, 
beschouw ik onze vriendschap als zeer hecht en waardevol. Zowel in goede tijden als 
in tijden wanneer het even tegenzat, kon ik altijd op jullie bouwen. 
Buiten het medische en het wetenschappelijk vlak zijn er natuurlijk ook veel mensen, 
die in zeer belangrijke mate hebben bijgedragen aan de voltooiing van dit proefschrift. 
Als eerste zou ik heel graag mijn vrouw Mariska Venhovens-Janssen willen bedanken 
voor alle fijne liefdevolle jaren samen en ook voor het op de wereld brengen van onze 
dochter Nienke en onze aankomende dochter, die binnenkort zal worden geboren. 
Zonder jouw steun was dit proefschrift er nooit geweest en was mijn leven een stuk 
minder compleet. Daarnaast wil ik ook heel erg graag mijn (schoon)ouders, (schoon)
familie en al mijn lieve vrienden bedanken voor hun onvoorwaardelijke steun. 
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Jeroen Venhovens werd op 14 maart 1981 geboren in Gorinchem. In 2000 behaalde 
hij zijn VWO diploma aan de Christelijke scholengemeenschap de Oude Hoven te 
Gorinchem. Vanwege de numerus fixus op de opleiding geneeskunde, heeft hij in de 
periode 2000-2001 de studie scheikunde aan de Universiteit Utrecht gevolgd als 
vooropleiding, waarbij het propaedeutisch examen met succes werd afgerond. In het 
daaropvolgende studiejaar is hij vanwege de numerus fixus uitgeweken naar de 
Universiteit Gent te België om aldaar de studie geneeskunde aan te vangen. Gedurende 
de studie geneeskunde groeide zijn interesse voor de neurologie (en met name de 
neurovestibulaire problematiek) door de verschillende wetenschappelijke en klinische 
stages bij de afdeling neurologie van het Universitair ziekenhuis Gent te België onder 
begeleiding van professor dr. Luc Crevits. Na het succesvol behalen van zijn master 
diploma geneeskunde aan de Universiteit Gent te België in 2008 (afstudeerrichting 
ziekenhuisarts – wetenschappelijk onderzoek), begon hij direct aansluitend met zijn 
werkzaamheden als arts-assistent neurologie niet in opleiding (ANIOS) in het Jeroen 
Bosch ziekenhuis te ‘s Hertogenbosch tot medio 2009. Eind 2009 begon hij met de 
opleiding tot neuroloog in het Canisius-Wilhelmina ziekenhuis te Nijmegen (opleider 
dr. Wim Verhagen). Het wetenschappelijk onderzoek wat uiteindelijke leidde tot dit 
proefschrift begon hij in 2012 en werd met name uitgevoerd tijdens zijn verdere 
verdieping in de klinische neurofysiologie in 2014 en 2015 (opleider dr. Jan Meulstee). 
Na het afronden van zijn opleiding tot neuroloog in 2015, is hij vanaf die tijd 
werkzaam in het Albert Schweitzer ziekenhuis te Dordrecht als neuroloog met de 
aandachtsgebieden klinische neurofysiologie en neurovestibulaire stoornissen.
201804 proefschrift Jeroen Venhovens.indd   164 26-01-18   15:06
N
eurovestibular analysis and falls in Parkinson’s disease and atypical parkinsonism
Jeroen Venhovens
Neurovestibular analysis and falls in
Parkinson’s disease and atypical parkinsonism
Jeroen Venhovens
N
eurovestibular analysis and falls in Parkinson’s disease and atypical parkinsonism
Jeroen Venhovens
Neurovestibular analysis and fa ls in
Parkinson’s disease and atypical parkinsonis
Jeroen Venhovens
N
eurovestibular analysis and falls in Parkinson’s disease and atypical parkinsonism
Jeroen Venhovens
i  i    i
i ’  i   i  i i
 
UITNODIGING
Graag wil ik u uitnodigen voor 
het bijwonen van de openbare 
verdediging van mijn proefschrift: 
Neurovestibular analysis and 
falls in Parkinson’s disease 
and atypical parkinsonism.
Op dinsdag 20 maart 2018 om 
10:30 uur precies in de aula 
van de Radboud Universiteit 
Nijmegen, Comeniuslaan 2 te 
Nijmegen. Aansluitend receptie 
ter plaatse.
Het feest ter gelegenheid van 
mijn promotie zal plaatsvinden 
op vrijdag 30 maart 2018 vanaf 
20:30 uur, locatie: 
More-Itz, Nieuwe Jachthaven 50 
te Drimmelen.
Graag verneem ik per e-mail 
op: Venhovens@hotmail.com 
of u aanwezig zal zijn op de 
openbare verdediging en/of het 
feest in verband met de catering 
(aanmelden voor het feest kan tot 
uiterlijk 20 maart). 
Jeroen Venhovens, 
Venhovens@hotmail.com, 
06-14420401.
